var title_f34_0_34816="Seated external rotation exercise for frozen shoulder";
var content_f34_0_34816=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1111px;\">",
"  <div class=\"videoplayer\" h264=\"./images/EM/83385/Seated_ext_rot_frozen_video.mp4?title=Seated+external+rotation+exercise+for+frozen+shoulder\" style=\"width:512px;height:304px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 479px\">",
"   <div class=\"ttl\">",
"    Seated external rotation exercise for frozen shoulder",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 459px; height: 333px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This exercise for the external rotators of the shoulder can be added to a rehabilitation regimen once shoulder motion begins to improve.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Tore Prestgaard, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_0_34816=[""].join("\n");
var outline_f34_0_34816=null;
var title_f34_0_34817="Spinal epidural abscess MRI";
var content_f34_0_34817=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F68878&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F68878&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Spinal epidural abscess",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 408px; height: 198px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    58 year old man with severe back pain and fever. Panel A: T-2-weighted sagittal MR image (3000/78) demonstrates loss of the normal T6-7 disc space with a posterior epidural fluid collection that is compressing the cord. Panel B: T1-weighted gadolinium enhanced sagittal MR image with fat saturation (500/8) demonstrates peripheral contrast enhancement of the epidural abscess with some adjacent dural enhancement. The T6-7 disc space and adjacent vertebral endplates also enhance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Andrew L Wagner, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_0_34817=[""].join("\n");
var outline_f34_0_34817=null;
var title_f34_0_34818="Calculator: Venous clinical severity score";
var content_f34_0_34818=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"VenousClinicalSeverityScore_form\" name=\"VenousClinicalSeverityScore_form\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Venous clinical severity score",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_main\">",
"     <div id=\"calc_input\">",
"      <center>",
"       <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Pain",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc1\" onclick=\"VenousClinicalSeverityScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           None (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc1\" onclick=\"VenousClinicalSeverityScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Occasional: not restricting activity or requiring analgesics (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc1\" onclick=\"VenousClinicalSeverityScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Daily: moderate activity limitation, occasional analgesics (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc1\" onclick=\"VenousClinicalSeverityScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Daily: severe limiting activities or requiring regular use of analgesics (3 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Varicose veins*",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onclick=\"VenousClinicalSeverityScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           None (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onclick=\"VenousClinicalSeverityScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Few: scattered, intersaphenous varicose veins (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onclick=\"VenousClinicalSeverityScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Multiple: great saphenous confined to calf or thigh (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onclick=\"VenousClinicalSeverityScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Extensive: Thigh and calf or great and small saphenous (3 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Venous edema**",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"VenousClinicalSeverityScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           None (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"VenousClinicalSeverityScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Evening: ankle edema only (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"VenousClinicalSeverityScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Afternoon: above ankle (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"VenousClinicalSeverityScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Morning: edema above ankle and requiring activity change (ie, elevation) (3 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Pigmentation***",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc4\" onclick=\"VenousClinicalSeverityScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           None (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc4\" onclick=\"VenousClinicalSeverityScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Diffuse: but limited in area (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc4\" onclick=\"VenousClinicalSeverityScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Diffuse: limited to lower third of leg (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc4\" onclick=\"VenousClinicalSeverityScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Wide: distribution (above lower third of leg) with recent pigmentation (3 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Inflammation",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc5\" onclick=\"VenousClinicalSeverityScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           None (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc5\" onclick=\"VenousClinicalSeverityScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Mild cellulitis:  limited to marginal area around ulcer (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc5\" onclick=\"VenousClinicalSeverityScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Moderate cellulitis: involving lower third of leg (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc5\" onclick=\"VenousClinicalSeverityScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Severe cellulitis: above and including lower third of leg or significant venous eczema (3 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Induration",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc6\" onclick=\"VenousClinicalSeverityScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           None (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc6\" onclick=\"VenousClinicalSeverityScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Focal: circummalleolar (&lt;5 cm) (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc6\" onclick=\"VenousClinicalSeverityScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Diffuse: medial or lateral, &lt;lower third of leg (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc6\" onclick=\"VenousClinicalSeverityScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Extensive: entire lower third of leg or more (3 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Number of active ulcers",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc7\" onclick=\"VenousClinicalSeverityScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           None (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc7\" onclick=\"VenousClinicalSeverityScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           1 (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc7\" onclick=\"VenousClinicalSeverityScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           2 (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc7\" onclick=\"VenousClinicalSeverityScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           3 (3 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Duration of active ulcers",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc8\" onclick=\"VenousClinicalSeverityScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           None (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc8\" onclick=\"VenousClinicalSeverityScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           &lt;3 months (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc8\" onclick=\"VenousClinicalSeverityScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           &gt;3 months &lt;1 year (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc8\" onclick=\"VenousClinicalSeverityScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           &gt;1 year (3 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Size of active ulcers",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc9\" onclick=\"VenousClinicalSeverityScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           None (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc9\" onclick=\"VenousClinicalSeverityScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           &lt;2 cm diameter (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc9\" onclick=\"VenousClinicalSeverityScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           2-6 cm diameter (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc9\" onclick=\"VenousClinicalSeverityScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           &gt;6 cm diameter (3 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Compression therapy",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc10\" onclick=\"VenousClinicalSeverityScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           None (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc10\" onclick=\"VenousClinicalSeverityScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Intermittent use (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc10\" onclick=\"VenousClinicalSeverityScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Most days (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc10\" onclick=\"VenousClinicalSeverityScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Continuous (3 points)",
"          </span>",
"         </td>",
"        </tr>",
"       </table>",
"      </center>",
"     </div>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <div id=\"calc_result\">",
"      <span class=\"medCalcFontCCTabBold\">",
"       Total Criteria Point Count:",
"      </span>",
"      <input name=\"cctotal\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <center>",
"       <input name=\"reset\" type=\"reset\" value=\"Reset Form\"/>",
"      </center>",
"     </div>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <span class=\"medCalcFontOneBold\">",
"      Notes",
"     </span>",
"     <ul class=\"medCalcFontOne\">",
"      <li>",
"       * Varicose veins must be greater than 4 mm in diameter to count in this score.",
"      </li>",
"      <li>",
"       ** Venous edema must be a regular finding, not occasional. It is typically brawny rather than pitting and it is altered by leg elvation or standing.",
"      </li>",
"      <li>",
"       *** Pigment changes must be relatively diffuse, not just focal over varicose veins.",
"      </li>",
"     </ul>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Rutherford RB, Padberg FT Jr, Comerota AJ, et. al.  Venous severity scoring: An adjunct to venous outcome assessment.",
"        <i>",
"         J Vasc Surg",
"        </i>",
"        . 2000 Jun;31(6):1307-12.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"   <script language=\"JavaScript1.1\" type=\"text/javascript\">",
"    &lt;!--",
"",
";",
"VenousClinicalSeverityScore_fx();",
"//--&gt;",
"   </script>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_0_34818=[" ",
"",
"var calctxt = '';",
"var xmltxt = '';",
"var htmtxt = '';",
"",
"",
"function VenousClinicalSeverityScore_fx() {",
"with(document.VenousClinicalSeverityScore_form){",
"",
"Score = 0.0;",
"doCalc = true;",
"",
"if (cc1[0].checked){",
"Score = Score + 0;",
"}",
"if (cc1[1].checked){",
"Score = Score + 1;",
"}",
"if (cc1[2].checked){",
"Score = Score + 2;",
"}",
"if (cc1[3].checked){",
"Score = Score + 3;",
"}",
"if (cc2[0].checked){",
"Score = Score + 0;",
"}",
"if (cc2[1].checked){",
"Score = Score + 1;",
"}",
"if (cc2[2].checked){",
"Score = Score + 2;",
"}",
"if (cc2[3].checked){",
"Score = Score + 3;",
"}",
"if (cc3[0].checked){",
"Score = Score + 0;",
"}",
"if (cc3[1].checked){",
"Score = Score + 1;",
"}",
"if (cc3[2].checked){",
"Score = Score + 2;",
"}",
"if (cc3[3].checked){",
"Score = Score + 3;",
"}",
"if (cc4[0].checked){",
"Score = Score + 0;",
"}",
"if (cc4[1].checked){",
"Score = Score + 1;",
"}",
"if (cc4[2].checked){",
"Score = Score + 2;",
"}",
"if (cc4[3].checked){",
"Score = Score + 3;",
"}",
"if (cc5[0].checked){",
"Score = Score + 0;",
"}",
"if (cc5[1].checked){",
"Score = Score + 1;",
"}",
"if (cc5[2].checked){",
"Score = Score + 2;",
"}",
"if (cc5[3].checked){",
"Score = Score + 3;",
"}",
"if (cc6[0].checked){",
"Score = Score + 0;",
"}",
"if (cc6[1].checked){",
"Score = Score + 1;",
"}",
"if (cc6[2].checked){",
"Score = Score + 2;",
"}",
"if (cc6[3].checked){",
"Score = Score + 3;",
"}",
"if (cc7[0].checked){",
"Score = Score + 0;",
"}",
"if (cc7[1].checked){",
"Score = Score + 1;",
"}",
"if (cc7[2].checked){",
"Score = Score + 2;",
"}",
"if (cc7[3].checked){",
"Score = Score + 3;",
"}",
"if (cc8[0].checked){",
"Score = Score + 0;",
"}",
"if (cc8[1].checked){",
"Score = Score + 1;",
"}",
"if (cc8[2].checked){",
"Score = Score + 2;",
"}",
"if (cc8[3].checked){",
"Score = Score + 3;",
"}",
"if (cc9[0].checked){",
"Score = Score + 0;",
"}",
"if (cc9[1].checked){",
"Score = Score + 1;",
"}",
"if (cc9[2].checked){",
"Score = Score + 2;",
"}",
"if (cc9[3].checked){",
"Score = Score + 3;",
"}",
"if (cc10[0].checked){",
"Score = Score + 0;",
"}",
"if (cc10[1].checked){",
"Score = Score + 1;",
"}",
"if (cc10[2].checked){",
"Score = Score + 2;",
"}",
"if (cc10[3].checked){",
"Score = Score + 3;",
"}",
"cctotal.value = Score;",
"}",
"}",
"",
"",
"",
"",
"",
"",
""].join("\n");
var outline_f34_0_34818=null;
var title_f34_0_34819="Phototoxic eruption on face";
var content_f34_0_34819=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F69140&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F69140&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 536px\">",
"   <div class=\"ttl\">",
"    Phototoxic eruption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 516px; height: 296px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diffuse, sunburn-like erythema is present on the face and ears. Note the relative sparing of shaded areas under the nose and lip.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_0_34819=[""].join("\n");
var outline_f34_0_34819=null;
var title_f34_0_34820="Histol superfic spread melanoma";
var content_f34_0_34820=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F62540&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F62540&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Superficial spreading melanoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 368px; height: 280px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Medium power light photomicrograph of a superficial spreading melanoma, demonstrating intraepidermal and dermal growth of atypical, hyperchromatic cells. Note the highly disorganized architecture of the lesion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Vincent Liu, MD and April Wang Armstrong, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_0_34820=[""].join("\n");
var outline_f34_0_34820=null;
var title_f34_0_34821="Pancuronium: Pediatric drug information";
var content_f34_0_34821=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pancuronium: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?19/33/19990?source=see_link\">",
"    see \"Pancuronium: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?33/24/34179?source=see_link\">",
"    see \"Pancuronium: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2980447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Pancuronium Bromide&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1060895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Neuromuscular Blocker Agent, Nondepolarizing",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Skeletal Muscle Relaxant, Paralytic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11444088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Paralysis/skeletal muscle relaxation:",
"     </b>",
"     I.V.: 0.05-0.1 mg/kg/dose (Kumar, 2010); may repeat dose every 30-60 minutes as needed or as continuous I.V. infusion of 0.02-0.04 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     or 0.4-0.6",
"     <b>",
"      mcg",
"     </b>",
"     /kg/minute",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1060888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?19/33/19990?source=see_link\">",
"      see \"Pancuronium: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Paralysis/skeletal muscle relaxation:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants: 0.1 mg/kg/dose every 30-60 minutes as needed or as continuous I.V. infusion of 0.02-0.04 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     or 0.4-0.6",
"     <b>",
"      mcg",
"     </b>",
"     /kg/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: 0.15 mg/kg/dose every 30-60 minutes as needed or as continuous I.V. infusion 0.03-0.1 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     or 0.5-1.7",
"     <b>",
"      mcg",
"     </b>",
"     /kg/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adolescents and Adults: 0.15 mg/kg/dose every 30-60 minutes as needed or as a continuous I.V. infusion 0.02-0.04 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     or 0.4-0.6",
"     <b>",
"      mcg",
"     </b>",
"     /kg/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment",
"     </b>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer 50% of normal dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Do not use",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F206121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as bromide: 1 mg/mL (10 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F206107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1060898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: May be administered undiluted by rapid I.V. injection; for continuous I.V. infusion, dilute to final concentration of 0.01-0.8 mg/mL in D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, or NS.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F206189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Aminophylline, amiodarone, caffeine citrate, calcium gluconate, cefazolin, cefuroxime, cimetidine, diltiazem, dobutamine, dopamine, epinephrine, esmolol, etomidate, fenoldopam, fentanyl, fluconazole, gentamicin, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), hydrocortisone sodium succinate, isoproterenol, labetalol, levofloxacin, lorazepam, magnesium sulfate, midazolam, milrinone, morphine, nitroglycerin, nitroprusside, potassium chloride, procainamide, ranitidine, sodium bicarbonate, trimethoprim/sulfamethoxazole, vancomycin.",
"     <b>",
"      Incompatible",
"     </b>",
"     Diazepam, pantoprazole, thiopental.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Propofol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Caffeine citrate, heparin, hydrocortisone, meperidine, methohexital, neostigmine, promethazine, succinylcholine, thiopental.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1060891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); also stable for up to 6 months at room temperature; compatible with D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, and LR injections",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1060897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct to anesthesia, to facilitate endotracheal intubation and provide skeletal muscle relaxation during surgery or mechanical ventilation (FDA approved in all ages)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F206191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       United States Pharmacopeia (USP) 2006: The Interdisciplinary Safe Medication Use Expert Committee of the USP has recommended the following:",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"       - Hospitals, clinics, and other practice sites should institute special safeguards in the storage, labeling, and use of these agents and should include these safeguards in staff orientation and competency training.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"       - Healthcare professionals should be on high alert (especially vigilant) whenever a neuromuscular-blocking agent (NMBA) is stocked, ordered, prepared, or administered.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F206188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Circulatory collapse, edema, elevated blood pressure and cardiac output, elevation in pulse rate, skin flushing, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Burning sensation along the vein, erythema, itching, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Excessive salivation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Profound muscle weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchospasm, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Acute quadriplegic myopathy syndrome (prolonged use), anaphylactoid reactions, anaphylaxis, myositis ossificans (prolonged use)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1060902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pancuronium, bromide, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1060887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with  renal, hepatic, and/or biliary tract  disease; some patients may experience prolonged recovery of neuromuscular function after administration (especially after prolonged use). Concurrent use of some antibiotics (eg, aminoglycosides, tetracyclines, polymixin B, bacitracin, colistin), particulary high doses, may enhance neuromuscular blocking effects. Many clinical conditions may affect the response to neuromuscular blockade; see table.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Clinical Conditions Affecting Neuromuscular Blockade",
"     </caption>",
"     <col align=\"left\" width=\"240\">",
"     </col>",
"     <col align=\"left\" width=\"200\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Potentiation",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Antagonism",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"top\">",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Acidosis",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Acute intermittent porphyria",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Electrolyte abnormalities",
"        </p>",
"        <p style=\"text-indent:0em;margin-left:2em;\">",
"         Severe hyponatremia",
"        </p>",
"        <p style=\"text-indent:0em;margin-left:2em;\">",
"         Severe hypocalcemia",
"        </p>",
"        <p style=\"text-indent:0em;margin-left:2em;\">",
"         Severe hypokalemia",
"        </p>",
"        <p style=\"text-indent:2em;\">",
"         Hypermagnesemia",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Hepatic failure",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Neuromuscular diseases",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Renal failure",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Alkalosis",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Demyelinating lesions",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Diabetes mellitus",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Hypercalcemia",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Peripheral neuropathies",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1060886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ventilation must be supported during neuromuscular blockade; pancuronium should only be administered by individuals who are experienced in the maintenance of an adequate airway and respiratory support",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Pancuronium does not alter consciousness; use in conjunction with adequate sedation or anesthesia. Severe allergic reactions have been reported with neuromuscular blocking agents, including pancuronium; cross-sensitivity with other neuromuscular-blocking agents may occur; use extreme caution in patients with previous anaphylactic reactions. Pancuronium injection contains benzyl alcohol which may cause allergic reactions in susceptible individuals; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate, a metabolite of benzyl alcohol, displaces bilirubin from protein binding sites; avoid use of benzyl alcohol containing products in neonates",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F206115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: May enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capreomycin: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Neuromuscular-Blocking Agents may enhance the arrhythmogenic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colistimethate: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Neuromuscular-Blocking Agents (Nondepolarizing) may enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Inhalational Anesthetics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Neuromuscular-Blocking Agents (Nondepolarizing). Specifically, episodes of apnea have been reported in patients using this combination.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Neuromuscular-Blocking Agents (Nondepolarizing). Specifically, episodes of apnea have been reported in patients using this combination.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lincosamide Antibiotics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Loop Diuretics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Neuromuscular-Blocking Agents may enhance the neuromuscular-blocking effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Polymyxin B: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Procainamide: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Neuromuscular-Blocking Agents may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: May enhance the adverse/toxic effect of Pancuronium. Theophylline Derivatives may diminish the neuromuscular-blocking effect of Pancuronium. Management: Pancuronium dosage adjustment may be necessary to induce paralysis  in patients receiving concomitant theophylline derivatives. Monitor closely for adverse effects (e.g., cardiac effects) with concomitant use of these agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F206117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13494861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Small amounts of pancuronium cross the placenta (Daily, 1984). May be used short-term in cesarean section; reduced doses recommended in patients also receiving magnesium sulfate due to enhanced effects.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1060894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Heart rate, blood pressure, assisted ventilation status, peripheral nerve stimulator measuring twitch response",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1060885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nondepolarizing neuromuscular blocker which blocks acetylcholine from binding to receptors on motor endplate thus inhibiting depolarization",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1060900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action (Martin, 1999):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: 2-5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 2-4 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 3-5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Dose-dependent",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 24 minutes (Martin, 1999)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 22 minutes (Martin, 1999)",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1060901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.24-0.28 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 87%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic: 30% to 40%; active metabolite 3-hydroxypancuronium (",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     the activity of parent drug)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 89-161 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (40%); bile (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: ~1-2 mL/kg/minute",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1060903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients with hepatic and biliary disease have a larger V",
"     <sub>",
"      d",
"     </sub>",
"     which may result in a higher total initial dose and possibly a slower onset of effect; the duration of neuromuscular blocking effects may be prolonged in patients with hepatic, biliary, or renal dysfunction",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Kumar P, Denson SE, Mancuso TJ, et al, \"Premedication for Nonemergency Endotracheal Intubation in the Neonate,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2010, 125(3):608-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/0/34821/abstract-text/20176672/pubmed\" id=\"20176672\" target=\"_blank\">",
"        20176672",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Martin LD, Bratton SL, and O'Rourke PP, &ldquo;Clinical Uses and Controversies of Neuromuscular Blocking Agents in Infants and Children,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1999, 27(7):1358-68.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/0/34821/abstract-text/10446832/pubmed\" id=\"10446832\" target=\"_blank\">",
"        10446832",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12676 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.72.80.101-9C98E7F444-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_0_34821=[""].join("\n");
var outline_f34_0_34821=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709194\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2980447\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060895\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11444088\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060888\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206121\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206107\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060898\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206189\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060891\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060897\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206191\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206188\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060902\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060887\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060886\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299816\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206115\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206117\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13494861\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060894\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060885\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060900\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060901\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060903\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12676\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12676|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?19/33/19990?source=related_link\">",
"      Pancuronium: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?33/24/34179?source=related_link\">",
"      Pancuronium: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_0_34822="Treatment of sporotrichosis";
var content_f34_0_34822=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of sporotrichosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/0/34822/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/0/34822/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/0/34822/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/0/34822/contributors\">",
"     Kieren A Marr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/0/34822/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/0/34822/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/0/34822/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/0/34822/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sporotrichosis is a subacute to chronic infection caused by the dimorphic fungus Sporothrix schenckii. Infection usually involves cutaneous and subcutaneous tissues but can occasionally occur in other sites, primarily in immunocompromised patients. Activities associated with the development of sporotrichosis include landscaping, rose gardening, and other activities that involve inoculation of soil through the skin.",
"   </p>",
"   <p>",
"    Treatment of sporotrichosis varies with the type of disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34822/abstract/1\">",
"     1",
"    </a>",
"    ]. Since most manifestations are subacute to chronic and localized, oral antifungal agents are usually preferred. The agent of choice is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34822/abstract/2\">",
"     2",
"    </a>",
"    ]. The rare cases of life-threatening, visceral, or disseminated infection require therapy with intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    , which is also used in patients who do not respond to itraconazole.",
"   </p>",
"   <p>",
"    The treatment of the various manifestations of sporotrichosis will be reviewed. The approach is consistent with the 2007 Infectious Diseases Society of America clinical practice guidelines for the management of sporotrichosis (",
"    <a class=\"graphic graphic_table graphicRef50353 \" href=\"mobipreview.htm?31/2/31788\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34822/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The basic biology, epidemiology, clinical manifestations, and diagnosis of sporotrichosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/60/8134?source=see_link\">",
"     \"Basic biology and epidemiology of sporotrichosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/11/12469?source=see_link\">",
"     \"Clinical features and diagnosis of sporotrichosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CHOICE OF ANTIFUNGAL AGENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of antifungal agent in patients with sporotrichosis is limited. In vitro susceptibility studies show good activity for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/22/33120?source=see_link\">",
"     terbinafine",
"    </a>",
"    and reasonable activity for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    ; both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    have poor activity in vitro against S. schenckii [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34822/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Clinical experience has shown that itraconazole is the treatment of choice for patients with most localized forms of sporotrichosis, and amphotericin B is the preferred treatment for patients who are severely ill [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34822/abstract/3\">",
"     3",
"    </a>",
"    ]. Fluconazole and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    are poor second-line choices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34822/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. There is no experience with voriconazole, primarily because of the lack of activity in vitro, and only one patient has been described for whom posaconazole was used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34822/abstract/9\">",
"     9",
"    </a>",
"    ]; neither of these azoles should be used for sporotrichosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34822/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     LYMPHOCUTANEOUS AND CUTANEOUS SPOROTRICHOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     Itraconazole",
"    </a>",
"    is the drug of choice for the treatment of lymphocutaneous and cutaneous sporotrichosis (",
"    <a class=\"graphic graphic_table graphicRef50353 \" href=\"mobipreview.htm?31/2/31788\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34822/abstract/1-3,10,11\">",
"     1-3,10,11",
"    </a>",
"    ]. The usual dose is 100 to 200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    orally, and treatment should be continued for two to four weeks after all lesions have resolved, usually for a total of three to six months. The success rate based upon observational studies is 90 to 100 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34822/abstract/2,11,12\">",
"     2,11,12",
"    </a>",
"    ]. We favor the 200 mg dose, since some patients will not respond to the lower dose and will require dose escalation. However, in a report about an established epidemic of sporotrichosis associated with exposure to cats in Rio de Janeiro, Brazil, a high rate of success was observed with the 100 mg dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34822/abstract/11\">",
"     11",
"    </a>",
"    ]. &nbsp;(See",
"    <a class=\"local\" href=\"#H2\">",
"     'Choice of antifungal agent'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients who don't respond to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    at 200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    should be given one of the following alternatives:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"       Itraconazole",
"      </a>",
"      200 mg orally twice daily",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/22/33120?source=see_link\">",
"       Terbinafine",
"      </a>",
"      at high doses, 500 mg twice daily, appears to be effective for sporotrichosis, but few patients have been treated to date [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34822/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Saturated solution of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/27/30134?source=see_link\">",
"       potassium iodide",
"      </a>",
"      (SSKI) had been the standard treatment until the 1990s. The initial dose is 5 drops in juice or milk three times daily, increasing weekly, as tolerated, to a maximum of 40 to 50 drops in juice or milk three times daily [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34822/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]. A once daily regimen using the same total daily dosage has also been shown to be effective in children and may help improve compliance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34822/abstract/15\">",
"       15",
"      </a>",
"      ]. Side effects include nausea, rash, metallic taste, fever, and salivary gland swelling. Therapy with SSKI is difficult for most patients, but is much less costly than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"       Fluconazole",
"      </a>",
"      is considered second-line therapy and, when necessary, should be used at a dose of 400 to 800 mg daily [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34822/abstract/3,6\">",
"       3,6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Local hyperthermia, induced by a variety of different warming devices or baths, also has been used successfully and with minimal side effects for cutaneous sporotrichosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34822/abstract/1,16\">",
"     1,16",
"    </a>",
"    ]. Heat therapy could be used, for example, in a pregnant patient who has cutaneous sporotrichosis and cannot safely be treated with any of the oral drugs that are useful for sporotrichosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PULMONARY SPOROTRICHOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary sporotrichosis is difficult to treat, perhaps due to delayed diagnosis or underlying illnesses in infected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34822/abstract/2,3,6,14,17,18\">",
"     2,3,6,14,17,18",
"    </a>",
"    ]. In addition to antifungal therapy, surgical resection has proven useful for patients who have localized disease and adequate pulmonary function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34822/abstract/17\">",
"     17",
"    </a>",
"    ]. Saturated solution of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/27/30134?source=see_link\">",
"     potassium iodide",
"    </a>",
"    (SSKI), which has efficacy in lymphocutaneous and cutaneous disease, has not been effective for pulmonary sporotrichosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Severe or life-threatening disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the patient is seriously ill,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    should be used initially; if not, then oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    can be given at a dose of 200 mg twice daily &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef50353 \" href=\"mobipreview.htm?31/2/31788\">",
"     table 1",
"    </a>",
"    )[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34822/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Choice of antifungal agent'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    When",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    is used, a lipid formulation is preferred at a dose of 3 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day intravenously because of reduced nephrotoxicity compared with amphotericin B deoxycholate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34822/abstract/3\">",
"     3",
"    </a>",
"    ]. Amphotericin B deoxycholate (0.7 to 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day intravenously) may be considered in patients without risk factors for renal insufficiency due to its lower cost. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/5/38998?source=see_link\">",
"     \"Amphotericin B nephrotoxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/41/15001?source=see_link\">",
"     \"Pharmacology of amphotericin B\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After the patient has shown a favorable response, therapy can be changed to oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    , 200 mg twice daily. The total duration of therapy should be at least one year and perhaps longer in some patients. Serum levels of itraconazole should be checked at least two weeks into therapy to ensure adequate levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Mild to moderate disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;For mild to moderate pulmonary sporotrichosis,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    200 mg orally twice daily for at least 12 months is recommended (",
"    <a class=\"graphic graphic_table graphicRef50353 \" href=\"mobipreview.htm?31/2/31788\">",
"     table 1",
"    </a>",
"    ). Serum levels of itraconazole should be checked after the patient has taken the drug for at least two weeks to ensure adequate levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     OSTEOARTICULAR SPOROTRICHOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Almost all patients with osteoarticular sporotrichosis can be treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    since the infection is usually chronic and localized (",
"    <a class=\"graphic graphic_table graphicRef50353 \" href=\"mobipreview.htm?31/2/31788\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34822/abstract/1-3,19\">",
"     1-3,19",
"    </a>",
"    ]. The minimum dose is 200 mg twice daily, and therapy should continue for at least one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34822/abstract/3\">",
"     3",
"    </a>",
"    ]. Serum levels of itraconazole should be checked after the patient has taken the drug for at least two weeks to ensure adequate levels. Even if the infection is cured, functional outcome following arthritis due to S. schenckii is often poor. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Choice of antifungal agent'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     Amphotericin B",
"    </a>",
"    is recommended in patients with extensive disease as initial therapy and in those who have not responded to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34822/abstract/3\">",
"     3",
"    </a>",
"    ]. A lipid formulation is preferred at a dose of 3 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day intravenously because of reduced nephrotoxicity compared with amphotericin B deoxycholate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34822/abstract/3\">",
"     3",
"    </a>",
"    ]. Amphotericin B deoxycholate (0.7 to 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day intravenously) may be considered in patients without risk factors for renal insufficiency due to its lower cost. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/5/38998?source=see_link\">",
"     \"Amphotericin B nephrotoxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/41/15001?source=see_link\">",
"     \"Pharmacology of amphotericin B\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After the patient has shown a favorable response, therapy can be changed to oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    , 200 mg twice daily.",
"   </p>",
"   <p>",
"    Intraarticular",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    has been used, but is rarely required [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34822/abstract/20\">",
"     20",
"    </a>",
"    ]. SSKI, which has efficacy in lymphocutaneous and cutaneous disease, is ineffective in osteoarticular sporotrichosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34822/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MENINGEAL SPOROTRICHOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     Amphotericin B",
"    </a>",
"    is the drug of choice for meningeal sporotrichosis (",
"    <a class=\"graphic graphic_table graphicRef50353 \" href=\"mobipreview.htm?31/2/31788\">",
"     table 1",
"    </a>",
"    ). A lipid formulation (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day intravenously for four to six weeks) is preferred because of reduced nephrotoxicity compared with amphotericin B deoxycholate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34822/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Choice of antifungal agent'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Step-down therapy with oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    , 200 mg twice daily, should be used after initial therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    is completed. A total of at least 12 months of therapy is required, and for patients with AIDS or ongoing immunosuppression from another cause, chronic suppression with 200 mg itraconazole daily is recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34822/abstract/3\">",
"     3",
"    </a>",
"    ]. Serum levels of itraconazole should be checked after the patient has taken the drug for at least two weeks to ensure adequate levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DISSEMINATED SPOROTRICHOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no clinical trials regarding the therapy of disseminated sporotrichosis. Based upon case reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34822/abstract/21-23\">",
"     21-23",
"    </a>",
"    ], we suggest that patients with disseminated infection be treated initially with a lipid formulation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    (3 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day intravenously) because of reduced nephrotoxicity compared with amphotericin B deoxycholate (",
"    <a class=\"graphic graphic_table graphicRef50353 \" href=\"mobipreview.htm?31/2/31788\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34822/abstract/3\">",
"     3",
"    </a>",
"    ]. Amphotericin B deoxycholate (0.7 to 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day intravenously) may be considered in patients without risk factors for renal insufficiency due to its lower cost. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/5/38998?source=see_link\">",
"     \"Amphotericin B nephrotoxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/41/15001?source=see_link\">",
"     \"Pharmacology of amphotericin B\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Step-down therapy with oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    , 200 mg twice daily, should be started after the patient has shown a favorable response. Serum levels of itraconazole should be checked at least two weeks into therapy to ensure adequate levels.",
"   </p>",
"   <p>",
"    A total of at least 12 months of therapy is required and chronic suppression should be considered for patients with AIDS or ongoing immunosuppression from another cause [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34822/abstract/3\">",
"     3",
"    </a>",
"    ]. Suppressive therapy may be discontinued in patients with AIDS who are taking antiretroviral therapy, have been treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    for at least one year, and have had CD4+ cell counts &gt;200",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    for more than one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34822/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172030614\">",
"    <span class=\"h2\">",
"     Treatment of HIV-infected patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;A report of 21 patients who had HIV infection and who developed sporotrichosis associated with a zoonotic outbreak in Rio de Janeiro, Brazil demonstrated a broader range of clinical infection than previously observed in HIV&ndash;infected patients. In this series, only 8 patients were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    , and 11 received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    ; the overall success rate was 81 percent. Itraconazole was used mostly in patients who had lymphocutaneous infection, but was also noted to be effective in several patients who had disseminated sporotrichosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34822/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TREATMENT OF PREGNANT WOMEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;For pregnant women with severe sporotrichosis, a lipid formulation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    (3 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day intravenously) is recommended because of reduced nephrotoxicity compared with amphotericin B deoxycholate (",
"    <a class=\"graphic graphic_table graphicRef50353 \" href=\"mobipreview.htm?31/2/31788\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34822/abstract/3\">",
"     3",
"    </a>",
"    ]. Amphotericin B deoxycholate (0.7 to 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day intravenously) may be considered in patients without risk factors for renal insufficiency due to its lower cost. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/5/38998?source=see_link\">",
"     \"Amphotericin B nephrotoxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/41/15001?source=see_link\">",
"     \"Pharmacology of amphotericin B\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Azoles should not be given during pregnancy due to their teratogenicity. Local hyperthermia can be used for cutaneous sporotrichosis in pregnant women. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Lymphocutaneous and cutaneous sporotrichosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TREATMENT OF CHILDREN",
"    </span>",
"    &nbsp;&mdash;&nbsp;For children with cutaneous or lymphocutaneous sporotrichosis, oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    6 to 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    up to a maximum dose of 400 mg daily is recommended (",
"    <a class=\"graphic graphic_table graphicRef50353 \" href=\"mobipreview.htm?31/2/31788\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34822/abstract/3\">",
"     3",
"    </a>",
"    ]. Saturated solution of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/27/30134?source=see_link\">",
"     potassium iodide",
"    </a>",
"    may be used as an alternative at a dose of one drop in milk or juice three times daily and increased weekly as tolerated, to a maximum of one drop per kg or 40 to 50 drops three times daily, whichever is lower [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34822/abstract/3\">",
"     3",
"    </a>",
"    ]. For disseminated sporotrichosis, intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate 0.7",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily should be given initially and can be followed by oral itraconazole 6 to 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    up to a maximum of 400 mg daily once clinical improvement has occurred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34822/abstract/3\">",
"     3",
"    </a>",
"    ]. For patients who require a prolonged course of intravenous therapy, such as those with meningeal sporotrichosis, we suggest a lipid formulation of amphotericin B at a dose of 3 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, which is less nephrotoxic than amphotericin B deoxycholate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For lymphocutaneous and cutaneous sporotrichosis, oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      200 mg once daily is the drug of choice and should be administered for two to four weeks after all lesions have resolved, usually three to six months. Patients who don't respond to itraconazole at 200",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      should be given one of the following alternatives: oral itraconazole at 200 mg twice daily,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/22/33120?source=see_link\">",
"       terbinafine",
"      </a>",
"      500 mg twice daily, or saturated solution of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/27/30134?source=see_link\">",
"       potassium iodide",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Lymphocutaneous and cutaneous sporotrichosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For severe pulmonary sporotrichosis, a lipid formulation of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      should be used initially. After the patient has shown a favorable response, therapy can be changed to oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      , 200 mg twice daily to complete at least 12 months of therapy. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Severe or life-threatening disease'",
"      </a>",
"      above.) For mild to moderate pulmonary sporotrichosis, oral itraconazole can be given at a dose of 200 mg twice daily for at least 12 months of therapy. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Mild to moderate disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Osteoarticular sporotrichosis can generally be treated with oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      200 mg twice daily for at least 12 months since the infection is usually chronic and localized.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"       Amphotericin B",
"      </a>",
"      is recommended in patients with extensive disease as initial therapy and in those who have not responded to itraconazole. After the patient has shown a favorable response, therapy can be changed to oral itraconazole, 200 mg twice daily. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Osteoarticular sporotrichosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For meningeal sporotrichosis, a lipid formulation of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      (5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day intravenously for four to six weeks) is the drug of choice. Step-down therapy with oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      , 200 mg twice daily, should be used after initial therapy with amphotericin B is completed and therapy should continue for at least 12 months. For patients with AIDS or ongoing immunosuppression from another cause, chronic suppression with 200 mg itraconazole daily is recommended. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Meningeal sporotrichosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For disseminated sporotrichosis, we suggest a lipid formulation of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      (3 to 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day intravenously). Step-down therapy with oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      , 200 mg twice daily, should be started after the patient has shown a favorable response and therapy should be continued for at least 12 months. Chronic suppression should be considered for patients with AIDS or ongoing immunosuppression from another cause. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Disseminated sporotrichosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serum levels of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      should be checked after the patient has taken the drug for at least at least two weeks for pulmonary, osteoarticular, meningeal, and disseminated sporotrichosis to ensure adequate levels. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pulmonary sporotrichosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For pregnant women with severe sporotrichosis, a lipid formulation of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      (3 to 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day intravenously) is recommended. Azoles should not be given during pregnancy due to their teratogenicity. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Treatment of pregnant women'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of sporotrichosis in children is similar to that in adults, although the dosing differs. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Treatment of children'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34822/abstract/1\">",
"      Kauffman CA. Old and new therapies for sporotrichosis. Clin Infect Dis 1995; 21:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34822/abstract/2\">",
"      Sharkey-Mathis PK, Kauffman CA, Graybill JR, et al. Treatment of sporotrichosis with itraconazole. NIAID Mycoses Study Group. Am J Med 1993; 95:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34822/abstract/3\">",
"      Kauffman CA, Bustamante B, Chapman SW, et al. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007; 45:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34822/abstract/4\">",
"      Galhardo MC, De Oliveira RM, Valle AC, et al. Molecular epidemiology and antifungal susceptibility patterns of Sporothrix schenckii isolates from a cat-transmitted epidemic of sporotrichosis in Rio de Janeiro, Brazil. Med Mycol 2008; 46:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34822/abstract/5\">",
"      Alvarado-Ram&iacute;rez E, Torres-Rodr&iacute;guez JM. In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods. Antimicrob Agents Chemother 2007; 51:2420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34822/abstract/6\">",
"      Kauffman CA, Pappas PG, McKinsey DS, et al. Treatment of lymphocutaneous and visceral sporotrichosis with fluconazole. Clin Infect Dis 1996; 22:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34822/abstract/7\">",
"      Horsburgh CR Jr, Cannady PB Jr, Kirkpatrick CH. Treatment of fungal infections in the bones and joints with ketoconazole. J Infect Dis 1983; 147:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34822/abstract/8\">",
"      Calhoun DL, Waskin H, White MP, et al. Treatment of systemic sporotrichosis with ketoconazole. Rev Infect Dis 1991; 13:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34822/abstract/9\">",
"      Bunce PE, Yang L, Chun S, et al. Disseminated sporotrichosis in a patient with hairy cell leukemia treated with amphotericin B and posaconazole. Med Mycol 2012; 50:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34822/abstract/10\">",
"      Restrepo A, Robledo J, G&oacute;mez I, et al. Itraconazole therapy in lymphangitic and cutaneous sporotrichosis. Arch Dermatol 1986; 122:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34822/abstract/11\">",
"      de Lima Barros MB, Schubach AO, de Vasconcellos Carvalhaes de Oliveira R, et al. Treatment of cutaneous sporotrichosis with itraconazole--study of 645 patients. Clin Infect Dis 2011; 52:e200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34822/abstract/12\">",
"      Conti D&iacute;az IA, Civila E, Gezuele E, et al. Treatment of human cutaneous sporotrichosis with itraconazole. Mycoses 1992; 35:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34822/abstract/13\">",
"      Chapman SW, Pappas P, Kauffmann C, et al. Comparative evaluation of the efficacy and safety of two doses of terbinafine (500 and 1000 mg day(-1)) in the treatment of cutaneous or lymphocutaneous sporotrichosis. Mycoses 2004; 47:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34822/abstract/14\">",
"      Kauffman CA. Sporotrichosis. Clin Infect Dis 1999; 29:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34822/abstract/15\">",
"      Cabezas C, Bustamante B, Holgado W, Begue RE. Treatment of cutaneous sporotrichosis with one daily dose of potassium iodide. Pediatr Infect Dis J 1996; 15:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34822/abstract/16\">",
"      Hiruma M, Kawada A, Noguchi H, et al. Hyperthermic treatment of sporotrichosis: experimental use of infrared and far infrared rays. Mycoses 1992; 35:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34822/abstract/17\">",
"      Pluss JL, Opal SM. Pulmonary sporotrichosis: review of treatment and outcome. Medicine (Baltimore) 1986; 65:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34822/abstract/18\">",
"      Tiwari A, Malani AN. Primary pulmonary sporotrichosis: Case report and review of the literature. Infect Dis Clin Pract 2012; 20:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34822/abstract/19\">",
"      Winn RE, Anderson J, Piper J, et al. Systemic sporotrichosis treated with itraconazole. Clin Infect Dis 1993; 17:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34822/abstract/20\">",
"      Downs NJ, Hinthorn DR, Mhatre VR, Liu C. Intra-articular amphotericin B treatment of Sporothrix schenckii arthritis. Arch Intern Med 1989; 149:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34822/abstract/21\">",
"      Gottlieb GS, Lesser CF, Holmes KK, Wald A. Disseminated sporotrichosis associated with treatment with immunosuppressants and tumor necrosis factor-alpha antagonists. Clin Infect Dis 2003; 37:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34822/abstract/22\">",
"      Rotz, LD, Slater, LN, Wack, MF, et al. Disseminated sporotrichosis with meningitis in a patient with AIDS. Infect Dis Clin Prac 1996; 5:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34822/abstract/23\">",
"      al-Tawfiq JA, Wools KK. Disseminated sporotrichosis and Sporothrix schenckii fungemia as the initial presentation of human immunodeficiency virus infection. Clin Infect Dis 1998; 26:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34822/abstract/24\">",
"      Freitas DF, de Siqueira Hoagland B, do Valle AC, et al. Sporotrichosis in HIV-infected patients: report of 21 cases of endemic sporotrichosis in Rio de Janeiro, Brazil. Med Mycol 2012; 50:170.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2431 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-8D13A6BE0D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_0_34822=[""].join("\n");
var outline_f34_0_34822=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CHOICE OF ANTIFUNGAL AGENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      LYMPHOCUTANEOUS AND CUTANEOUS SPOROTRICHOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PULMONARY SPOROTRICHOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Severe or life-threatening disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Mild to moderate disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      OSTEOARTICULAR SPOROTRICHOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MENINGEAL SPOROTRICHOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DISSEMINATED SPOROTRICHOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H172030614\">",
"      Treatment of HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TREATMENT OF PREGNANT WOMEN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TREATMENT OF CHILDREN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2431\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2431|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/2/31788\" title=\"table 1\">",
"      Sporo treatment recs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/5/38998?source=related_link\">",
"      Amphotericin B nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/60/8134?source=related_link\">",
"      Basic biology and epidemiology of sporotrichosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/11/12469?source=related_link\">",
"      Clinical features and diagnosis of sporotrichosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/41/15001?source=related_link\">",
"      Pharmacology of amphotericin B",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_0_34823="Airway stents";
var content_f34_0_34823=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Airway stents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/0/34823/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/0/34823/contributors\">",
"     Henri G Colt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/0/34823/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/0/34823/contributors\">",
"     Praveen N Mathur, MB, BS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/0/34823/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/0/34823/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/0/34823/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Airway stents, also known as tracheobronchial prostheses, are tube-shaped devices that are inserted into an airway. They are usually placed bronchoscopically and can be used to treat a variety of large airway diseases. The indications for airway stenting, types of stents, insertion technique, and potential complications are reviewed here. Other strategies for managing central airway obstruction are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/30/37351?source=see_link\">",
"     \"Diagnosis and management of central airway obstruction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21535733\">",
"    <span class=\"h1\">",
"     PATIENT SELECTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many indications for airway stenting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34823/abstract/1-13\">",
"     1-13",
"    </a>",
"    ], including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Malignant tracheobronchial obstruction in a patient who is undergoing external beam radiation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      chemotherapy, or who has exhausted his or her curative therapeutic options.",
"     </li>",
"     <li>",
"      Malignant tracheobronchial obstruction that persists despite endobronchial resection and dilation.",
"     </li>",
"     <li>",
"      Postintubation subglottic stenosis that fails endobronchial resection and dilation.",
"     </li>",
"     <li>",
"      Benign tracheal or bronchial stenosis in a patient who is not a surgical candidate, who is awaiting a response to systemic therapy, or for whom surgical resection is pending.",
"     </li>",
"     <li>",
"      Localized severe expiratory central airway collapse, such as tracheobronchomalacia or selected cases of excessive dynamic airway collapse of any etiology [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34823/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Anastomotic stricture or dehiscence following lung or heart-lung transplantation.",
"     </li>",
"     <li>",
"      Tracheal- or bronchial-esophageal fistula (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef64447 \" href=\"mobipreview.htm?39/53/40799\">",
"       image 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21535741\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Airways stents are generally inserted bronchoscopically using either general anesthesia or procedural sedation. Thus, contraindications to bronchoscopy, general anesthesia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    procedural sedation are also considered contraindications to airway stenting. These are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/15/38135?source=see_link\">",
"     \"Flexible bronchoscopy: Indications and contraindications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19817?source=see_link\">",
"     \"Overview of anesthesia and anesthetic choices\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34618?source=see_link&amp;anchor=H4#H4\">",
"     \"Procedural sedation in adults\", section on 'Contraindications and precautions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Airway stenting is also contraindicated prior to laser therapy, endobronchial electrocautery, or argon plasma coagulation because such therapies can burn or break airway stents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34823/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/47/38645?source=see_link\">",
"     \"Bronchoscopic laser resection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/11/11447?source=see_link\">",
"     \"Endobronchial electrocautery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/57/24468?source=see_link\">",
"     \"Argon plasma coagulation in the management of airway disease\"",
"    </a>",
"    .) In contrast, external beam radiation therapy and brachytherapy are NOT contraindications to airway stenting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21536560\">",
"    <span class=\"h1\">",
"     TYPES OF STENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stents are made from several different materials and are available in varying sizes and shapes. The main classes of stents are silicone stents, metal stents, and hybrid stents. The advantages and disadvantages of each are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef58596 graphicRef54642 \" href=\"mobipreview.htm?35/30/36333\">",
"     table 1A-B",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Silicone stents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Silicone stents are the type of stents that are used most commonly to manage central airway obstruction. They have several desirable qualities: they are firm, stable in high temperatures, and able to repel water. In addition, they are relatively inexpensive, well tolerated, do not break down, and resist extrinsic compression from tumor, enlarged lymph nodes, and circumferential fibrotic scars. However, silicone stents also have an undesirable quality: they tend to migrate more commonly than other types of airway stents and may require repeated bronchoscopic procedures for stent repositioning.",
"   </p>",
"   <p>",
"    Deployment of a silicone stent usually requires rigid bronchoscopy and general anesthesia, although insertion via flexible bronchoscopy has been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34823/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Multiple stents can be inserted if the airway obstruction is long. Once a stent has been deployed, it can be repositioned or removed using rigid grasping forceps.",
"   </p>",
"   <p>",
"    Silicone stents of various lengths, shapes, and diameters are available. It is advisable to have a large stock available so that the most appropriate one for each individual patient may be chosen. Custom made airway stents can be ordered from several manufacturers. In our clinical practice, we have airway stents custom made more often if the indication is a benign, complex airway stricture from granulomatosis with polyangiitis (formerly called Wegener's granulomatosis), tuberculosis, or tracheobronchomalacia, than if the indication is airway narrowing due to tracheobronchial malignancy because such patients generally live with an indwelling airway stent for a more prolonged duration.",
"   </p>",
"   <p>",
"    There are several types of silicone airway stents:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Smooth-walled Hood stent",
"      </strong>",
"      &ndash; The smooth-walled Hood stent (from the Hood Manufacturing Company) was one of the first silicone airway stents [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34823/abstract/18\">",
"       18",
"      </a>",
"      ]. It is a straight, smooth-walled silicone tube that can be ordered in varying lengths and diameters, or in the shape of a Y (",
"      <a class=\"graphic graphic_picture graphicRef58973 \" href=\"mobipreview.htm?22/41/23198\">",
"       picture 1",
"      </a>",
"      ). Newer versions of the smooth-walled Hood stent have a small flange on its proximal and distal aspects to prevent the stent from being easily displaced within the airway by coughing. Despite this modification, stent migration still occurs.",
"     </li>",
"     <li>",
"      <strong>",
"       Studded Dumon stent",
"      </strong>",
"      &ndash; The studded Dumon stent (from Novatech) has become the most widely used airway stent in the world (",
"      <a class=\"graphic graphic_picture graphicRef68066 \" href=\"mobipreview.htm?28/36/29263\">",
"       picture 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34823/abstract/19\">",
"       19",
"      </a>",
"      ]. It is manufactured in several different shapes, including straight, L-shaped, and Y-shaped [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34823/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]. The stent has small studs on its external surface to help prevent migration. These studs embed themselves slightly within the airway wall mucosa, but do not cause permanent damage. Larger diameter stents can be specially made and stent loading devices exist that assist with loading large Y-stents into the stent introducer tubes.",
"     </li>",
"     <li>",
"      <strong>",
"       Studded Hood stent",
"      </strong>",
"      &ndash; The studded Hood stent (from the Hood Manufacturing Company) contains studs in a similar configuration as the studded Dumon stent (",
"      <a class=\"graphic graphic_picture graphicRef66659 \" href=\"mobipreview.htm?27/30/28142\">",
"       picture 3",
"      </a>",
"      ). Its performance and characteristics appear to be equivalent to those of the studded Dumon stent.",
"     </li>",
"     <li>",
"      <strong>",
"       Reynders-Noppen tygon stent",
"      </strong>",
"      &ndash; The Reynders-Noppen tygon stent (from Reynders Medical Supply) is a cylindrical tygon plastic tube that has been molded into a screw-thread shape (",
"      <a class=\"graphic graphic_picture graphicRef64690 \" href=\"mobipreview.htm?10/2/10287\">",
"       picture 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34823/abstract/22\">",
"       22",
"      </a>",
"      ]. It is more rigid than the other silicone stents; thus, it must be pushed into position along the outside of a specific introducer because it cannot be folded into an applicator for bronchoscopic insertion. The Reynders-Noppen is available in Europe and Asia, but not in the United States.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The different stents have seldom been compared to one another. One study compared 50 patients with tracheal stenosis who were treated with either the studded Dumon stent or the Reynders-Noppen Tygon stent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34823/abstract/23\">",
"     23",
"    </a>",
"    ]. Stent migration occurred more often in more patients who received studded Dumon stents than in patients who received Reynders-Noppen stents (24 versus 5 percent), although the difference was not statistically significant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Metal stents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metal airway stents have several advantages over silicone stents: they are usually inserted via flexible bronchoscopy, which requires only topical airway anesthesia and procedural sedation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34823/abstract/24\">",
"     24",
"    </a>",
"    ]; metal stents rarely migrate within the tracheobronchial tree; and, self-expanding metal stents may generate sufficient force to distend even the firmest of strictures, which is helpful if the airway cannot be dilated before stent insertion.",
"   </p>",
"   <p>",
"    Metal airway stents also have disadvantages compared to silicone stents: there is greater risk of airway perforation due to their expansile force, which makes the proper selection of stent size (particularly maximal dilated diameter) essential; they are more difficult, if not impossible, to remove or reposition following deployment; granulation tissue or tumor easily grows through the spaces between the uncovered metal struts, which may lead to obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34823/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]; and, metal stents are more expensive. Complications related to metal stents have prompted a black box warning from the United States Food and Drug Administration and most operators avoid their use in patients with benign strictures. When absolutely necessary, most operators will only use covered metal airway stents.",
"   </p>",
"   <p>",
"    There are several types of metal airway stents:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Wallstent (also called the Schneider stent)",
"      </strong>",
"      &ndash; The Wallstent (from Schneider International, Ltd), is a self-expanding airway tubular mesh of cobalt-alloy braided filaments (",
"      <a class=\"graphic graphic_picture graphicRef82035 \" href=\"mobipreview.htm?1/18/1313\">",
"       picture 5",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34823/abstract/27\">",
"       27",
"      </a>",
"      ]. It is loaded into a delivery catheter and then expands and shortens upon deployment. A variety of lengths and diameters are available. Despite being an attractive option to clinicians who do not perform rigid bronchoscopy, the Wallstent is seldom used because recurrent obstruction due to the growth of tumor or granulation tissue through the spaces between the mesh is common.",
"     </li>",
"     <li>",
"      <strong>",
"       Ultraflex stent",
"      </strong>",
"      &ndash; The Ultraflex airway stent (from Boston Scientific Corporation) consists of a single layer of braided, knitted flexible nitinol (nickel-titanium alloy) wire [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34823/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]. It is deployed by gradually removing a suture that holds the stent in a compressed state. Ultraflex stents are available with or without an outer silicone covering, although the covered stent is used more often because the uncovered stent is susceptible to ingrowth by tumor or granulation tissue.",
"     </li>",
"     <li>",
"      <strong>",
"       Cook-Gianturco stent",
"      </strong>",
"      &ndash; The Cook-Gianturco stent (from Cook Instruments) is a continuous loop of stainless steel wire (",
"      <a class=\"graphic graphic_picture graphicRef76360 \" href=\"mobipreview.htm?40/7/41086\">",
"       picture 6",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34823/abstract/30,31\">",
"       30,31",
"      </a>",
"      ]. It is compressed into a narrow cylinder, which expands immediately following bronchoscopic deployment. The stent comes in varying diameters, as well as in single and double post-expansion lengths. Multiple stents can be attached to one another to bridge long lesions. The Cook-Gianturco stent maintains an expansive force once deployed and small hooks embed in the airway mucosa to retard migration. While these devices are well designed to resist migration, airway wall damage may occur after prolonged deployment and the growth of tumor or granulation tissue through the spaces between the stainless-steel wires can impair airway patency [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34823/abstract/32,33\">",
"       32,33",
"      </a>",
"      ]. The Cook-Gianturco stent is used in Asia and Europe, but it is no longer available in the United States.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Hybrid stents",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several airway stents that incorporate two or more different materials. Such hybrid airway stents were designed to remedy the drawbacks of silicone stents and metal stents described above. As an example, a hybrid airway stent may consist of expandable metal struts (resist compression) covered by a silicone membrane (limits the ingrowth of tumor or granulation tissue) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34823/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. Hybrid stents tend to be more expensive than airway stents that are made exclusively of one material.",
"   </p>",
"   <p>",
"    There are several types of hybrid stents:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Covered Wallstent",
"      </strong>",
"      &ndash; The covered Wallstent is similar to the Schneider stent that was described above, except the covered Wallstent is partially covered by a thin silicone membrane. The purpose of the membrane is to prevent the extension of tumor or granulation tissue between the thin wire struts (",
"      <a class=\"graphic graphic_picture graphicRef70395 \" href=\"mobipreview.htm?5/39/5744\">",
"       picture 7",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34823/abstract/35\">",
"       35",
"      </a>",
"      ]. The covered Wallstent is available in multiple lengths and diameters, fits into a catheter for bronchoscopic insertion, is self-expanding following deployment, and maintains its expansile force. However, it is difficult to reposition or remove.",
"     </li>",
"     <li>",
"      <strong>",
"       Dynamic&trade; Y stent",
"      </strong>",
"      &ndash; Formerly called the R&uuml;sch Y-stent, the Dynamic&trade; Y stent (from Boston Scientific Corporation) is a silicone Y-shaped airway stent that has a firm anterior wall made of horseshoe-shaped metal struts and a posterior wall made of soft silicone (",
"      <a class=\"graphic graphic_picture graphicRef68617 \" href=\"mobipreview.htm?20/60/21454\">",
"       picture 8",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34823/abstract/36\">",
"       36",
"      </a>",
"      ]. The firm anterior and soft posterior walls simulate the trachea. The Dynamic&trade; Y stent comes in three different diameters and is quite long. Its length makes it an appropriate choice for patients with significant tracheobronchomalacia or long strictures involving the trachea",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      mainstem bronchi. However, its length also makes it difficult for patients to effectively clear airway secretions and obstruction can occur. The Dynamic&trade; Y stent is a difficult stent to insert (specially designed forceps deploy the stent during rigid laryngoscopy) or remove.",
"     </li>",
"     <li>",
"      <strong>",
"       Polyflex stent",
"      </strong>",
"      &ndash; The Polyflex stent (from Boston Scientific Corporation) is a self-expanding plastic airway stent that consists of polyester mesh covered with silicone. Some are studded. The Polyflex stent is removable and causes less trauma to surrounding tissues than metal stents, which may lessen tissue hyperplasia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the development of a fistula [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34823/abstract/34\">",
"       34",
"      </a>",
"      ]. However, migration of the stent is common.",
"     </li>",
"     <li>",
"      <strong>",
"       Aero stent",
"      </strong>",
"      &ndash; Formerly called the Alveolus stent, the Aero stent (from Merit Endotek) is a hybrid stent that consists of a covered piece of nitinol that may comply with irregular airway anatomy better than other stents. It is inserted using a specially designed deployment device and an airway measuring device, during either rigid bronchoscopy or flexible bronchoscopy with fluoroscopic guidance. The cost of the Aero stent is high compared to silicone airway stents and has a high migration rate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34823/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21536308\">",
"    <span class=\"h1\">",
"     INSERTION TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;An airway lesion that requires stenting is generally detected by diagnostic flexible bronchoscopy. Indications, contraindications, and flexible bronchoscopic techniques are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/15/38135?source=see_link\">",
"     \"Flexible bronchoscopy: Indications and contraindications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/50/43816?source=see_link\">",
"     \"Flexible bronchoscopy: Equipment, procedure, and complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whenever a lesion amenable to stenting is identified, the distance from the vocal cords to the lesion, the length of the lesion, and the diameter of the lesion should be measured (",
"    <a class=\"graphic graphic_movie graphicRef62908 \" href=\"mobipreview.htm?19/47/20223\">",
"     movie 1",
"    </a>",
"    ). Once this is complete, the optimal airway stent (type and size) can be selected and insertion planned. The choice of an airway stent is usually based upon operator preference. Considerations include cost, availability, and experience. Insertion of the airway stent may be part of a bronchoscopic intervention (eg, dilatation, cryosurgery, electrosurgery, or laser resection) or may be done days or weeks later as a palliative measure if the lesion recurs (",
"    <a class=\"graphic graphic_movie graphicRef60271 \" href=\"mobipreview.htm?28/39/29309\">",
"     movie 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34823/abstract/38\">",
"     38",
"    </a>",
"    ]. These approaches are equally acceptable and depend upon the clinical circumstances and the patient&rsquo;s preferences.",
"   </p>",
"   <p>",
"    If a stenotic lesion cannot be resected, dilation should be performed prior to stenting. This allows the stent of greatest diameter to be inserted. If the rigidity of a lesion makes dilation unsafe or impractical, sequential stents of increasing size can be inserted instead. This is best accomplished with silicone stents because they are easily removed and replaced. A self-expanding metal stent is a reasonable alternative that may restore airway patency; however, the United States Food and Drug Administration issued a warning regarding use of metal airway stents in patients with benign airway disorders due to reports of metallic airway stent complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34823/abstract/37,39,40\">",
"     37,39,40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27126?source=see_link\">",
"     \"Flexible bronchoscopy balloon dilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Occasionally, identification of the critically narrowed airway segment (ie, the \"choke point\") is difficult during bronchoscopy. Sequential multimodality assessment with spirometry, ultrathin bronchoscopy, and endobronchial ultrasound can be used to guide placement of an airway stent over the choke point, but this approach is technically difficult and experimental [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34823/abstract/41\">",
"     41",
"    </a>",
"    ]. In addition, the choke point may migrate following stent placement, requiring revision or placement of a second stent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H856793\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any patient with an airway stent who develops new respiratory symptoms (eg, cough, dyspnea) should undergo bronchoscopy to determine whether the airway is patent and the stent is in the correct position (",
"    <a class=\"graphic graphic_table graphicRef75119 \" href=\"mobipreview.htm?10/48/11019\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34823/abstract/5\">",
"     5",
"    </a>",
"    ]. The role of surveillance bronchoscopy two to three months after stent placement is controversial because its yield in detecting major stent-related complications in asymptomatic individuals appears to be small [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34823/abstract/42\">",
"     42",
"    </a>",
"    ]. In our practice, we have a low threshold to perform bronchoscopy, but we do not perform routine surveillance bronchoscopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21536315\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most airway stents are well tolerated. The following complications can occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34823/abstract/43-45\">",
"     43-45",
"    </a>",
"    ], but serious life-threatening complications are rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34823/abstract/46\">",
"     46",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A local inflammatory reaction can be provoked, resulting in the growth of granulation tissue at the proximal and distal ends of the stent (",
"      <a class=\"graphic graphic_picture graphicRef75967 \" href=\"mobipreview.htm?32/15/33023\">",
"       picture 9",
"      </a>",
"      ). It is uncertain if corticosteroids given at the time of stent placement diminish the inflammatory reaction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34823/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Obstruction of the stent by accumulated respiratory secretions or recurrent tumor growth.",
"     </li>",
"     <li>",
"      Migration of the stent, usually due to a violent or persistent cough, tumor growth, or resolution of the extrinsic compression that maintained the stent in position.",
"     </li>",
"     <li>",
"      Airway wall perforation or stent rupture from self-expanding metal stents.",
"     </li>",
"     <li>",
"      Broken wires or metal fatigue (ie, decreased strength).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Stents that cause significant complications can sometimes be removed and replaced. However, the removal process itself can be difficult, particularly with metal airway stents. In an observational study conducted over ten years, 58 percent of procedures to remove a metal stent had a complication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34823/abstract/47\">",
"     47",
"    </a>",
"    ]. The most common complication was re-obstruction (46 percent), followed by post-procedure respiratory failure (33 percent), a mucosal tear (16 percent), and tension pneumothorax (2 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H856714\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Airway stents mitigate or prevent external compression and airway narrowing. By widening a stenotic airway, the symptoms and signs of central airway obstruction (eg, dyspnea, cough,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    respiratory insufficiency) decrease or resolve immediately [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34823/abstract/1,2,48-53\">",
"     1,2,48-53",
"    </a>",
"    ], while lung function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34823/abstract/54-58\">",
"     54-58",
"    </a>",
"    ], exercise capacity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34823/abstract/59\">",
"     59",
"    </a>",
"    ], and quality of life improve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34823/abstract/1,2,48-53\">",
"     1,2,48-53",
"    </a>",
"    ]. Airway stents may also impede the extension of tumor into the airway lumen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Airway stents, also known as tracheobronchial prostheses, are tube-shaped devices that are inserted into an airway and used to treat a variety of large airway diseases. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are many indications for airway stenting, including malignant tracheobronchial obstruction, postintubation subglottic stenosis, benign tracheal or bronchial stenosis, localized severe expiratory central airway collapse, anastomotic stricture or dehiscence following lung or heart-lung transplantation, and tracheal- or bronchial-esophageal fistula. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Contraindications to bronchoscopy, general anesthesia,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      procedural sedation are also considered contraindications to airway stenting. In addition, airway stenting is contraindicated prior to laser therapy, endobronchial electrocautery, or argon plasma coagulation because such therapies can burn or break airway stents. (See",
"      <a class=\"local\" href=\"#H21535741\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Stents are made from several different materials and are available in varying sizes and shapes. The main classes of stents are silicone stents, metal stents, and hybrid stents. The advantages and disadvantages of each are summarized in the table (",
"      <a class=\"graphic graphic_table graphicRef58596 graphicRef54642 \" href=\"mobipreview.htm?35/30/36333\">",
"       table 1A-B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21536560\">",
"       'Types of stents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The choice of an airway stent is usually based upon operator preference. Airway stents are often inserted as part of a bronchoscopic intervention, such as dilatation, cryosurgery, electrosurgery, or laser resection. However, they may be placed days or weeks later as a palliative measure if the lesion recurs. (See",
"      <a class=\"local\" href=\"#H21536308\">",
"       'Insertion technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Any patient with an airway stent who develops new respiratory symptoms (eg, cough, dyspnea) should undergo bronchoscopy to determine whether the airway is patent and the stent is in the correct position. However, for patients without respiratory symptoms, we suggest NOT performing routine surveillance bronchoscopy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H856793\">",
"       'Follow-up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serious life-threatening complications due to airway stents are rare. Occasional complications include a local inflammatory reaction, obstruction of the stent by secretions or recurrent tumor growth, migration of the stent, airway perforation, or stent rupture. (See",
"      <a class=\"local\" href=\"#H21536315\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      By widening a stenotic airway, airway stents decrease or eliminate the symptoms and signs of central airway obstruction (eg, dyspnea, cough,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      respiratory insufficiency), while improving lung function, exercise capacity, and quality of life. (See",
"      <a class=\"local\" href=\"#H856714\">",
"       'Outcomes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/1\">",
"      Bolliger CT, Mathur PN, Beamis JF, et al. ERS/ATS statement on interventional pulmonology. European Respiratory Society/American Thoracic Society. Eur Respir J 2002; 19:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/2\">",
"      Ernst A, Silvestri GA, Johnstone D, American College of Chest Physicians. Interventional pulmonary procedures: Guidelines from the American College of Chest Physicians. Chest 2003; 123:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/3\">",
"      Puma F, Ragusa M, Avenia N, et al. The role of silicone stents in the treatment of cicatricial tracheal stenoses. J Thorac Cardiovasc Surg 2000; 120:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/4\">",
"      Saad CP, Murthy S, Krizmanich G, Mehta AC. Self-expandable metallic airway stents and flexible bronchoscopy: long-term outcomes analysis. Chest 2003; 124:1993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/5\">",
"      Colt HG, Dumon JF. Airway stents. Present and future. Clin Chest Med 1995; 16:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/6\">",
"      Chhajed PN, Malouf MA, Tamm M, Glanville AR. Ultraflex stents for the management of airway complications in lung transplant recipients. Respirology 2003; 8:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/7\">",
"      Saad CP, Ghamande SA, Minai OA, et al. The role of self-expandable metallic stents for the treatment of airway complications after lung transplantation. Transplantation 2003; 75:1532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/8\">",
"      Noppen M, Poppe K, D'Haese J, et al. Interventional bronchoscopy for treatment of tracheal obstruction secondary to benign or malignant thyroid disease. Chest 2004; 125:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/9\">",
"      Chan KP, Eng P, Hsu AA, et al. Rigid bronchoscopy and stenting for esophageal cancer causing airway obstruction. Chest 2002; 122:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/10\">",
"      Wan IY, Lee TW, Lam HC, et al. Tracheobronchial stenting for tuberculous airway stenosis. Chest 2002; 122:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/11\">",
"      Low SY, Hsu A, Eng P. Interventional bronchoscopy for tuberculous tracheobronchial stenosis. Eur Respir J 2004; 24:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/12\">",
"      Carden KA, Boiselle PM, Waltz DA, Ernst A. Tracheomalacia and tracheobronchomalacia in children and adults: an in-depth review. Chest 2005; 127:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/13\">",
"      Mughal MM, Gildea TR, Murthy S, et al. Short-term deployment of self-expanding metallic stents facilitates healing of bronchial dehiscence. Am J Respir Crit Care Med 2005; 172:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/14\">",
"      Murgu SD, Colt HG. Tracheobronchomalacia and excessive dynamic airway collapse. Respirology 2006; 11:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/15\">",
"      Colt HG, Crawford SW. In vitro study of the safety limits of bronchoscopic argon plasma coagulation in the presence of airway stents. Respirology 2006; 11:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/16\">",
"      Strausz, J, Kis, S, Papai, Z, et al. Tracheobronchial silicone stent implantation with the flexible bronchoscope. J Bronchol 1994; 1:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/17\">",
"      Nomori H, Horio H, Suemasu K. Dumon stent placement via endotracheal tube. Chest 1999; 115:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/18\">",
"      Cooper JD, Pearson FG, Patterson GA, et al. Use of silicone stents in the management of airway problems. Ann Thorac Surg 1989; 47:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/19\">",
"      Dumon JF. A dedicated tracheobronchial stent. Chest 1990; 97:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/20\">",
"      Dutau H, Toutblanc B, Lamb C, Seijo L. Use of the Dumon Y-stent in the management of malignant disease involving the carina: a retrospective review of 86 patients. Chest 2004; 126:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/21\">",
"      Oki M, Saka H. Double Y-stenting for tracheobronchial stenosis. Eur Respir J 2012; 40:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/22\">",
"      Noppen, M, Dhaese, J, Meysman, M, et al. A new screw thread tracheal endoprosthesis. J Bronchol 1996; 3:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/23\">",
"      Noppen M, Meysman M, Claes I, et al. Screw-thread vs Dumon endoprosthesis in the management of tracheal stenosis. Chest 1999; 115:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/24\">",
"      Coolen D, Slabbynck H, Galdermans D, et al. Insertion of a self-expandable endotracheal metal stent using topical anaesthesia and a fibreoptic bronchoscope: a comfortable way to offer palliation. Thorax 1994; 49:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/25\">",
"      de Mello-Filho FV, Antonio SM, Carrau RL. Endoscopically placed expandable metal tracheal stents for the management of complicated tracheal stenosis. Am J Otolaryngol 2003; 24:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/26\">",
"      Lunn W, Feller-Kopman D, Wahidi M, et al. Endoscopic removal of metallic airway stents. Chest 2005; 127:2106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/27\">",
"      Rousseau H, Dahan M, Lauque D, et al. Self-expandable prostheses in the tracheobronchial tree. Radiology 1993; 188:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/28\">",
"      Miyazawa T, Yamakido M, Ikeda S, et al. Implantation of ultraflex nitinol stents in malignant tracheobronchial stenoses. Chest 2000; 118:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/29\">",
"      Madden BP, Park JE, Sheth A. Medium-term follow-up after deployment of ultraflex expandable metallic stents to manage endobronchial pathology. Ann Thorac Surg 2004; 78:1898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/30\">",
"      Varela A, Maynar M, Irving D, et al. Use of Gianturco self-expandable stents in the tracheobronchial tree. Ann Thorac Surg 1990; 49:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/31\">",
"      Stockton PA, Ledson MJ, Hind CR, Walshaw MJ. Bronchoscopic insertion of Gianturco stents for the palliation of malignant lung disease: 10 year experience. Lung Cancer 2003; 42:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/32\">",
"      Puma F, Farabi R, Urbani M, et al. Long-term safety and tolerance of silicone and self-expandable airway stents: an experimental study. Ann Thorac Surg 2000; 69:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/33\">",
"      Gaissert HA, Grillo HC, Wright CD, et al. Complication of benign tracheobronchial strictures by self-expanding metal stents. J Thorac Cardiovasc Surg 2003; 126:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/34\">",
"      Bolliger CT, Breitenbuecher A, Brutsche M, et al. Use of studded Polyflex stents in patients with neoplastic obstructions of the central airways. Respiration 2004; 71:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/35\">",
"      Bolliger, CT, Arnoux, A, Oeggerli, MV, et al. Covered Wallstent insertion in a patient with conical tracheobronchial stenosis. J Bronchol 1995; 2:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/36\">",
"      Freitag L, Eicker R, Linz B, Greschuchna D. Theoretical and experimental basis for the development of a dynamic airway stent. Eur Respir J 1994; 7:2038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/37\">",
"      Dooms C, De Keukeleire T, Janssens A, Carron K. Performance of fully covered self-expanding metallic stents in benign airway strictures. Respiration 2009; 77:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/38\">",
"      Dumon, JF, Cavaliere, S, Diaz-Jimenez, JP, et al. Seven year experience with the Dumon prosthesis. J Bronchol 1996; 3:6.",
"     </a>",
"    </li>",
"    <li>",
"     Food and Drug Administration. FDA public health notification: complications from metallic tracheal stents in patients with benign airway disorders, 2005 www.fda.gov/cdrh/safety/072905-tracheal.html (Accessed on January 15, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/40\">",
"      Madden BP, Loke TK, Sheth AC. Do expandable metallic airway stents have a role in the management of patients with benign tracheobronchial disease? Ann Thorac Surg 2006; 82:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/41\">",
"      Miyazawa T, Miyazu Y, Iwamoto Y, et al. Stenting at the flow-limiting segment in tracheobronchial stenosis due to lung cancer. Am J Respir Crit Care Med 2004; 169:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/42\">",
"      Matsuo T, Colt HG. Evidence against routine scheduling of surveillance bronchoscopy after stent insertion. Chest 2000; 118:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/43\">",
"      Zakaluzny SA, Lane JD, Mair EA. Complications of tracheobronchial airway stents. Otolaryngol Head Neck Surg 2003; 128:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/44\">",
"      Burningham AR, Wax MK, Andersen PE, et al. Metallic tracheal stents: complications associated with long-term use in the upper airway. Ann Otol Rhinol Laryngol 2002; 111:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/45\">",
"      Lemaire A, Burfeind WR, Toloza E, et al. Outcomes of tracheobronchial stents in patients with malignant airway disease. Ann Thorac Surg 2005; 80:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/46\">",
"      Ranu H, Madden BP. Endobronchial stenting in the management of large airway pathology. Postgrad Med J 2009; 85:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/47\">",
"      Alazemi S, Lunn W, Majid A, et al. Outcomes, health-care resources use, and costs of endoscopic removal of metallic airway stents. Chest 2010; 138:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/48\">",
"      Ernst A, Feller-Kopman D, Becker HD, Mehta AC. Central airway obstruction. Am J Respir Crit Care Med 2004; 169:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/49\">",
"      Wood DE, Liu YH, Valli&egrave;res E, et al. Airway stenting for malignant and benign tracheobronchial stenosis. Ann Thorac Surg 2003; 76:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/50\">",
"      Rafanan AL, Mehta AC. Stenting of the tracheobronchial tree. Radiol Clin North Am 2000; 38:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/51\">",
"      Profili S, Manca A, Feo CF, et al. Palliative airway stenting performed under radiological guidance and local anesthesia. Cardiovasc Intervent Radiol 2007; 30:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/52\">",
"      Cosano Povedano A, Mu&ntilde;oz Cabrera L, Cosano Povedano FJ, et al. [Endoscopic treatment of central airway stenosis: five years' experience]. Arch Bronconeumol 2005; 41:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/53\">",
"      Thornton RH, Gordon RL, Kerlan RK, et al. Outcomes of tracheobronchial stent placement for benign disease. Radiology 2006; 240:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/54\">",
"      Eisner MD, Gordon RL, Webb WR, et al. Pulmonary function improves after expandable metal stent placement for benign airway obstruction. Chest 1999; 115:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/55\">",
"      Gelb AF, Zamel N, Colchen A, et al. Physiologic studies of tracheobronchial stents in airway obstruction. Am Rev Respir Dis 1992; 146:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/56\">",
"      Hauck RW, R&ouml;mer W, Schulz C, et al. Ventilation perfusion scintigraphy and lung function testing to assess metal stent efficacy. J Nucl Med 1997; 38:1584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/57\">",
"      Vergnon JM, Costes F, Bayon MC, Emonot A. Efficacy of tracheal and bronchial stent placement on respiratory functional tests. Chest 1995; 107:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/58\">",
"      Breitenb&uuml;cher A, Chhajed PN, Brutsche MH, et al. Long-term follow-up and survival after Ultraflex stent insertion in the management of complex malignant airway stenoses. Respiration 2008; 75:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34823/abstract/59\">",
"      Madden, BP, Sheth, A, Walters, N. Does large airway intervention for patients with malignant disease result in early clinical benefit? Am J Respir Crit Care Med 2007; 175:A622.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4403 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-F7325097AE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_0_34823=[""].join("\n");
var outline_f34_0_34823=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21535733\">",
"      PATIENT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21535741\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21536560\">",
"      TYPES OF STENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Silicone stents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Metal stents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Hybrid stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21536308\">",
"      INSERTION TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H856793\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21536315\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H856714\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4403\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4403|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?39/53/40799\" title=\"diagnostic image 1\">",
"      Bronchogenic carcinoma CT III",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4403|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?22/41/23198\" title=\"picture 1\">",
"      Hood silicone stent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?28/36/29263\" title=\"picture 2\">",
"      Dumon silicone stent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/30/28142\" title=\"picture 3\">",
"      Hood silicone stent studded",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?10/2/10287\" title=\"picture 4\">",
"      Reynders Noppen Tygon stent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?1/18/1313\" title=\"picture 5\">",
"      Schneider tracheal stent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?40/7/41086\" title=\"picture 6\">",
"      Cook Gianturco Z stent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?5/39/5744\" title=\"picture 7\">",
"      Schneider silicone stent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/60/21454\" title=\"picture 8\">",
"      Dynamic Y stent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/15/33023\" title=\"picture 9\">",
"      Granulation tissue nr stent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4403|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?19/47/20223\" title=\"movie 1\">",
"      Bronchial obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?28/39/29309\" title=\"movie 2\">",
"      Airway stent deployment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4403|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/58/42923\" title=\"table 1A\">",
"      Types of airway stents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/29/4573\" title=\"table 1B\">",
"      Commercially available stents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/48/11019\" title=\"table 2\">",
"      Airway stent complications",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/57/24468?source=related_link\">",
"      Argon plasma coagulation in the management of airway disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/47/38645?source=related_link\">",
"      Bronchoscopic laser resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/30/37351?source=related_link\">",
"      Diagnosis and management of central airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/11/11447?source=related_link\">",
"      Endobronchial electrocautery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27126?source=related_link\">",
"      Flexible bronchoscopy balloon dilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/50/43816?source=related_link\">",
"      Flexible bronchoscopy: Equipment, procedure, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/15/38135?source=related_link\">",
"      Flexible bronchoscopy: Indications and contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19817?source=related_link\">",
"      Overview of anesthesia and anesthetic choices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34618?source=related_link\">",
"      Procedural sedation in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_0_34824="Occupational asthma: Definitions, epidemiology, causes, and risk factors";
var content_f34_0_34824=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Occupational asthma: Definitions, epidemiology, causes, and risk factors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/0/34824/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/0/34824/contributors\">",
"     Moira Chan-Yeung, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/0/34824/contributors\">",
"     Jean-Luc Malo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/0/34824/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/0/34824/contributors\">",
"     Peter J Barnes, DM, DSc, FRCP, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/0/34824/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/0/34824/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/0/34824/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occupational asthma (OA) is a form of work-related asthma characterized by variable airflow obstruction, airway hyperresponsiveness, and airway inflammation attributable to a particular exposure in the workplace and not due to stimuli encountered outside the workplace [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Occupational asthma accounts for approximately 10 to 25 percent of adult onset asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. A high degree of clinical suspicion is needed as the latency period for sensitization varies from a few months to several years, depending on several factors, including the intensity of exposure, the specific sensitizing agent, and individual susceptibility.",
"   </p>",
"   <p>",
"    The definition, epidemiology, causes, and risk factors of OA are reviewed here. The pathophysiology, clinical assessment, diagnosis, and management of OA are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38903?source=see_link\">",
"     \"Occupational asthma: Pathogenesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/15/36089?source=see_link\">",
"     \"Occupational asthma: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several terms are used to define the various forms of work-related asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Occupational asthma (OA) begins during adulthood and is induced by exposure to immunologic or non-immunologic stimuli found in the workplace [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Work-exacerbated asthma (also known as work-aggravated asthma) is defined as preexisting or concurrent asthma that subjectively worsens in the workplace [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/1/19482?source=see_link\">",
"       \"Diagnosis of asthma in adolescents and adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Irritant-induced asthma results from single or multiple exposures to a nonimmunologic, irritant substance at a high level of intensity. When workplace exposure(s) cause irritant-induced asthma, it is considered a subset of occupational asthma. However, the airway histopathology is different from immunologic OA (",
"      <a class=\"graphic graphic_table graphicRef80475 \" href=\"mobipreview.htm?18/17/18715\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/28/8650?source=see_link\">",
"       \"Reactive airways dysfunction syndrome and irritant-induced asthma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Reactive airways dysfunction syndrome (RADS) is a form of irritant-induced asthma that is triggered by a single acute high level exposure to a nonimmunologic stimulus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/7\">",
"       7",
"      </a>",
"      ]. Symptoms begin within minutes of the exposure, and the initial symptoms are followed by on-going asthma-like symptoms and bronchial hyperresponsiveness that last for a prolonged period. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/28/8650?source=see_link&amp;anchor=H2#H2\">",
"       \"Reactive airways dysfunction syndrome and irritant-induced asthma\", section on 'Definitions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Occupational nonasthmatic eosinophilic bronchitis is an asthma variant that develops in the workplace and causes symptoms that mimic asthma, but is not associated with bronchial hyperresponsiveness. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/18/5418?source=see_link&amp;anchor=H13#H13\">",
"       \"Evaluation of subacute and chronic cough in adults\", section on 'Nonasthmatic eosinophilic bronchitis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In immunologic occupational asthma, sensitization refers to the development of specific antigen recognition via elaboration of specific IgE antibodies or cellular immune mechanisms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31848?source=see_link\">",
"     \"The biology of IgE\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/52/4937?source=see_link\">",
"     \"Pathogenesis of asthma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38903?source=see_link&amp;anchor=H5#H5\">",
"     \"Occupational asthma: Pathogenesis\", section on 'Immunologic mechanisms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occupational asthma (OA) is the most common occupational lung disease in developed countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/8\">",
"     8",
"    </a>",
"    ]. A number of factors appear to influence the incidence and prevalence of OA, including gender, geographic location, underlying prevalence of atopy, and type of workplace exposures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several studies have reported on the proportion of asthma attributable to occupational exposure. Most estimates are in the range of 5 to 10 percent of adult onset asthma, although a wide range of rates have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. Based on data from the 2006-2009 Behavioral Risk Factor Surveillance System, the proportion of ever-employed adults with work-related asthma in the United States is 9 percent with a variation of 5 to 14 percent among individual states [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/13\">",
"     13",
"    </a>",
"    ]. The European Community Respiratory Health Survey (ECRHS) found a work-attributable risk of asthma of 10 to 25 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. The variability of prevalence rates probably reflects differences in methodology, case definitions, and immunogenicity of specific workplace agents. Furthermore, the fact that asthma is a common disease that often presents de novo or worsens during adulthood due to non-occupational factors, further complicates epidemiologic assessment of OA. Based on the European Community Respiratory Health Survey results, it was estimated that occupational exposures contribute to one in seven cases of severe exacerbation of asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of gender on the reported incidence of OA was examined in a 12 year study in Finland [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/11\">",
"     11",
"    </a>",
"    ]. The risk of OA among men was highest among bakers, laundry workers, shoemakers and shoe repairers, tanners, fellmongers and pelt dressers (removing fur from hides for leather work), and also metal plating and coating workers. For the women, the risk was highest among shoemakers and repairers, railway and station personnel, jewelry engravers, engine room crew, molders, round-timber workers, and bakers.",
"   </p>",
"   <p>",
"    The geographic location influences the distribution of asthma and bronchial responsiveness in the population and, thus, the prevalence of OA. As an example, there is a low prevalence of OA, atopy, and bronchial hyperresponsiveness in Mediterranean and Eastern European countries, compared with English-speaking countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several cross-sectional studies of populations at high risk of developing OA demonstrate that approximately 2 to 8 percent per person-year of those exposed to high-molecular-weight (proteinaceous) agents, such as laboratory animals, latex, and flour, and 5 to 10 percent of subjects exposed to low-molecular-weight (chemical) agents develop OA (",
"    <a class=\"graphic graphic_table graphicRef66185 \" href=\"mobipreview.htm?27/53/28508\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/9,10,15,16\">",
"     9,10,15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The proportion of individuals with asthma who have worsening asthma symptoms at work (work-exacerbated asthma) is approximately 10 percent. This figure was derived from a meta-analysis of 43 risk estimates from 19 different countries that suggested that 10 percent of all adult-onset asthma cases appear to be occupationally related [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1191269\">",
"    <span class=\"h1\">",
"     CAUSATIVE AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The agents that cause OA include a wide variety of airborne agents in the workplace [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/18\">",
"     18",
"    </a>",
"    ]. More than 350 agents have been reported to cause OA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/4\">",
"     4",
"    </a>",
"    ]. Common workplace stimuli are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef66185 \" href=\"mobipreview.htm?27/53/28508\">",
"     table 2",
"    </a>",
"    ) and a more complete list is available online (",
"    <a class=\"external\" href=\"file://www.asthme.csst.qc.ca/document/Info_Med/IdCauses/Bernstein/AgentsAnglais.pdf\">",
"     file://www.asthme.csst.qc.ca/document/Info_Med/IdCauses/Bernstein/AgentsAnglais.pdf",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Stimuli that cause immunologic OA are divided into two categories, high and low-molecular-weight agents. Flour (high-molecular-weight agent) and isocyanates (low-molecular-weight compounds used in plastics and rubber manufacturing) are the most common causative agents in developed countries, accounting for approximately 20 percent of OA cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/8,19\">",
"     8,19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38903?source=see_link&amp;anchor=H5#H5\">",
"     \"Occupational asthma: Pathogenesis\", section on 'Immunologic mechanisms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nonimmunologic causes of OA include a large number of irritant gases, fumes, smoke, and aerosols. These are discussed separately (",
"    <a class=\"graphic graphic_table graphicRef55545 \" href=\"mobipreview.htm?34/4/34893\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef68367 \" href=\"mobipreview.htm?31/32/32269\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/28/8650?source=see_link&amp;anchor=H2#H2\">",
"     \"Reactive airways dysfunction syndrome and irritant-induced asthma\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H344156415\">",
"    <span class=\"h2\">",
"     High-molecular-weight",
"    </span>",
"    &nbsp;&mdash;&nbsp;High-molecular-weight (HMW) agents include proteins and polysaccharides of plant or animal origin (&gt;5-10 kD) that are complete sensitizing antigens, capable of causing IgE-dependent OA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/4\">",
"     4",
"    </a>",
"    ]. Thus, they require an initial period of exposure, elaboration of specific IgE antibodies, presence of these specific antibodies on the surface of airway mast cells, and activation of the mast cells following re-exposure to the antigen leading to the clinical features of occupational asthma (",
"    <a class=\"graphic graphic_algorithm graphicRef80111 \" href=\"mobipreview.htm?2/63/3071\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38903?source=see_link&amp;anchor=H6#H6\">",
"     \"Occupational asthma: Pathogenesis\", section on 'IgE-mediated'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    A list of the most common causes of OA due to HMW compounds is provided in the table (",
"    <a class=\"graphic graphic_table graphicRef66185 \" href=\"mobipreview.htm?27/53/28508\">",
"     table 2",
"    </a>",
"    ). The main classes of HMW compounds associated with OA and the associated occupations are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Animals",
"      </strong>",
"      &ndash; Laboratory and farm animal workers are exposed to animal proteins from",
"      <span class=\"nowrap\">",
"       fur/hair,",
"      </span>",
"      saliva, urine, and dander [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/18,20\">",
"       18,20",
"      </a>",
"      ]. Proteins excreted in animal urine are a common cause of sensitization among laboratory and veterinary workers. A personal history of sensitization to dogs or cats is a risk factor for laboratory animal sensitization, although general atopy is less predictive [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/18\">",
"       18",
"      </a>",
"      ]. The role of concomitant exposure to endotoxin in rates of sensitization and symptomatology is not known.",
"     </li>",
"     <li>",
"      <strong>",
"       Fish and shellfish",
"      </strong>",
"      &ndash; Occupations with exposure to fish and shellfish can lead to occupational asthma, particularly crab and lobster processing.",
"     </li>",
"     <li>",
"      <strong>",
"       Flours and cereals",
"      </strong>",
"      &ndash; Bakers, food processors, and dock workers are at risk for OA from flours and cereals due to intrinsic proteins of the flour and also",
"      <span class=\"nowrap\">",
"       additives/contaminants",
"      </span>",
"      such as mites and enzymes (see below) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Enzymes",
"      </strong>",
"      &ndash; Enzymes are used in a variety of occupations, such as detergent manufacturing (amylases, lipases, proteases), pharmaceutical preparation, and baking (amylase) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/8,18,21\">",
"       8,18,21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <strong>",
"       Natural rubber latex",
"      </strong>",
"      &ndash; Natural rubber latex, which is derived from the rubber tree Hevea brasiliensis (Hev b), can induce IgE-mediated anaphylaxis, allergic contact dermatitis, rhinitis, and occupational asthma. Healthcare workers have the highest rate of sensitization to latex. A description of the Hevea latex allergens and the evaluation and management of patients with latex-associated respiratory complaints are described separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/35/9785?source=see_link\">",
"       \"Latex allergy: Epidemiology, clinical manifestations, and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40070?source=see_link\">",
"       \"Latex allergy: Management\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Dermatitis is uncommon among workers with OA due to HMW compounds, although a history of contact dermatitis to latex is reported by some workers with latex OA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H344156515\">",
"    <span class=\"h2\">",
"     Low-molecular-weight",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low-molecular-weight chemicals (eg, isocyanates, trimellitic anhydride, formaldehyde) are incomplete antigens (ie, haptens) that combine with a human protein to produce a sensitizing neoantigen (",
"    <a class=\"graphic graphic_table graphicRef66185 \" href=\"mobipreview.htm?27/53/28508\">",
"     table 2",
"    </a>",
"    ). In addition, some of these agents also appear to cause OA through a non-IgE mechanism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38903?source=see_link&amp;anchor=H5#H5\">",
"     \"Occupational asthma: Pathogenesis\", section on 'Immunologic mechanisms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common LMW chemicals that cause OA include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acid anhydrides &ndash; Phthalic anhydride, trimellitic anhydride, maleic anhydride, and tetrachlorophthalic anhydride are used in the manufacture of plastics, epoxy resins, and some dyes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/3,18\">",
"       3,18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cleaning agents &ndash; A variety of cleaning agents are used by professional and domestic cleaners, including",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/62/33763?source=see_link\">",
"       hexachlorophene",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/36/12870?source=see_link\">",
"       chlorhexidine",
"      </a>",
"      , hypochlorite, quaternary ammonium compounds, and formaldehyde. Perfumes (eg, D-limonene, terpenes) are often added to the cleaning agents and may also cause sensitization [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/18\">",
"       18",
"      </a>",
"      ]. As some cleaning agents are irritants, they may contribute to work-exacerbated asthma due to the irritant effect rather than via actual sensitization.",
"     </li>",
"     <li>",
"      Isocyanates &ndash; Toluene diisocyanate, methylene diphenyl diisocyanate, and hexamethylene diisocyanate are used in polyurethane and plastics production, spray painting, foam coating manufacturing, and",
"      <span class=\"nowrap\">",
"       adhesive/sealant",
"      </span>",
"      production use [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Platinum salts &ndash; Jewelry, alloy, and catalyst workers are exposed to platinum salts [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Colophony &ndash; Abietic acid is derived from pine trees and is the sensitizing chemical in colophony, which is used as flux in soldering by electronic workers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/18\">",
"       18",
"      </a>",
"      ]. It is highly sensitizing, as the prevalence of respiratory symptoms among electronic workers is 22 percent. Four years after cessation of exposure, half of workers with colophony-induced OA continue to have symptoms.",
"     </li>",
"     <li>",
"      Plicatic acid &ndash; Plicatic acid is the sensitizing chemical in Western red cedar [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/18\">",
"       18",
"      </a>",
"      ]. Sawmill workers, carpenters, woodcarvers, and furniture makers who work with Western red cedar and certain other species of cedar are all at risk for OA. Workers exposed to oak or mahogany wood dust are also at risk for OA, but the sensitizing chemical is not known. It appears likely that an immunologic mechanism contributes to the pathogenesis of plicatic acid OA as certain HLA class II antigens are associated with increased risk and others with relative protection. However, specific IgE has only been identified in a small portion of affected workers. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/22/44391?source=see_link&amp;anchor=H4#H4\">",
"       \"Overview of in vitro allergy tests\", section on 'Immunoassays'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Persulfate salts &ndash; Persulfate salts are the major causative agents of OA in hairdressers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/22,23\">",
"       22,23",
"      </a>",
"      ]. Skin prick and patch tests to persulfate are variably positive [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/22,23\">",
"       22,23",
"      </a>",
"      ]. Specific bronchial provocation challenge to persulfate salts in the laboratory yields early, late, and dual responses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/22-24\">",
"       22-24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/31/26104?source=see_link&amp;anchor=H16#H16\">",
"       \"Contact dermatitis in children\", section on 'Patch testing'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/15/36089?source=see_link&amp;anchor=H13#H13\">",
"       \"Occupational asthma: Clinical features and diagnosis\", section on 'Specific bronchoprovocation challenge'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/4/1098?source=see_link&amp;anchor=H26846610#H26846610\">",
"       \"Bronchoprovocation testing\", section on 'Antigen challenge'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H344157047\">",
"    <span class=\"h2\">",
"     Combined exposures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Workers in certain professions (eg, bakers, health care workers, auto body repair, hairdressers) may be exposed to several different sensitizers and these may be of both high and low -molecular-weight [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among bakers, OA associated with wheat flour inhalation may be caused by sensitization to &omega;-5 gliadin (Tri a 19), &alpha;-amylase inhibitors, thioredoxins (cross react with grass allergens), wheat lipid transfer protein (Tri a 14), wheat serine protease inhibitor, mites, and baking additives such as fungal &alpha;-amylase (Asp o 21) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. Furthermore, partial homology between wheat thioredoxins and human thioredoxins may lead to cross-reactivity of the specific IgE and perpetuation of the IgE-mediated mast cell activation after removal from airborne wheat exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Health care workers may be exposed to latex, glutaraldehyde (instrument sterilization), antibiotics,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/26/8614?source=see_link\">",
"     psyllium",
"    </a>",
"    , aerosolized medications (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    ), methacrylates (orthopedic adhesives), methylene diphenyl diisocyanate (synthetic plaster casts), metals in dental alloys, formaldehyde, and quaternary ammonium compounds (cleaning agents) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/18,28\">",
"     18,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Workers in auto body repair shops are often exposed to isocyanates (polyurethane, spray paints), acrylates (adhesives), amines (polyurethane, epoxies), and anhydrides (epoxy resin, dye) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to persulfate salts, hairdressers are exposed to bleaching agents, henna dye, latex, and also secondary, tertiary, and quaternary amines (in hair dyes) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/18,22,23\">",
"     18,22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H866399125\">",
"    <span class=\"h1\">",
"     OCCUPATIONAL RISK FACTORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H866399132\">",
"    <span class=\"h2\">",
"     Exposure intensity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intensity of the exposure is the most important factor in the development of OA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/10\">",
"     10",
"    </a>",
"    ]. A dose-response relationship between the exposure and both the prevalence and incidence of OA has been demonstrated for both high- and low-molecular-weight compounds including Western red cedar, diisocyanate, colophony (ie, soft core solder), acid anhydride, flour, alpha-amylase, natural rubber latex, cow dander, and rat urine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/18,29-31\">",
"     18,29-31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the known dose-response relationship, Permissible Exposure Limits have not been established for many stimuli because it is unknown if it is the intensity, duration, or cumulative dose of exposure that is most important. As an example, intermittent short-term exposure to elevated levels of isocyanates may represent the greatest risk for the subsequent development of OA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/32\">",
"     32",
"    </a>",
"    ]. After an individual becomes sensitized to an occupational agent, even a low-level exposure (well below permissible limits) can precipitate life-threatening bronchospasm.",
"   </p>",
"   <p>",
"    Reducing the exposure intensity in the workplace can reduce the rate of OA. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/9/14489?source=see_link&amp;anchor=H293008304#H293008304\">",
"     \"Occupational asthma: Management, prognosis, and prevention\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Exposure to very high concentrations of some agents associated with occupational asthma (eg, isocyanates) has been reported to cause reactive airways dysfunction syndrome (RADS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/33\">",
"     33",
"    </a>",
"    ]. In addition, one case report has described development of immunological sensitization to diphenylmethane diisocyanate and onset of immunological OA following an episode of reactive airways dysfunction syndrome (RADS) caused by irritant levels of that isocyanate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/28/8650?source=see_link\">",
"     \"Reactive airways dysfunction syndrome and irritant-induced asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H866399139\">",
"    <span class=\"h2\">",
"     Specific occupational exposures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The specific agent to which a worker is exposed influences the frequency of developing OA. Using skin test positivity as a marker of immunological sensitization, the following prevalences of OA due to high-molecular-weight compounds were determined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/9,16,35\">",
"     9,16,35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      13 to 33 percent of technicians exposed to laboratory animals",
"     </li>",
"     <li>",
"      9 to 18 percent of bakers exposed to flour-related antigens",
"     </li>",
"     <li>",
"      5 to 11 percent of dental hygienists exposed to latex",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similarly, a prospective study of nearly 800 apprentices with new exposure to high-molecular-weight agents identified the following incidences of OA over the 44 months of the study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/36\">",
"     36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      8 percent of technicians exposed to laboratory animals",
"     </li>",
"     <li>",
"      4 percent of bakers exposed to flour-related antigens",
"     </li>",
"     <li>",
"      2 percent of dental hygienists exposed to latex",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     OTHER RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most workers exposed to occupational sensitizing agents do not develop occupational asthma (OA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/10,37\">",
"     10,37",
"    </a>",
"    ]. The likelihood of developing the disease is influenced by a variety of host factors, including atopy, cigarette smoking, and genetic predisposition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Atopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atopy is consistently associated with sensitization to high-molecular-weight agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/10,18,38\">",
"     10,18,38",
"    </a>",
"    ]. Thus, atopic individuals who wish to enter high-risk workplaces should be advised of the potential for developing OA or exacerbating preexisting asthma and should receive regular medical follow-up. Despite this increased risk, atopy should not be used as a screening tool in high-risk workplaces because the positive predictive value of atopy for the subsequent development of symptoms is low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Among supermarket bakery workers, specific sensitization to work-related proteins was two to four times as likely among atopic compared with nonatopic workers, but overall, less than 30 percent of atopic bakery workers developed OA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Cigarette smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cigarette smoking is a risk factor for sensitization to some high-molecular-weight occupational allergens, including coffee, castor beans, shrimp, and snow-crab, but not to laboratory animal allergens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/8,41-43\">",
"     8,41-43",
"    </a>",
"    ]. Cigarette smoking is also a risk factor for sensitization to a few low-molecular-weight agents, such as platinum and phthalic anhydride, but appears to be less important in promoting sensitization to other low-molecular-weight agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/8,44,45\">",
"     8,44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, among platinum refinery workers, smoking is the most important risk factor for sensitization. In an observational cohort study of 91 workers followed for approximately seven years, there was an increased risk of developing skin test reactivity to workplace antigens in smokers when compared to nonsmoking controls (relative risk 5, 95% CI 1.7-15.2) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/45\">",
"     45",
"    </a>",
"    ]. Similarly, synergistic interaction between smoking and atopy has been noted in workers exposed to laboratory animals or tetrachlorophthalic anhydride, with atopic smokers demonstrating the highest prevalence of sensitization to these antigens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have examined whether genetic characteristics would explain why some exposed workers develop OA, while other exposed workers do not.",
"   </p>",
"   <p>",
"    The human leukocyte antigen (HLA) system, which is synonymous with the major histocompatibility complex (MHC), encodes a variety of cell surface markers, antigen-presenting molecules, and other proteins involved in immune function. The role of HLA molecules in antigen presentation has been implicated in the pathogenesis of OA, as HLA class II antigens are induced by certain stimuli, especially low-molecular-weight chemicals. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/29/10713?source=see_link\">",
"     \"Genetics of asthma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/38/24167?source=see_link\">",
"     \"Human leukocyte antigens (HLA): A roadmap\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some examples of HLA associations include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Leukocyte expression of HLA-DQB1*0503 is associated with susceptibility to isocyanate- induced OA, while HLA-DQB1*0501 confers protection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Western red cedar dust-induced OA is associated with increased frequency of DQB1*0302 and decreased frequency of DQB1*0501 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An excess of HLA-DR3 and a deficit of HLA-DR6 is associated with skin test reactivity in platinum refinery workers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The allelic frequencies of HLA DQB1*06-DPB1*05 and DRB1*15-DQB1*06-DPB1*05 are significantly higher among subjects with toluene diisocyanate-induced OA than asymptomatic exposed controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      HLA-DR7 is associated with work-related respiratory symptoms and specific IgE that recognizes rat urine protein among laboratory animals compared with nonsensitized, asymptomatic pharmaceutical workers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/52\">",
"       52",
"      </a>",
"      ]. On the other hand, most studies have not found a strong correlation between HLA markers and OA caused by high-molecular weight allergens [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Oxidative stress is a major component of inflammation, and impaired detoxification of reactive oxygen species (ROS) may perpetuate the inflammatory process in the airways. Glutathione-S-transferase (GST) enzymes play an important role in protecting cells against ROS. Polymorphisms of the gene regulating the GSTP1 enzyme are associated with diisocyanate-induced asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/53\">",
"     53",
"    </a>",
"    ]. In addition, GSTM1 null and GSTM3 AA genotypes are significantly related to late asthmatic reactions induced by diisocyanates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34824/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Occupational asthma (OA) begins during adulthood and can be caused by immunologic or non-immunologic stimuli. OA due to an immunologic stimulus has a latency period between exposure and symptom onset, while OA due to a non-immunologic stimulus does not. When a non-immunologic stimulus triggers OA, it is referred to as reactive airways dysfunction syndrome (RADS) or irritant-induced asthma. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/28/8650?source=see_link\">",
"       \"Reactive airways dysfunction syndrome and irritant-induced asthma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Stimuli that cause immunologic OA are divided into two categories, high-molecular-weight (eg, flour, laboratory animal proteins) and low-molecular-weight (eg, isocyanates, trimellitic anhydride, formaldehyde) molecular weight. (See",
"      <a class=\"local\" href=\"#H1191269\">",
"       'Causative agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Low-molecular-weight chemicals are incomplete antigens (ie, haptens) that combine with a protein to produce a sensitizing neoantigen. High-molecular-weight organic agents are complete sensitizing antigens. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38903?source=see_link\">",
"       \"Occupational asthma: Pathogenesis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      OA should be suspected and evaluated in every patient with adult-onset asthma. It is estimated that 5 to 25 percent of all adult-onset asthma cases are occupationally related. Common workplace stimuli are listed in the table (",
"      <a class=\"graphic graphic_table graphicRef66185 \" href=\"mobipreview.htm?27/53/28508\">",
"       table 2",
"      </a>",
"      ). A more complete list is available online (",
"      <a class=\"external\" href=\"file://www.asthme.csst.qc.ca/document/Info_Med/IdCauses/Bernstein/AgentsAnglais.pdf\">",
"       file://www.asthme.csst.qc.ca/document/Info_Med/IdCauses/Bernstein/AgentsAnglais.pdf",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1191269\">",
"       'Causative agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most workers who are exposed to allergens in the workplace do not develop occupational asthma (OA). The likelihood of developing OA is influenced by occupational factors, such as intensity of exposure and the particular sensitizing agent, and host factors, such as atopy, cigarette smoking, and genetic predisposition. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Other risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical evaluation, diagnosis, and management of OA are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/15/36089?source=see_link\">",
"       \"Occupational asthma: Clinical features and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/9/14489?source=see_link\">",
"       \"Occupational asthma: Management, prognosis, and prevention\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Bernstein, IL, Bernstein, DI, Chan-Yeung, M, Malo, JL. Definition and classification of asthma. In: Asthma in the workplace, 3rd, Bernstein, IL, Chan-Yeung, M, Malo, JL, Berstein, DI (Eds), Francis &amp; Taylor, New York 2006. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34824/abstract/2\">",
"      Tarlo SM, Balmes J, Balkissoon R, et al. Diagnosis and management of work-related asthma: American College Of Chest Physicians Consensus Statement. Chest 2008; 134:1S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34824/abstract/3\">",
"      Dykewicz MS. Occupational asthma: current concepts in pathogenesis, diagnosis, and management. J Allergy Clin Immunol 2009; 123:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34824/abstract/4\">",
"      Maestrelli P, Boschetto P, Fabbri LM, Mapp CE. Mechanisms of occupational asthma. J Allergy Clin Immunol 2009; 123:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34824/abstract/5\">",
"      Tarlo SM, Malo JL, Third Jack Pepys Workshop on Asthma in the Workplace Participants. An official ATS proceedings: asthma in the workplace: the Third Jack Pepys Workshop on Asthma in the Workplace: answered and unanswered questions. Proc Am Thorac Soc 2009; 6:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34824/abstract/6\">",
"      Henneberger PK, Redlich CA, Callahan DB, et al. An official american thoracic society statement: work-exacerbated asthma. Am J Respir Crit Care Med 2011; 184:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34824/abstract/7\">",
"      Mapp CE, Boschetto P, Maestrelli P, Fabbri LM. Occupational asthma. Am J Respir Crit Care Med 2005; 172:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34824/abstract/8\">",
"      Nicholson PJ, Cullinan P, Taylor AJ, et al. Evidence based guidelines for the prevention, identification, and management of occupational asthma. Occup Environ Med 2005; 62:290.",
"     </a>",
"    </li>",
"    <li>",
"     Taylor, AN. Asthma. In: Epidemiology of work related disease, McDonald, JC (Eds), BMJ Publishing Group, London 1995. p.117.",
"    </li>",
"    <li>",
"     Becklake, MR, Chan-Yeung, M, Malo, JL. Epidemiological Approaches in Occupational Asthma. In: Asthma in the Workplace, 3rd, Bernstein, IL, Chan-Yeung, M, Malo, JL, Bernstein, DI (Eds), Francis &amp; Taylor, New York 2006. p.37.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34824/abstract/11\">",
"      Karjalainen A, Kurppa K, Martikainen R, et al. Exploration of asthma risk by occupation--extended analysis of an incidence study of the Finnish population. Scand J Work Environ Health 2002; 28:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34824/abstract/12\">",
"      Janson C, Anto J, Burney P, et al. The European Community Respiratory Health Survey: what are the main results so far? European Community Respiratory Health Survey II. Eur Respir J 2001; 18:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34824/abstract/13\">",
"      Centers for Disease Control and Prevention (CDC). Work-related asthma--38 states and District of Columbia, 2006-2009. MMWR Morb Mortal Wkly Rep 2012; 61:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34824/abstract/14\">",
"      Henneberger PK, Mirabelli MC, Kogevinas M, et al. The occupational contribution to severe exacerbation of asthma. Eur Respir J 2010; 36:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34824/abstract/15\">",
"      Malo JL, Chan-Yeung M. Occupational asthma. J Allergy Clin Immunol 2001; 108:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34824/abstract/16\">",
"      Gautrin D, Newman-Taylor AJ, Nordman H, Malo JL. Controversies in epidemiology of occupational asthma. Eur Respir J 2003; 22:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34824/abstract/17\">",
"      Blanc PD, Toren K. How much adult asthma can be attributed to occupational factors? Am J Med 1999; 107:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34824/abstract/18\">",
"      Malo JL, Chan-Yeung M. Agents causing occupational asthma. J Allergy Clin Immunol 2009; 123:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34824/abstract/19\">",
"      McDonald JC, Keynes HL, Meredith SK. Reported incidence of occupational asthma in the United Kingdom, 1989-97. Occup Environ Med 2000; 57:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34824/abstract/20\">",
"      Piipari R, Keskinen H. Agents causing occupational asthma in Finland in 1986-2002: cow epithelium bypassed by moulds from moisture-damaged buildings. Clin Exp Allergy 2005; 35:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34824/abstract/21\">",
"      Cullinan P, Harris JM, Newman Taylor AJ, et al. An outbreak of asthma in a modern detergent factory. Lancet 2000; 356:1899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34824/abstract/22\">",
"      Moscato G, Pignatti P, Yacoub MR, et al. Occupational asthma and occupational rhinitis in hairdressers. Chest 2005; 128:3590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34824/abstract/23\">",
"      Mu&ntilde;oz X, Cruz MJ, Orriols R, et al. Occupational asthma due to persulfate salts: diagnosis and follow-up. Chest 2003; 123:2124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34824/abstract/24\">",
"      Mu&ntilde;oz X, Cruz MJ, Orriols R, et al. Validation of specific inhalation challenge for the diagnosis of occupational asthma due to persulphate salts. Occup Environ Med 2004; 61:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34824/abstract/25\">",
"      Weichel M, Glaser AG, Ballmer-Weber BK, et al. Wheat and maize thioredoxins: a novel cross-reactive cereal allergen family related to baker's asthma. J Allergy Clin Immunol 2006; 117:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34824/abstract/26\">",
"      Palacin A, Quirce S, Armentia A, et al. Wheat lipid transfer protein is a major allergen associated with baker's asthma. J Allergy Clin Immunol 2007; 120:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34824/abstract/27\">",
"      Constantin C, Quirce S, Grote M, et al. Molecular and immunological characterization of a wheat serine proteinase inhibitor as a novel allergen in baker's asthma. J Immunol 2008; 180:7451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34824/abstract/28\">",
"      Donnelly R, Buick JB, Macmahon J. Occupational asthma after exposure to plaster casts containing methylene diphenyl diisocyanate. Occup Med (Lond) 2004; 54:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34824/abstract/29\">",
"      Heederik D, Houba R. An exploratory quantitative risk assessment for high molecular weight sensitizers: wheat flour. Ann Occup Hyg 2001; 45:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34824/abstract/30\">",
"      Cullinan P, Cook A, Nieuwenhuijsen MJ, et al. Allergen and dust exposure as determinants of work-related symptoms and sensitization in a cohort of flour-exposed workers; a case-control analysis. Ann Occup Hyg 2001; 45:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34824/abstract/31\">",
"      Baur X, Chen Z, Liebers V. Exposure-response relationships of occupational inhalative allergens. Clin Exp Allergy 1998; 28:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34824/abstract/32\">",
"      Butcher BT, Jones RN, O'Neil CE, et al. Longitudinal study of workers employed in the manufacture of toluene-diisocyanate. Am Rev Respir Dis 1977; 116:411.",
"     </a>",
"    </li>",
"    <li>",
"     Gautrin, D, Bernstein, IL, Brooks, SM, Henneberger, PK. Reactive Airways Dysfunction Syndrome and Irritant-Induced Asthma. In: Asthma in the Workplace, 3rd, Bernstein, IL, Chan-Yeung, M, Malo, JL, Bernstein, DI (Eds), &amp; Taylor, New York 2006. p.579.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34824/abstract/34\">",
"      Leroyer C, Perfetti L, Cartier A, Malo JL. Can reactive airways dysfunction syndrome (RADS) transform into occupational asthma due to \"sensitisation\" to isocyanates? Thorax 1998; 53:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34824/abstract/35\">",
"      Baatjies R, Lopata AL, Sander I, et al. Determinants of asthma phenotypes in supermarket bakery workers. Eur Respir J 2009; 34:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34824/abstract/36\">",
"      Gautrin D, Ghezzo H, Infante-Rivard C, Malo JL. Incidence and determinants of IgE-mediated sensitization in apprentices. A prospective study. Am J Respir Crit Care Med 2000; 162:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34824/abstract/37\">",
"      Le Moual N, Kauffmann F, Eisen EA, Kennedy SM. The healthy worker effect in asthma: work may cause asthma, but asthma may also influence work. Am J Respir Crit Care Med 2008; 177:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34824/abstract/38\">",
"      Wang TN, Lin MC, Wu CC, et al. Risks of exposure to occupational asthmogens in atopic and nonatopic asthma: a case-control study in Taiwan. Am J Respir Crit Care Med 2010; 182:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34824/abstract/39\">",
"      Gautrin D, Infante-Rivard C, Dao TV, et al. Specific IgE-dependent sensitization, atopy, and bronchial hyperresponsiveness in apprentices starting exposure to protein-derived agents. Am J Respir Crit Care Med 1997; 155:1841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34824/abstract/40\">",
"      Slovak AJ, Hill RN. Does atopy have any predictive value for laboratory animal allergy? A comparison of different concepts of atopy. Br J Ind Med 1987; 44:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34824/abstract/41\">",
"      Chan-Yeung M, Lam S, Koener S. Clinical features and natural history of occupational asthma due to western red cedar (Thuja plicata). Am J Med 1982; 72:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34824/abstract/42\">",
"      Patiwael JA, Jong NW, Burdorf A, et al. Occupational allergy to bell pepper pollen in greenhouses in the Netherlands, an 8-year follow-up study. Allergy 2010; 65:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34824/abstract/43\">",
"      Nicholson PJ, Mayho GV, Roomes D, et al. Health surveillance of workers exposed to laboratory animal allergens. Occup Med (Lond) 2010; 60:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34824/abstract/44\">",
"      Paggiaro PL, Loi AM, Rossi O, et al. Follow-up study of patients with respiratory disease due to toluene diisocyanate (TDI). Clin Allergy 1984; 14:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34824/abstract/45\">",
"      Venables KM, Dally MB, Nunn AJ, et al. Smoking and occupational allergy in workers in a platinum refinery. BMJ 1989; 299:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34824/abstract/46\">",
"      Venables KM, Topping MD, Howe W, et al. Interaction of smoking and atopy in producing specific IgE antibody against a hapten protein conjugate. Br Med J (Clin Res Ed) 1985; 290:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34824/abstract/47\">",
"      Venables KM, Upton JL, Hawkins ER, et al. Smoking, atopy, and laboratory animal allergy. Br J Ind Med 1988; 45:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34824/abstract/48\">",
"      Bignon JS, Aron Y, Ju LY, et al. HLA class II alleles in isocyanate-induced asthma. Am J Respir Crit Care Med 1994; 149:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34824/abstract/49\">",
"      Teramoto S, Nagase T, Fukuchi Y. Inflammatory chemical mediators during conventional mechanical ventilation and during high frequency oscillatory ventilation. Am J Respir Crit Care Med 1997; 155:2114.",
"     </a>",
"    </li>",
"    <li>",
"     Newman-Taylor, AJ, Yucesov, B. Genetics and Occupational Asthma. In: Asthma in the Workplace, 3rd, Bernstein, IL, Chan-Yeung, M, Malo, JL, Bernstein, DI (Eds), Francis &amp; Taylor, New York 2006. p.87.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34824/abstract/51\">",
"      Kim SH, Oh HB, Lee KW, et al. HLA DRB1*15-DPB1*05 haplotype: a susceptible gene marker for isocyanate-induced occupational asthma? Allergy 2006; 61:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34824/abstract/52\">",
"      Jeal H, Draper A, Jones M, et al. HLA associations with occupational sensitization to rat lipocalin allergens: a model for other animal allergies? J Allergy Clin Immunol 2003; 111:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34824/abstract/53\">",
"      Mapp CE, Fryer AA, De Marzo N, et al. Glutathione S-transferase GSTP1 is a susceptibility gene for occupational asthma induced by isocyanates. J Allergy Clin Immunol 2002; 109:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34824/abstract/54\">",
"      Piiril&auml; P, Wikman H, Luukkonen R, et al. Glutathione S-transferase genotypes and allergic responses to diisocyanate exposure. Pharmacogenetics 2001; 11:437.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 537 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-190.92.87.114-02329B04FB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_0_34824=[""].join("\n");
var outline_f34_0_34824=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1191269\">",
"      CAUSATIVE AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H344156415\">",
"      High-molecular-weight",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H344156515\">",
"      Low-molecular-weight",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H344157047\">",
"      Combined exposures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H866399125\">",
"      OCCUPATIONAL RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H866399132\">",
"      Exposure intensity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H866399139\">",
"      Specific occupational exposures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      OTHER RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Atopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Cigarette smoking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/537\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/537|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?2/63/3071\" title=\"algorithm 1\">",
"      Natural hx occupational asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/537|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/17/18715\" title=\"table 1\">",
"      Occupational asthma vs RADS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/53/28508\" title=\"table 2\">",
"      Causes of occupational asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/4/34893\" title=\"table 3\">",
"      Agents responsible for RADS-I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/32/32269\" title=\"table 4\">",
"      Agents responsible for RADS-II",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/4/1098?source=related_link\">",
"      Bronchoprovocation testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/31/26104?source=related_link\">",
"      Contact dermatitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/1/19482?source=related_link\">",
"      Diagnosis of asthma in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/18/5418?source=related_link\">",
"      Evaluation of subacute and chronic cough in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/29/10713?source=related_link\">",
"      Genetics of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/38/24167?source=related_link\">",
"      Human leukocyte antigens (HLA): A roadmap",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/35/9785?source=related_link\">",
"      Latex allergy: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40070?source=related_link\">",
"      Latex allergy: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/15/36089?source=related_link\">",
"      Occupational asthma: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/9/14489?source=related_link\">",
"      Occupational asthma: Management, prognosis, and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38903?source=related_link\">",
"      Occupational asthma: Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/22/44391?source=related_link\">",
"      Overview of in vitro allergy tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/52/4937?source=related_link\">",
"      Pathogenesis of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/28/8650?source=related_link\">",
"      Reactive airways dysfunction syndrome and irritant-induced asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31848?source=related_link\">",
"      The biology of IgE",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_0_34825="Head and neck squamous cell carcinogenesis: Molecular and genetic alterations";
var content_f34_0_34825=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Head and neck squamous cell carcinogenesis: Molecular and genetic alterations",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/0/34825/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/0/34825/contributors\">",
"     Charles M Rudin, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/0/34825/contributors\">",
"     Shanthi Marur, MD, MBBS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/0/34825/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/0/34825/contributors\">",
"     Bruce E Brockstein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/0/34825/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/0/34825/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/0/34825/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Squamous cell carcinogenesis in the mucosa of the head and neck involves the progressive accumulation of a large series of genetic abnormalities in genes regulating cell cycle progression, mitogenic and differentiative signaling pathways, angiogenesis, and cell death. This mutagenic progression, called multistep carcinogenesis, parallels the genetic model of colorectal carcinogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/33/30234?source=see_link\">",
"     \"Molecular genetics of colorectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evidence for a mutational progression in tumorigenesis of head and neck squamous cell carcinoma (HNSCC) first derived from cytogenetic studies that demonstrated nonrandom clonal losses, duplications, and rearrangements of chromosome segments in head and neck tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Within many of these regions of recurring chromosomal abnormality, candidate oncogenes or tumor suppressors have since been identified, some of which appear to play critical roles in carcinogenic transformation. Subsequent detailed progression models for carcinogenesis of the head and neck have been based upon mutational models and differential gene expression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Identification of some of the critical genetic events leading to head and neck cancer has clarified the molecular basis for epidemiologic observations regarding risk factors (eg, tobacco), identified previously unknown risk factors (eg, human papillomavirus infection), and is yielding information that may be critical for risk stratification. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/6/20583?source=see_link\">",
"     \"Epidemiology and risk factors for head and neck cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/55/887?source=see_link\">",
"     \"Human papillomavirus associated head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, these studies have unveiled a new series of targets for chemotherapeutic and chemopreventive intervention, which ultimately may result in more rational and successful therapies for this disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/36/19017?source=see_link\">",
"     \"Chemoprevention in oral dysplasia and head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FIELD CANCERIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term field cancerization was first used to describe observations from microscopic examination of 738 lip, oral cavity, and pharyngeal carcinomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/8\">",
"     8",
"    </a>",
"    ]. The grossly normal epithelium adjacent to the cancer in this study frequently contained dysplasia, carcinoma in situ, or invasive carcinoma as though the entire mucosal field had been damaged and preconditioned by a carcinogen.",
"   </p>",
"   <p>",
"    The molecular basis for field cancerization has been studied by evaluating matched dysplastic and malignant lesions within the oral cavity for genetic alterations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/9\">",
"     9",
"    </a>",
"    ]. Two important observations were made.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Four of the 15 dysplastic lesions harbored the same genetic abnormalities detected in the tumor. The finding of identical genetic lesions in dysplastic lesions and invasive cancer in the same patient provided further evidence that dysplasias were precursor lesions and that multiple lesions can arise due to the lateral migration of genetically altered cells through the oral mucosa (a phenomenon termed clonal cancerization [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/10\">",
"       10",
"      </a>",
"      ]).",
"     </li>",
"     <li>",
"      Eight of the 15 dysplastic lesions showed genetic alterations not found in the matched cancer. This provided evidence that multifocal disease can arise from the development of several genetically altered clones from different initiating events.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The importance of dysplastic lesions as precursors to malignancy was illustrated in a retrospective study of 97 cases of epithelial dysplasia in the head and neck region [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/11\">",
"     11",
"    </a>",
"    ]. Fifty patients developed a squamous cell carcinoma in the same area as the dysplastic lesion at a mean follow-up of 30 months.",
"   </p>",
"   <p>",
"    Support for field cancerization is also provided by the development of second or multiple primaries in patients with HNSCC. Cancer at one site in the head and neck is a strong predictor for the development of a second primary tumor elsewhere. Second tumors can either occur at or close to the same time as the primary lesion (synchronous) or at least six months later (metachronous). As with dysplasia, the second tumors may be clonally similar to or distinct from the primary tumor. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36537?source=see_link&amp;anchor=H19#H19\">",
"     \"Overview of the diagnosis and staging of head and neck cancer\", section on 'Incidence of second and multiple primaries'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENOMIC ALTERATIONS AND MULTISTEP CARCINOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multistep carcinogenesis describes the series of events (initiation, promotion, progression) that leads to the development of invasive carcinoma. Although the specific sequence of genetic events has not been defined, numerous molecular mutations and genetic alterations have been found in both carcinomas and premalignant tissue and genetic alterations.",
"   </p>",
"   <p>",
"    A large number of studies examining chromosomal abnormalities in HNSCC serve as the foundation for current models of squamous cell carcinogenesis and indicate the complexity of the transformation process. Cytogenetic analysis and more detailed loss of heterozygosity (LOH) studies based upon microsatellite analysis have demonstrated that particular chromosomal abnormalities are consistently observed in HNSCC. Among many others, regions found to be commonly lost include 9p21 (the site of the p16 and p14 ARF tumor suppressor genes), 17p13 (site of the p53 tumor suppressor gene and perhaps another tumor suppressor that remains to be identified), 3p (the site of potential tumor suppressor genes, including FHIT [fragile histidine triad] and RASSF1A), and 13q21 (unknown tumor suppressor near the retinoblastoma locus) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/6,12,13\">",
"     6,12,13",
"    </a>",
"    ], and 18q21 (the site of the DCC [Deleted in Colon cancer] gene) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study performed microsatellite analysis on a series of hyperplastic lesions, dysplastic lesions, carcinomas in situ, and invasive squamous cell carcinomas, examining these and other chromosomal loci [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/6\">",
"     6",
"    </a>",
"    ]. The findings generated the first model of sequential genetic progression in head and neck squamous cell carcinogenesis, as illustrated in the figure (",
"    <a class=\"graphic graphic_figure graphicRef79860 \" href=\"mobipreview.htm?36/33/37400\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Loss of 9p, leading to inactivation of the p16 tumor suppressor gene, was a very early event, occurring even in transition from normal to hyperplastic mucosa. Deletion involving the 9p21 locus is found in 70 percent of all HNSCC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      This was frequently followed by loss of 3p and 17p in transition to dysplasia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/15\">",
"       15",
"      </a>",
"      ]. Among other putative tumor suppressors, 17p includes the p53 gene. The transition from dysplasia to carcinoma in situ was frequently associated with specific additional losses (11q, 13q, 14q) and still others (6p, 8, 4q) in the transition to invasive squamous cell carcinoma.",
"     </li>",
"     <li>",
"      Despite early loss of 17p in this model, sequencing of p53 alleles indicated that loss of p53 function may occur significantly later in the course of malignant transformation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data were recently confirmed and extended by using comparative genomic hybridization, a relatively new technique that permits concurrent analysis of genetic gain and loss throughout the genome. When well differentiated and poorly differentiated HNSCC were evaluated by this technique, there was evidence of genetic progression from well to poorly differentiated cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Well differentiated tumors consistently demonstrated under representation (loss) of chromosomes 3p, 5q, and 9p, together with overrepresentation (gain) of 3q.",
"     </li>",
"     <li>",
"      Poorly differentiated tumors typically shared these aberrations, but had other abnormalities such as evidence of deletion of 4q, 6q, 8p, 11q, 13q, 18q, and 21q, and overrepresentation of 1p34-pter, 11q13, 19, and 22q.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The inactivation of tumor suppressor genes by epigenetic mechanisms has now been reported in HNSCC. Promoter hypermethylation as a mechanism of tumor suppressor gene inactivation has been noted with the DCC gene, the retinoic acid receptor (RAR)-beta2, P16, and the MGMT gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/14,18\">",
"     14,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These arrays of genomic alterations underscore the complexity of carcinogenic transformation, and are consistent with studies in other tumor models suggesting that many genetic alterations, perhaps involving 10 or more genes, are necessary for fully malignant growth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/19\">",
"     19",
"    </a>",
"    ]. There is currently great interest in defining the extent to which individual molecular markers dictate prognosis in HNSCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DISRUPTION OF MITOGENIC SIGNALING PATHWAYS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitogenic signaling pathways initiated through cell surface receptors are disrupted in most cancers, including HNSCC. Dysregulated factors have included both downstream signaling molecules, such as Ras [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/22\">",
"     22",
"    </a>",
"    ], and a number of transmembrane receptors and their ligands. Particular attention has focused on the epidermal growth factor receptor (EGFR) as a factor in carcinogenesis and as a therapeutic target, as well as the closely related HER2 (c-erbB-2) receptor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/23-30\">",
"     23-30",
"    </a>",
"    ]. Both of these receptors have cytoplasmic domains with tyrosine kinase activity and activate a number of intracellular second messenger pathways.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     EGFR and transforming growth factor-alpha",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both EGFR and its principal ligand, transforming growth factor-alpha (TGF-alpha), are upregulated in HNSCC, constituting an autocrine activation loop [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/27\">",
"     27",
"    </a>",
"    ]. TGF-alpha overexpression is frequently induced relatively early in carcinogenesis, being elevated in mild dysplasia, with no further increases in advanced dysplasias or carcinoma. In contrast, EGFR expression usually increases progressively with increasing degree of dysplasia and is markedly elevated in many fully transformed HNSCCs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/23,27\">",
"     23,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    EGFR appears to be upregulated to some extent in more than 90 percent of HNSCCs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. High EGFR levels in HNSCC have been associated with shorter relapse-free and overall survival, making it a focus of attention as a prognostic factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/25,31-34\">",
"     25,31-34",
"    </a>",
"    ]. In addition, clinical studies have confirmed the importance of EGFR as a therapeutic target for HNSCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/25/40345?source=see_link\">",
"     \"Treatment of metastatic and recurrent head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    High EGFR gene copy number, as determined by fluorescent in situ (FISH), is frequent in HNSCC and has been associated with worse progression-free and overall survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/36\">",
"     36",
"    </a>",
"    ]. Furthermore, a mutant allele of the EGFR (EGFRvIII, variant III) has been identified, and may be responsible for relative resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    , an anti-EGFR monoclonal antibody [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     HER2 gene product",
"    </span>",
"    &nbsp;&mdash;&nbsp;The HER2 gene product (also known as c-erbB-2) has extensive structural homology to EGFR and is overexpressed in many solid tumors, including breast, lung, ovarian, and gastric cancers. In all of these sites, HER2 overexpression has been identified as a negative prognostic factor. Upregulation of HER2 occurs in approximately 50 percent of all HNSCCs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to its role in mitogenesis, HER2 signaling is thought to increase metastatic potential through induction of a diverse collection of factors involved in altering cell-cell adhesion and invasiveness. Like EGFR, HER2 expression has been correlated with decreased overall survival in HNSCC in many [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/30,38,39\">",
"     30,38,39",
"    </a>",
"    ] but not all studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Gastrin-releasing peptide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrin-releasing peptide (GRP) is a potent mitogen for both normal and neoplastic tissues. Autocrine growth mediated through the GRP receptor has been implicated as an early marker of susceptibility to tobacco-related lung cancers and as a mediator of autocrine growth in human lung cancers. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/35/42552?source=see_link\">",
"     \"Pathobiology and staging of small cell carcinoma of the lung\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    GRP may also play a role in the development",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    growth of HNSCC, another tobacco-related malignancy. In one report, significantly higher expression of GRP receptor mRNA was found both in tumor tissue and adjacent non-cancerous upper airway mucosa from 25 patients with HNSCC, compared to normal mucosal tissue from non cancer-bearing control patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/41\">",
"     41",
"    </a>",
"    ]. Furthermore, GRP stimulated the proliferation of cultured HNSCC cells in vivo, suggesting the presence of an autocrine growth loop.",
"   </p>",
"   <p>",
"    GRP-induced EGFR activation has been reported in HNSCC, leading to downstream phosphorylation of MAPK (mitogen activated protein kinase) and stimulation of tumor proliferation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/42\">",
"     42",
"    </a>",
"    ]. Targeting the GRP receptor to overcome resistance to EGFR inhibitors and combining inhibition of both GRP and EGFR to enhance the antitumor effects is under investigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Src kinase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the discovery of EGFR and targeted agents that inhibit the EGFR, research has been focused on mechanisms of resistance to EGFR inhibitors. One emerging target is the non-receptor kinase, src, a downstream component of the EGFR signaling complex [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/43\">",
"     43",
"    </a>",
"    ]. Activated src phosphorylates the intracellular domain of EGFR and mediates the activation of the STAT3 pathway by EGFR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/44\">",
"     44",
"    </a>",
"    ]. Src-kinase is also integral to GRP-induced EGFR activation and downstream signaling via the MAPK pathway. In one study, targeted inhibition of src-family tyrosine kinase activity resulted in decreased GRP-induced EGFR activation and MAPK phosphorylation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Constitutive activation of src may mediate resistance to EGFR inhibitors, and resistance might be overcome clinically by combined inhibition of both targets, src and EGFR. Among small molecule tyrosine kinase inhibitors (TKIs) in clinical development,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    inhibits the src family kinase activity in a highly selective manner [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/46\">",
"     46",
"    </a>",
"    ]. Phase",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    trials targeting src pathway and EGFR pathways in patients with HNSCC are ongoing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Insulin-like growth factor1 receptor",
"    </span>",
"    &nbsp;&mdash;&nbsp;The insulin-like growth factor I receptor (IGF-IR) pathway has also been implicated in resistance to therapies targeting the EGFR. The mechanisms involved in IGF-IR-mediated acquired resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    , a small molecule TK inhibitor, have been explored in non-small cell lung cancer (NSCLC) cells. Erlotinib promotes heterodimerization of EGFR and IGF-IR within the cell membrane, which transmits a survival signal through IGF-IR and its downstream mediators, thus counteracting the antitumor action of erlotinib [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/47\">",
"     47",
"    </a>",
"    ]. A similar mechanism could explain",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    resistance in HNSCC. Targeting IGF-IR to overcome resistance to anti-EGFR therapies is under investigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DISRUPTION OF CELL CYCLE CONTROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the factors that are known to play a critical role in regulating cell cycle entry (particularly cyclin D1, the p16 CDK inhibitor, p53, and c-myc) are dysregulated in HNSCC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Overexpression of cyclin D1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overexpression of cyclin D1, encoded by CCND1, has been observed in HNSCC. Cyclin D1 pairs with the cyclin-dependent kinases 4 and 6 (CDK4, CDK6) to promote cell cycle progression in the G1-S transition that is critical to commitment to replication and division [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/48\">",
"     48",
"    </a>",
"    ]. CCND1 polymorphism, thought to alter cyclin D1 expression, has been associated with HNSCC risk, tumor grade, tumor recurrence, and survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/49-53\">",
"     49-53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Inactivation of the p16/p14 ARF locus",
"    </span>",
"    &nbsp;&mdash;&nbsp;p16",
"    <span class=\"nowrap\">",
"     (CDKN2/MTS1)",
"    </span>",
"    and p14 ARF are overlapping genes in the same locus, encoded by distinct open reading frames and distinct mRNA splice forms. Inactivation of this locus is the most common genetic alteration that has been described in HNSCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/54\">",
"     54",
"    </a>",
"    ]. The gene product p16 is a potent inhibitor of both CDK4 and CDK6. Thus, inactivation of p16, as with overexpression of cyclin D1, increases",
"    <span class=\"nowrap\">",
"     CDK4/6",
"    </span>",
"    activity and promotes cell proliferation. On the other hand, reexpression of p16 in HNSCC cells results in significant antitumor effects both in tissue culture and in animal models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. p14 ARF blocks association of p53 with its inhibitor MDM2. Thus loss of p14 ARF leads to indirect inhibition of p53 function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Inactivation of p53 tumor suppressor gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;p53 is a critical antineoplastic factor, suppressing aberrant proliferation both by inhibition of cell cycle progression and by induction of apoptotic cell death. The regulation of cell cycle by p53 is mediated primarily at the G1-S transition, both through transcriptional induction of cell cycle inhibitors such as p21, and through transcription-independent mechanisms that are poorly understood.",
"   </p>",
"   <p>",
"    The p53 gene is inactivated in at least one-half of HNSCCs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/57-64\">",
"     57-64",
"    </a>",
"    ], although some reports suggest that the mutation rate is higher, approaching 80 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/65\">",
"     65",
"    </a>",
"    ]. The timing of p53 inactivation in HNSCC tumorigenesis is controversial, with some reports demonstrating aberrant expression in early dysplasia, and the majority suggesting mutation only late in tumor evolution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/6,57-59\">",
"     6,57-59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism underlying loss of p53 expression depends on the risk factor for the development of HNSCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. Loss of p53 expression through mutations or loss of heterozygosity is associated with a history of alcohol and tobacco use. As an example, in one study of 129 patients with primary HNSCC, p53 mutations were found in tumor samples in 58 percent of those who both smoked and used alcohol, 33 percent who smoked but abstained from alcohol, and 17 percent who neither smoked nor drank alcohol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, there is an inverse relationship between the presence of p53 mutations and infection with human papillomavirus (HPV) infection. In the setting of HPV infection, p53 is inactivated by binding to the E6 viral protein. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Human papillomavirus'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Prognostic impact",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in the p53 gene may also influence prognosis and response to treatment in both localized and locoregionally advanced HNSCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/64,68-72\">",
"     64,68-72",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 105 patients with locoregionally advanced HNC, the presence of a p53 mutation was associated with a statistically significant 70 percent less chance of responding to neoadjuvant chemotherapy as compared to wild-type p53 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/71\">",
"       71",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/15/29946?source=see_link\">",
"       \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The correlation between p53 mutations and outcome after surgical treatment was addressed in a retrospective analysis of 420 patients who underwent curative intent surgery for HNC on a prospective multicenter trial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/64\">",
"       64",
"      </a>",
"      ]. The mutations were classified as disruptive or nondisruptive, based upon the degree of predicted disturbance of the p53 protein structure. Patients whose tumors harbored p53 mutations (53 percent of all patients) had significantly reduced overall survival after surgical treatment compared to those with wild-type p53 (hazard ratio [HR] for death 1.4) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/64\">",
"       64",
"      </a>",
"      ]. The association was strongest for disruptive mutations (HR for death 1.7)",
"     </li>",
"     <li>",
"      The association between p53 mutations and response to larynx-preserving surgery was studied in a series of 71 patients with locoregionally advanced HNC who treated on larynx-preserving protocols [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/72\">",
"       72",
"      </a>",
"      ]. Tumors were assayed for IHC expression of p53, its upstream regulator mdm2, and its downstream transcriptional target",
"      <span class=\"nowrap\">",
"       p21/WAF1.",
"      </span>",
"      In multivariate analysis, no molecular marker significantly predicted the response to induction chemotherapy. However, compared to those with WT p53, patients with p53-positive tumors had significantly worse five-year survival (29 versus 51 percent) with larynx preservation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     c-myc oncogene",
"    </span>",
"    &nbsp;&mdash;&nbsp;The c-myc oncogene is a potent proliferative factor that, when overexpressed, can promote G1-S transition by mechanisms that have not been defined. Amplification of the c-myc locus occurs frequently in HNSCC, and c-myc upregulation has been correlated with decreased overall survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Human papillomavirus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oncogenic viruses are another factor that can affect cell cycle regulation. In situ hybridization and PCR-based detection have demonstrated that as many as one-third of all HNSCCs and 60 percent of oropharyngeal cancers contain human papillomavirus (HPV), with the majority of these containing high risk, oncogenic HPV types 16, 18 or 33. The molecular profile of HPV positive HNSCCs is distinct from those that are HPV negative, with almost all HPV associated tumors expressing wild-type tumor suppressor genes, p53 and p16. This would suggest different mechanisms of oncogenesis for HPV positive as compared to HPV negative tumors, and that HPV infection is an early event in head and neck squamous cell carcinogenesis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/55/887?source=see_link&amp;anchor=H3#H3\">",
"     \"Human papillomavirus associated head and neck cancer\", section on 'Biology of HPV'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Impact on prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emerging data from prospective clinical trials suggest that patients with HPV related HNC may respond more favorably to regimens combining induction chemotherapy and chemoradiotherapy than those with HPV negative tumors. These data are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/6/20583?source=see_link&amp;anchor=H8#H8\">",
"     \"Epidemiology and risk factors for head and neck cancer\", section on 'Human papillomavirus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DISRUPTION OF CELL-CELL CONTACT AND DIFFERENTIATION PATHWAYS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cellular differentiation is in part regulated by a transcriptional program determined by expression of nuclear retinoic acid receptors. Retinoic acid receptors are bipartite transcription factors composed of RAR and RXR components, and multiple members of both the RAR and RXR families can associate to differentially regulate arrays of downstream targets.",
"   </p>",
"   <p>",
"    Histologic progression in premalignant dysplastic lesions of the head and neck has been associated with loss of nuclear RAR-beta expression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/74\">",
"     74",
"    </a>",
"    ]. Treatment of such lesions with 13-cis retinoic acid can result in recovery of normal nuclear RAR-beta expression and may lead to reestablishment of a normal differentiation program in the affected mucosa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. These observations have spawned an enormous interest in retinoid research, particularly among investigators interested in chemoprevention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Doc-1 gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;The doc-1 gene (",
"    <strong>",
"     d",
"    </strong>",
"    eleted in",
"    <strong>",
"     o",
"    </strong>",
"    ral",
"    <strong>",
"     c",
"    </strong>",
"    ancer-1) is frequently inactivated in HNSCC and has been implicated in cellular differentiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/77\">",
"     77",
"    </a>",
"    ]. Reexpression of doc-1 in doc-1 negative HNSCC lines in culture by transfection of doc-1 cDNA results in phenotypic reversion to an apparently normal growth pattern. A related factor in murine cells has also been implicated in cytokine-mediated regulation of keratinocyte differentiation. Doc-1 associates with DNA polymerase a, suggesting a role in regulating DNA replication and proliferation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     E-cadherin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epithelial tissue structure is dependent on a complex network of cell-cell adhesions, and loss of cell-cell contact has been associated with tumor invasiveness and metastatic potential in many cancers. One of the critical factors in these networks that has been most clearly linked to cancer progression is E-cadherin (CDH1). Invasion in an E-cadherin negative tumor cell line can be suppressed by transfection with E-cadherin and invasiveness restored by anti-E-cadherin antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Loss of E-cadherin expression in HNSCC has been found to correlate with both the extent of dedifferentiation of the tumor and, more importantly, with the probability of lymph node metastasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. The mechanism of E-cadherin inactivation in HNSCC is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Matrix metalloproteinases",
"    </span>",
"    &nbsp;&mdash;&nbsp;The matrix metalloproteinases (MMPs), a family of secreted enzymes that degrade extracellular matrix proteins, have been implicated in the normal processes of tissue regeneration and remodeling. Expression of certain members of the MMP family, including MMP-2, MMP-9, and MMP-13, has been associated with increased local invasion, high metastatic potential, and poor clinical outcome in HNSCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/82-84\">",
"     82-84",
"    </a>",
"    ]. In addition, expression of a natural inhibitor of MMPs, TIMP-1, also appears to have prognostic significance in patients with HNSCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. Tumor expression of MMPs may be an important determinant of tumor growth, spread, and clinical outcome.",
"   </p>",
"   <p>",
"    A recent prospective study from Johns Hopkins collected tumor samples from 124 patients with HNSCC and evaluated for promoter hypermethylation for TIMP-3 (tissue inhibitor of metalloproteinase-3) and DAPK (death associated protein kinase) using quantitative methylation specific polymerase chain reaction (qMSP) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/87\">",
"     87",
"    </a>",
"    ]. TIMP-3 is a known tumor suppressor gene on chromosome 12q 12.3 and is part of a family of genes that inhibit MMPs. TIMP-3 regulates processes including invasion, migration, differentiation, and proliferation. DAPK is a serine-threonine kinase, found to be an integral part of the interferon induced apoptotic pathway. TIMP-3 was hypermethylated in 71.8 percent of the tumor samples and DAPK was hypermethylated in 74.2 percent, both significantly higher than in control specimens. There was a strong correlation for hypermethylation between the two genes. The roles of these genes in HNSCC tumorigenesis are being actively studied.",
"   </p>",
"   <p>",
"    MMPs represent a potential therapeutic target. Although initial clinical trials with small molecule MMP inhibitors (MMPIs) in advanced solid tumors have been disappointing, evaluation in patients with very early stage disease (in which these agents might be predicted to be of greatest potential efficacy) has not been undertaken [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     DISRUPTION OF CELL DEATH PATHWAYS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhibition of programmed cell death (apoptosis) pathways by either cellular or viral mechanisms is a characteristic feature of many human cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/89\">",
"     89",
"    </a>",
"    ]. Overexpression of transforming oncogenes, in the absence of apoptotic inhibition, efficiently triggers programmed cell death in many contexts, including cultured epithelial cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/90,91\">",
"     90,91",
"    </a>",
"    ]. These observations suggest that apoptotic dysregulation may be a critical event in the process of carcinogenesis.",
"   </p>",
"   <p>",
"    Among the many other factors known to regulate apoptotic pathways are the B cell",
"    <span class=\"nowrap\">",
"     leukemia/lymphoma",
"    </span>",
"    2 (Bcl-2) family members. This family consists of both proapoptotic and antiapoptotic members that form heterodimers that determine apoptotic threshold [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/92\">",
"     92",
"    </a>",
"    ]. Approximately 70 percent of HNSCCs demonstrate upregulated expression of one of two antiapoptotic genes in this family, Bcl-xL and Bcl-2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple studies have found an association between Bcl-2 overexpression and better clinical outcome, including response to chemotherapy, local control, time to progression, and survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/93-95\">",
"     93-95",
"    </a>",
"    ]. This finding is surprising since apoptotic inhibition by factors such as Bcl-2 confers both chemotherapeutic and radiation resistance in cell lines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34825/abstract/96\">",
"     96",
"    </a>",
"    ] and might be expected to promote viability of micrometastases, resulting in a highly resistant and rapidly spreading cancer. Although a similar paradoxical finding has been noted in other solid tumors, the basis for this association has not been determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past several years, tremendous progress toward a molecular understanding of the development of HNSCC has been made. These studies reiterate the complexity of carcinogenic transformation noted in other solid tumor models. There are several clinical implications from these findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With respect to risk factor avoidance, molecular analysis of the p53 gene mutations in smokers versus nonsmokers solidified the causal relationship between carcinogens in tobacco and HNSCC. In addition, the association of HNSCC with oncogenic human papillomavirus clarifies observations relating oropharyngeal cancer to sexual history. HPV positive tumors appear to have a better prognosis than do those that are HPV negative, and HPV status may ultimately impact treatment. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Disruption of cell cycle control'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      With respect to chemoprevention, the genetic alterations associated with progressive stages of carcinogenic transformation may be relevant to the success of chemopreventative strategies in addition to histologic analysis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/36/19017?source=see_link\">",
"       \"Chemoprevention in oral dysplasia and head and neck cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      With respect to novel therapeutic approaches, many of the molecular defects identified in the above studies have yielded new targets for directed therapeutic intervention in HNSCC and other cancers. Strategies have been developed to target cells with aberrant expression of EGF, HER2, Bcl-2, p53, and p16, among others. Strategies to address EGFR resistance by targeting alternative downstream signals (such as src) are the focus of several ongoing therapeutic trials.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/1\">",
"      Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/2\">",
"      Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/3\">",
"      Patel V, Yeudall WA, Gardner A, et al. Consistent chromosomal anomalies in keratinocyte cell lines derived from untreated malignant lesions of the oral cavity. Genes Chromosomes Cancer 1993; 7:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/4\">",
"      Van Dyke DL, Worsham MJ, Benninger MS, et al. Recurrent cytogenetic abnormalities in squamous cell carcinomas of the head and neck region. Genes Chromosomes Cancer 1994; 9:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/5\">",
"      Cowan JM, Beckett MA, Ahmed-Swan S, Weichselbaum RR. Cytogenetic evidence of the multistep origin of head and neck squamous cell carcinomas. J Natl Cancer Inst 1992; 84:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/6\">",
"      Califano J, van der Riet P, Westra W, et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 1996; 56:2488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/7\">",
"      Ha PK, Benoit NE, Yochem R, et al. A transcriptional progression model for head and neck cancer. Clin Cancer Res 2003; 9:3058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/8\">",
"      SLAUGHTER DP, SOUTHWICK HW, SMEJKAL W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953; 6:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/9\">",
"      Partridge M, Emilion G, Pateromichelakis S, et al. Field cancerisation of the oral cavity: comparison of the spectrum of molecular alterations in cases presenting with both dysplastic and malignant lesions. Oral Oncol 1997; 33:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/10\">",
"      Partridge M, Pateromichelakis S, Phillips E, et al. Profiling clonality and progression in multiple premalignant and malignant oral lesions identifies a subgroup of cases with a distinct presentation of squamous cell carcinoma. Clin Cancer Res 2001; 7:1860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/11\">",
"      Bosatra A, Bussani R, Silvestri F. From epithelial dysplasia to squamous carcinoma in the head and neck region: an epidemiological assessment. Acta Otolaryngol Suppl 1997; 527:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/12\">",
"      Rosin MP, Cheng X, Poh C, et al. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res 2000; 6:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/13\">",
"      Mao L, Lee JS, Fan YH, et al. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med 1996; 2:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/14\">",
"      Carvalho AL, Chuang A, Jiang WW, et al. Deleted in colorectal cancer is a putative conditional tumor-suppressor gene inactivated by promoter hypermethylation in head and neck squamous cell carcinoma. Cancer Res 2006; 66:9401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/15\">",
"      Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med 2001; 345:1890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/16\">",
"      van der Riet P, Nawroz H, Hruban RH, et al. Frequent loss of chromosome 9p21-22 early in head and neck cancer progression. Cancer Res 1994; 54:1156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/17\">",
"      Bockm&uuml;hl U, Wolf G, Schmidt S, et al. Genomic alterations associated with malignancy in head and neck cancer. Head Neck 1998; 20:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/18\">",
"      Mithani SK, Mydlarz WK, Grumbine FL, et al. Molecular genetics of premalignant oral lesions. Oral Dis 2007; 13:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/19\">",
"      Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/20\">",
"      Wreesmann VB, Shi W, Thaler HT, et al. Identification of novel prognosticators of outcome in squamous cell carcinoma of the head and neck. J Clin Oncol 2004; 22:3965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/21\">",
"      B&eacute;rgamo NA, da Silva Veiga LC, dos Reis PP, et al. Classic and molecular cytogenetic analyses reveal chromosomal gains and losses correlated with survival in head and neck cancer patients. Clin Cancer Res 2005; 11:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/22\">",
"      Kiaris H, Spandidos DA, Jones AS, et al. Mutations, expression and genomic instability of the H-ras proto-oncogene in squamous cell carcinomas of the head and neck. Br J Cancer 1995; 72:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/23\">",
"      Shin DM, Ro JY, Hong WK, Hittelman WN. Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 1994; 54:3153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/24\">",
"      Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993; 53:3579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/25\">",
"      Temam S, Kawaguchi H, El-Naggar AK, et al. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 2007; 25:2164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/26\">",
"      Eisbruch A, Blick M, Lee JS, et al. Analysis of the epidermal growth factor receptor gene in fresh human head and neck tumors. Cancer Res 1987; 47:3603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/27\">",
"      Rubin Grandis J, Tweardy DJ, Melhem MF. Asynchronous modulation of transforming growth factor alpha and epidermal growth factor receptor protein expression in progression of premalignant lesions to head and neck squamous cell carcinoma. Clin Cancer Res 1998; 4:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/28\">",
"      Craven JM, Pavelic ZP, Stambrook PJ, et al. Expression of c-erbB-2 gene in human head and neck carcinoma. Anticancer Res 1992; 12:2273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/29\">",
"      Field JK, Spandidos DA, Yiagnisis M, et al. C-erbB-2 expression in squamous cell carcinoma of the head and neck. Anticancer Res 1992; 12:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/30\">",
"      Xia W, Lau YK, Zhang HZ, et al. Strong correlation between c-erbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma. Clin Cancer Res 1997; 3:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/31\">",
"      Ulanovski D, Stern Y, Roizman P, et al. Expression of EGFR and Cerb-B2 as prognostic factors in cancer of the tongue. Oral Oncol 2004; 40:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/32\">",
"      Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002; 62:7350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/33\">",
"      Rubin Grandis J, Melhem MF, Gooding WE, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998; 90:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/34\">",
"      Rubin Grandis J, Melhem MF, Barnes EL, Tweardy DJ. Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 1996; 78:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/35\">",
"      Pomerantz RG, Grandis JR. The epidermal growth factor receptor signaling network in head and neck carcinogenesis and implications for targeted therapy. Semin Oncol 2004; 31:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/36\">",
"      Chung CH, Ely K, McGavran L, et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006; 24:4170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/37\">",
"      Sok JC, Coppelli FM, Thomas SM, et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 2006; 12:5064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/38\">",
"      Xia W, Lau YK, Zhang HZ, et al. Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res 1999; 5:4164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/39\">",
"      Chen IH, Chang JT, Liao CT, et al. Prognostic significance of EGFR and Her-2 in oral cavity cancer in betel quid prevalent area cancer prognosis. Br J Cancer 2003; 89:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/40\">",
"      Giatromanolaki A, Koukourakis MI, Sivridis E, Fountzilas G. c-erbB-2 oncoprotein is overexpressed in poorly vascularised squamous cell carcinomas of the head and neck, but is not associated with response to cytotoxic therapy or survival. Anticancer Res 2000; 20:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/41\">",
"      Lango MN, Dyer KF, Lui VW, et al. Gastrin-releasing peptide receptor-mediated autocrine growth in squamous cell carcinoma of the head and neck. J Natl Cancer Inst 2002; 94:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/42\">",
"      Zhang Q, Bhola NE, Lui VW, et al. Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer. Mol Cancer Ther 2007; 6:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/43\">",
"      Yeatman TJ. A renaissance for SRC. Nat Rev Cancer 2004; 4:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/44\">",
"      Leeman RJ, Lui VW, Grandis JR. STAT3 as a therapeutic target in head and neck cancer. Expert Opin Biol Ther 2006; 6:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/45\">",
"      Zhang Q, Thomas SM, Xi S, et al. SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells. Cancer Res 2004; 64:6166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/46\">",
"      Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354:2531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/47\">",
"      Morgillo F, Woo JK, Kim ES, et al. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res 2006; 66:10100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/48\">",
"      Kotelnikov VM, Coon JS 4th, Mundle S, et al. Cyclin D1 expression in squamous cell carcinomas of the head and neck and in oral mucosa in relation to proliferation and apoptosis. Clin Cancer Res 1997; 3:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/49\">",
"      Akervall JA, Michalides RJ, Mineta H, et al. Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 overexpression. Cancer 1997; 79:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/50\">",
"      Holley SL, Matthias C, Jahnke V, et al. Association of cyclin D1 polymorphism with increased susceptibility to oral squamous cell carcinoma. Oral Oncol 2005; 41:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/51\">",
"      Matthias C, Harr&eacute;us U, Strange R. Influential factors on tumor recurrence in head and neck cancer patients. Eur Arch Otorhinolaryngol 2006; 263:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/52\">",
"      Michalides R, van Veelen N, Hart A, et al. Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res 1995; 55:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/53\">",
"      Marsit CJ, Black CC, Posner MR, Kelsey KT. A genotype-phenotype examination of cyclin D1 on risk and outcome of squamous cell carcinoma of the head and neck. Clin Cancer Res 2008; 14:2371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/54\">",
"      Reed AL, Califano J, Cairns P, et al. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 1996; 56:3630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/55\">",
"      Liggett WH Jr, Sewell DA, Rocco J, et al. p16 and p16 beta are potent growth suppressors of head and neck squamous carcinoma cells in vitro. Cancer Res 1996; 56:4119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/56\">",
"      Rocco JW, Li D, Liggett WH Jr, et al. p16INK4A adenovirus-mediated gene therapy for human head and neck squamous cell cancer. Clin Cancer Res 1998; 4:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/57\">",
"      Shin DM, Kim J, Ro JY, et al. Activation of p53 gene expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 1994; 54:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/58\">",
"      Chung KY, Mukhopadhyay T, Kim J, et al. Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract. Cancer Res 1993; 53:1676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/59\">",
"      Boyle JO, Hakim J, Koch W, et al. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 1993; 53:4477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/60\">",
"      Gasco M, Crook T. The p53 network in head and neck cancer. Oral Oncol 2003; 39:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/61\">",
"      Olshan AF, Weissler MC, Pei H, Conway K. p53 mutations in head and neck cancer: new data and evaluation of mutational spectra. Cancer Epidemiol Biomarkers Prev 1997; 6:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/62\">",
"      Gonz&aacute;lez MV, Pello MF, L&oacute;pez-Larrea C, et al. Loss of heterozygosity and mutation analysis of the p16 (9p21) and p53 (17p13) genes in squamous cell carcinoma of the head and neck. Clin Cancer Res 1995; 1:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/63\">",
"      Scheffner M, Werness BA, Huibregtse JM, et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 63:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/64\">",
"      Poeta ML, Manola J, Goldwasser MA, et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med 2007; 357:2552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/65\">",
"      Balz V, Scheckenbach K, G&ouml;tte K, et al. Is the p53 inactivation frequency in squamous cell carcinomas of the head and neck underestimated? Analysis of p53 exons 2-11 and human papillomavirus 16/18 E6 transcripts in 123 unselected tumor specimens. Cancer Res 2003; 63:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/66\">",
"      Brennan JA, Boyle JO, Koch WM, et al. Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med 1995; 332:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/67\">",
"      Field JK, Zoumpourlis V, Spandidos DA, Jones AS. p53 expression and mutations in squamous cell carcinoma of the head and neck: expression correlates with the patients' use of tobacco and alcohol. Cancer Detect Prev 1994; 18:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/68\">",
"      Koch WM, Brennan JA, Zahurak M, et al. p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma. J Natl Cancer Inst 1996; 88:1580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/69\">",
"      Mineta H, Borg A, Dictor M, et al. p53 mutation, but not p53 overexpression, correlates with survival in head and neck squamous cell carcinoma. Br J Cancer 1998; 78:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/70\">",
"      Geisler SA, Olshan AF, Weissler MC, et al. p16 and p53 Protein expression as prognostic indicators of survival and disease recurrence from head and neck cancer. Clin Cancer Res 2002; 8:3445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/71\">",
"      Temam S, Flahault A, P&eacute;ri&eacute; S, et al. p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck. J Clin Oncol 2000; 18:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/72\">",
"      Osman I, Sherman E, Singh B, et al. Alteration of p53 pathway in squamous cell carcinoma of the head and neck: impact on treatment outcome in patients treated with larynx preservation intent. J Clin Oncol 2002; 20:2980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/73\">",
"      Field JK, Spandidos DA, Stell PM, et al. Elevated expression of the c-myc oncoprotein correlates with poor prognosis in head and neck squamous cell carcinoma. Oncogene 1989; 4:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/74\">",
"      Xu XC, Ro JY, Lee JS, et al. Differential expression of nuclear retinoid receptors in normal, premalignant, and malignant head and neck tissues. Cancer Res 1994; 54:3580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/75\">",
"      Khuri FR, Lippman SM, Spitz MR, et al. Molecular epidemiology and retinoid chemoprevention of head and neck cancer. J Natl Cancer Inst 1997; 89:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/76\">",
"      Papadimitrakopoulou VA, Hong WK. Retinoids in head and neck chemoprevention. Proc Soc Exp Biol Med 1997; 216:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/77\">",
"      Todd R, McBride J, Tsuji T, et al. Deleted in oral cancer-1 (doc-1), a novel oral tumor suppressor gene. FASEB J 1995; 9:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/78\">",
"      Tsuji T, Duh FM, Latif F, et al. Cloning, mapping, expression, function, and mutation analyses of the human ortholog of the hamster putative tumor suppressor gene Doc-1. J Biol Chem 1998; 273:6704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/79\">",
"      Frixen UH, Behrens J, Sachs M, et al. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 1991; 113:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/80\">",
"      Schipper JH, Frixen UH, Behrens J, et al. E-cadherin expression in squamous cell carcinomas of head and neck: inverse correlation with tumor dedifferentiation and lymph node metastasis. Cancer Res 1991; 51:6328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/81\">",
"      Lim SC, Zhang S, Ishii G, et al. Predictive markers for late cervical metastasis in stage I and II invasive squamous cell carcinoma of the oral tongue. Clin Cancer Res 2004; 10:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/82\">",
"      Johansson N, Airola K, Gr&eacute;nman R, et al. Expression of collagenase-3 (matrix metalloproteinase-13) in squamous cell carcinomas of the head and neck. Am J Pathol 1997; 151:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/83\">",
"      de Vicente JC, Lequerica-Fern&aacute;ndez P, L&oacute;pez-Arranz JS, et al. Expression of matrix metalloproteinase-9 in high-grade salivary gland carcinomas is associated with their metastatic potential. Laryngoscope 2008; 118:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/84\">",
"      O-Charoenrat P, Rhys-Evans P, Modjtahedi H, et al. Overexpression of epidermal growth factor receptor in human head and neck squamous carcinoma cell lines correlates with matrix metalloproteinase-9 expression and in vitro invasion. Int J Cancer 2000; 86:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/85\">",
"      Ruokolainen H, P&auml;&auml;kk&ouml; P, Turpeenniemi-Hujanen T. Tissue inhibitor of matrix metalloproteinase-1 is prognostic in head and neck squamous cell carcinoma: comparison of the circulating and tissue immunoreactive protein. Clin Cancer Res 2005; 11:3257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/86\">",
"      Katayama A, Bandoh N, Kishibe K, et al. Expressions of matrix metalloproteinases in early-stage oral squamous cell carcinoma as predictive indicators for tumor metastases and prognosis. Clin Cancer Res 2004; 10:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/87\">",
"      Nayak CS, Carvalho AL, Jeronimo C, et al. Positive correlation of tissue inhibitor of metalloproteinase-3 and death-associated protein kinase hypermethylation in head and neck squamous cell carcinoma. Laryngoscope 2007; 117:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/88\">",
"      Vihinen P, Ala-aho R, K&auml;h&auml;ri VM. Matrix metalloproteinases as therapeutic targets in cancer. Curr Cancer Drug Targets 2005; 5:203.",
"     </a>",
"    </li>",
"    <li>",
"     Rudin CM, Thompson CB. Apoptosis and cancer. In: The Genetic Basis of Human Cancer, Vogelstein B, Kinzler KW (Eds), McGraw-Hill, New York 1997. p.193.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/90\">",
"      Evan GI, Wyllie AH, Gilbert CS, et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992; 69:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/91\">",
"      White E. Life, death, and the pursuit of apoptosis. Genes Dev 1996; 10:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/92\">",
"      Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med 1997; 3:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/93\">",
"      Pena JC, Thompson CB, Recant W, et al. Bcl-xL and Bcl-2 expression in squamous cell carcinoma of the head and neck. Cancer 1999; 85:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/94\">",
"      Wilson GD, Grover R, Richman PI, et al. Bcl-2 expression correlates with favourable outcome in head and neck cancer treated by accelerated radiotherapy. Anticancer Res 1996; 16:2403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/95\">",
"      Trask DK, Wolf GT, Bradford CR, et al. Expression of Bcl-2 family proteins in advanced laryngeal squamous cell carcinoma: correlation with response to chemotherapy and organ preservation. Laryngoscope 2002; 112:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34825/abstract/96\">",
"      Miyashita T, Reed JC. bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res 1992; 52:5407.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3387 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-0C172D990F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_0_34825=[""].join("\n");
var outline_f34_0_34825=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FIELD CANCERIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENOMIC ALTERATIONS AND MULTISTEP CARCINOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DISRUPTION OF MITOGENIC SIGNALING PATHWAYS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EGFR and transforming growth factor-alpha",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      HER2 gene product",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Gastrin-releasing peptide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Src kinase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Insulin-like growth factor1 receptor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DISRUPTION OF CELL CYCLE CONTROL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Overexpression of cyclin D1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Inactivation of the p16/p14 ARF locus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Inactivation of p53 tumor suppressor gene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Prognostic impact",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      c-myc oncogene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Human papillomavirus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Impact on prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DISRUPTION OF CELL-CELL CONTACT AND DIFFERENTIATION PATHWAYS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Doc-1 gene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      E-cadherin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Matrix metalloproteinases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      DISRUPTION OF CELL DEATH PATHWAYS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3387\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3387|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/33/37400\" title=\"figure 1\">",
"      Molec progress oral CA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/36/19017?source=related_link\">",
"      Chemoprevention in oral dysplasia and head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/6/20583?source=related_link\">",
"      Epidemiology and risk factors for head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/55/887?source=related_link\">",
"      Human papillomavirus associated head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/15/29946?source=related_link\">",
"      Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/33/30234?source=related_link\">",
"      Molecular genetics of colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36537?source=related_link\">",
"      Overview of the diagnosis and staging of head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/35/42552?source=related_link\">",
"      Pathobiology and staging of small cell carcinoma of the lung",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/25/40345?source=related_link\">",
"      Treatment of metastatic and recurrent head and neck cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_0_34826="Adjuvant systemic therapy for older women with early stage breast cancer";
var content_f34_0_34826=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Adjuvant systemic therapy for older women with early stage breast cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/0/34826/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/0/34826/contributors\">",
"     Gretchen Kimmick, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/0/34826/contributors\">",
"     Pearl H Seo, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/0/34826/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/0/34826/contributors\">",
"     Daniel F Hayes, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/0/34826/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/0/34826/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/0/34826/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast cancer is a major health concern in the geriatric population. For most women, increasing age is the primary risk factor. Of the approximately 230,480 new cases of female breast cancer diagnosed annually in the US, over one-half arise in women 65 years of age or older [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will focus on issues related to adjuvant systemic therapy in older women with early breast cancer. General principles of treatment of early stage disease in older women (including a discussion on assessment tools to estimate functional reserve and the degree of frailty or vulnerability) are covered elsewhere, as is the rationale for adjuvant systemic therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/58/13226?source=see_link\">",
"     \"General principles on the treatment of early stage and locally advanced breast cancer in older women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjuvant systemic therapy refers to the administration of systemic anticancer therapy following primary surgery for early stage breast cancer in order to prevent or delay the subsequent appearance of metastatic disease. Occult, clinically unapparent micrometastases are thought to account for distant treatment failures after local treatment alone (ie, surgery with or without radiation therapy).",
"   </p>",
"   <p>",
"    The same general principles that guide the use of adjuvant systemic therapy in younger individuals also apply to older women, although modifications in the treatment approach may be needed for frail individuals or those with multiple or serious comorbidities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Comprehensive geriatric assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consensus guidelines recommend the routine use of a geriatric assessment for older patients with cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Although there is a lack of agreement on the best tool to use, a comprehensive geriatric assessment (CGA) can be useful in formulating treatment decisions for the older patient with cancer. The information derived from a CGA has been used by some authors to classify older populations based upon their functional status, rehabilitative potential, life expectancy and tolerance of stress (",
"    <a class=\"graphic graphic_table graphicRef60632 \" href=\"mobipreview.htm?20/18/20779\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef67375 \" href=\"mobipreview.htm?4/10/4270\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most of the CGA studies have been descriptive, revealing degrees of deviation from estimated health status in older patients. One report illustrates how the results of the CGA led to modifications in the treatment plan according to the degree of",
"    <span class=\"nowrap\">",
"     frailty/vulnerability",
"    </span>",
"    in elderly patients with a variety of tumor types [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/7\">",
"     7",
"    </a>",
"    ]. This topic is addressed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/56/41864?source=see_link&amp;anchor=H15#H15\">",
"     \"Comprehensive geriatric assessment for patients with cancer\", section on 'Use of CGA results'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/58/13226?source=see_link&amp;anchor=H10#H10\">",
"     \"General principles on the treatment of early stage and locally advanced breast cancer in older women\", section on 'Comprehensive geriatric assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28327637\">",
"    <span class=\"h2\">",
"     Organ function and drug metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;A detailed discussion of the pharmacology of chemotherapeutic agents in older patients is beyond the scope of this discussion; several excellent reviews are available. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/42/10922?source=see_link\">",
"     \"Systemic chemotherapy for cancer in elderly persons\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pertinent aspects of organ function as it pertains to drug metabolism in the elderly population are summarized below. The management of chemotherapy drug doses in patients with hepatic or renal impairment is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/2/44074?source=see_link\">",
"     \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41738?source=see_link\">",
"     \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28327644\">",
"    <span class=\"h3\">",
"     Hepatic insufficiency and hepatotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The liver is the main organ where drugs are metabolized. There is lack of agreement as to whether there are age-related changes in hepatic drug metabolizing activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/8\">",
"     8",
"    </a>",
"    ]. However, with few exceptions, only patients with major liver function abnormalities are at substantially increased risk of toxicity.",
"   </p>",
"   <p>",
"    General guidelines for dose modifications in patients with liver disease are shown in the following table (",
"    <a class=\"graphic graphic_table graphicRef69104 \" href=\"mobipreview.htm?21/11/21694\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/2/44074?source=see_link&amp;anchor=H11#H11\">",
"     \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\", section on 'Cytotoxic agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some chemotherapy drugs can also lead to hepatotoxicity. If liver function tests become abnormal during therapy for reasons that are unclear, consideration should also be given to reactivation of hepatitis B or hepatitis C virus replication and worsening hepatitis. Issues related to screening and prophylaxis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26009?source=see_link\">",
"     \"Hepatitis B virus reactivation associated with immunosuppression\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/26/30122?source=see_link&amp;anchor=H16#H16\">",
"     \"Clinical manifestations and natural history of hepatitis B virus infection\", section on 'Reactivation associated with immunosuppression'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/51/24378?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of the management of hepatitis B and case examples\", section on 'Who should be tested'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/24/6538?source=see_link&amp;anchor=H27#H27\">",
"     \"Lamivudine monotherapy for chronic hepatitis B virus infection\", section on 'With immunosuppression'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28327651\">",
"    <span class=\"h3\">",
"     Renal insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aging is associated with a gradual loss of renal mass and decline in renal function. In the elderly, reduction in glomerular filtration may not be reflected by an increase in serum creatinine because of the simultaneous loss of muscle mass that accompanies advancing age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Estimates of the creatinine clearance rather than the serum creatinine should be used to determine the dosing for chemotherapy drugs that are excreted by the kidneys [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/10\">",
"     10",
"    </a>",
"    ]. General guidelines for dose modification of chemotherapy agents in patients with compromised renal function are shown in the following table (",
"    <a class=\"graphic graphic_table graphicRef56245 \" href=\"mobipreview.htm?1/42/1708\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41738?source=see_link&amp;anchor=H4#H4\">",
"     \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\", section on 'Cytotoxic drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28329344\">",
"    <span class=\"h3\">",
"     Cardiotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues related to cardiotoxicity in patients receiving anthracyclines or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    are discussed below. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Anthracycline versus nonanthracycline-based regimens'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H33\">",
"     'Cardiotoxicity'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Prognostic and predictive factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;An estimation of the risk of disease relapse is of paramount importance when considering the use of adjuvant therapy, particularly chemotherapy since it is more toxic than endocrine therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/28/43465?source=see_link\">",
"     \"Measurement of prognostic factors in breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the past, prognostic estimates were based primarily on pathologic factors such axillary lymph node metastases, primary tumor size, and the histologic grade of differentiation. Increasingly, biologic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    molecular factors are used to individualize adjuvant treatment decisions. Well-known and established biologic characteristics, such as tumor expression of hormone receptors and HER2, are prognostic and predictive factors, allowing for selection of patients who are most likely to benefit from endocrine therapy and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    , respectively. Multiparameter gene expression analyses, which are inclusive of information about hormone receptor and HER2-related genes, have both prognostic and predictive value too. These will help stratify patients into those with node-negative, hormone receptor positive breast cancer who have a high risk of disease recurrence to justify the addition of adjuvant chemotherapy to hormone therapy, and those who are at a low enough risk to justify using hormone therapy alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Hormone receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Expression of steroid hormone receptors (estrogen receptor [ER] and progesterone receptor [PR]) predicts response to hormone therapy, and is probably the most important of the predictive factors. Patients whose tumors are hormone receptor ER-positive are very likely to benefit from endocrine therapies, while those with ER-negative cancers do not benefit. In addition, the absolute magnitude of clinical benefit derived from chemotherapy is smaller in ER-positive as compared to ER-negative breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/47/19194?source=see_link\">",
"     \"Hormone receptors in breast cancer: Clinical utility and guideline recommendations to improve test accuracy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     HER2 overexpression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amplification",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    overexpression of the gene encoding the cell surface receptor-like molecule HER2 is used to select patients who might benefit from adjuvant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    , a humanized, anti-HER2 monoclonal antibody.",
"   </p>",
"   <p>",
"    HER2 overexpression also predicts benefit from anthracycline-based, as compared to nonanthracycline-based CMF-type (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    ) adjuvant chemotherapy. However, preliminary data from at least one study suggests that patients with HER2+ breast cancer who receive a nonanthracycline taxane-containing adjuvant chemotherapy regimen coupled with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    have similar outcomes as do those treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , cyclophosphamide, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    plus trastuzumab [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/14\">",
"     14",
"    </a>",
"    ]. These data suggest that the addition of trastuzumab to a nonanthracycline-containing regimen containing a taxane might provide comparable benefit for HER2+ tumors while avoiding the excess risk of heart failure and treatment-related leukemia associated with anthracyclines and a more favorable side effect profile overall [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/14\">",
"     14",
"    </a>",
"    ]. However, early data from the BCIRG 006 study also suggest the possibility that tumors which also express topoisomerase II derive benefit from anthracycline-based as compared to nonanthracycline-based but trastuzumab-containing adjuvant regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/7\">",
"     7",
"    </a>",
"    ]. This remains an active area of research. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Choice of regimen'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Analysis of gene expression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Analyzing patterns of gene expression in individual tumors holds great promise as a means of customizing adjuvant therapy recommendations. There are two types of molecular assays that have the potential to impact on adjuvant therapy decisions: multiplex reverse-transcriptase polymerase chain reaction (RT-PCR), which is used in the 21-gene recurrence score assay (eg, Oncotype DX&trade;), and gene expression arrays, such as that used in the MammaPrint assay. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/22/6503?source=see_link\">",
"     \"Prognostic molecular profiles of breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Estimating the risks and benefits of systemic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Judicious use of prognostic and predictive factors can help patients and clinicians to estimate the risk of disease recurrence and the relative",
"    <span class=\"nowrap\">",
"     risk/benefit",
"    </span>",
"    ratio of receiving one or more elements of adjuvant systemic therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/28/43465?source=see_link\">",
"     \"Measurement of prognostic factors in breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whether a patient accepts therapy depends in part on her perception of how much benefit she feels is needed to justify the toxicity of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/15\">",
"     15",
"    </a>",
"    ]. This decision is particularly difficult with chemotherapy, since side effects are common and may be severe; life threatening toxicities occur in approximately 1 in every 300 to 500 treated women. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/33/41496?source=see_link\">",
"     \"Acute side effects of adjuvant chemotherapy for early stage breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5367648\">",
"    <span class=\"h3\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, studies show that most clinicians and patients routinely accept adjuvant chemotherapy if the absolute improvement in 10 year disease-free survival (DFS) is 10 percent or more [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. On the other hand, they typically do not accept the risks of therapy if DFS is improved by 3 to 5 percent or less. Variability exists in the acceptance of adjuvant chemotherapy if the estimated benefit falls between these two extremes. Given the less favorable toxicity profile of chemotherapy, it is not surprising that the available data in premenopausal women suggest that acceptable survival gains tend to be lower when adjuvant endocrine therapy is considered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Models have been generated to determine the relative benefits of adjuvant chemotherapy, taking into account age and comorbidity. These are discussed below. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Life expectancy, comorbidity, and expected benefit from chemotherapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Tools such as Adjuvant! and the 21-gene recurrence score assay provide information that may be helpful when discussing the benefits and risks of adjuvant therapies with patients. Their application in making treatment decisions in the adjuvant setting is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/22/6503?source=see_link\">",
"     \"Prognostic molecular profiles of breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5367655\">",
"    <span class=\"h3\">",
"     Endocrine therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tools such as Adjuvant! and the 21-gene recurrence score are useful for decisions regarding adjuvant systemic chemotherapy. There are few tools to assist in decision-making regarding adjuvant endocrine therapy for women with hormone receptor-positive tumors. In fact, consensus-based guidelines from expert groups disagree in this area. Guidelines from a consensus conference panel, commonly called the St. Gallen guidelines, recommend adjuvant endocrine treatment in almost all patients whose tumors show evidence of endocrine responsiveness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/18\">",
"     18",
"    </a>",
"    ], while the National Comprehensive Cancer Network (NCCN) recommends adjuvant hormone therapy for women with hormone responsive tumors &lt;1 cm only if they have unfavorable histologic characteristics (angiolymphatic invasion, high nuclear grade, and high histologic grade) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/46/19177?source=see_link\">",
"     \"Overview of the treatment of newly diagnosed, non-metastatic breast cancer\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    At least some data suggest that there is a small subgroup of patients aged 60 or older with small (&lt;1 cm), grade 1, hormone receptor positive, and node-negative tumors who do not have a higher mortality rate than age-matched members of the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/19\">",
"     19",
"    </a>",
"    ]. It is unlikely that such women would gain a survival benefit from the use of adjuvant hormone therapy, because the risk of mortality is already extremely low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/20\">",
"     20",
"    </a>",
"    ]. However, these patients may still benefit from reduction in the risk of ipsilateral and contralateral breast events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5367501\">",
"    <span class=\"h3\">",
"     Frail elderly patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Frailty is a physiologic syndrome, characterized by decreased reserve and diminished resistance to stressors, that results from cumulative decline across multiple physiologic systems and causes vulnerability to adverse outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/22\">",
"     22",
"    </a>",
"    ]. The factors that contribute to frailty include physiologic changes of aging, decreased physical strength, chronic disease, and diminished physical activity. Frailty limits survival and increases the risk of treatment-related complications. For a definition of frailty (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/26/34215?source=see_link&amp;anchor=H3#H3\">",
"     \"Failure to thrive in elderly adults: Evaluation\", section on 'Frailty'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In general, because their life expectancy is limited by their frail condition, frail elders are not felt to be candidates for adjuvant systemic therapy with either endocrine therapy or chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/23\">",
"     23",
"    </a>",
"    ]. Estimates of the benefits of treatment can be made using Adjuvant! Online, which factors in US Census-derived mortality data by age and allows an estimation of the impact of comorbidity and overall health on treatment benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/24\">",
"     24",
"    </a>",
"    ]. The presence of frailty increases the risk of death from causes other than cancer and decreases the percentage gain from adjuvant systemic therapy to a level where benefit is negligible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ADJUVANT ENDOCRINE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefits of adjuvant endocrine therapy in improving both relapse-free survival (RFS) and overall survival in women with hormone receptor-positive early breast cancer have been most clearly shown in a series of overview analyses from the Early Breast Cancer Trialists' Collaborative Group (EBCTCG). The following sections will focus on the data in older women. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20106?source=see_link\">",
"     \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Tamoxifen",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the most recent EBCTCG overview analysis, among postmenopausal women with estrogen receptor (ER)-positive breast cancer, five years of adjuvant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    compared to no tamoxifen reduced the 15-year risk of a breast cancer recurrence by approximately 40 percent and reduced breast cancer mortality by 35 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/25\">",
"     25",
"    </a>",
"    ]. The benefits were consistent and substantial for woman in each age range, including the few who entered the trials at age 70 or older. The relative risk reduction was also similar in women with node-negative and node-positive disease, although the absolute magnitude of benefit was greatest in node-positive disease. Women with ER-negative tumors did not benefit from tamoxifen, regardless of age. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20106?source=see_link&amp;anchor=H933462070#H933462070\">",
"     \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\", section on 'Tamoxifen'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Until recently,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    was the only approved agent for adjuvant endocrine therapy. However, the most concerning side effects of tamoxifen (thromboembolism, endometrial cancer) occur primarily in postmenopausal women over the age of 55, especially elderly women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. Furthermore, up to 15 percent of postmenopausal women discontinue tamoxifen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/29-31\">",
"     29-31",
"    </a>",
"    ], a rate that is higher than that seen in younger patients. Treatment discontinuation is more likely in patients reporting side effects and in those with poor physical function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Aromatase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from clinical trials comparing aromatase inhibitors (AIs,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/49/22294?source=see_link\">",
"     anastrozole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/26/36261?source=see_link\">",
"     letrozole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/4/7238?source=see_link\">",
"     exemestane",
"    </a>",
"    ) to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    in the adjuvant setting show that AIs are more effective than tamoxifen alone in decreasing the risk of disease relapse and contralateral breast cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20106?source=see_link&amp;anchor=H933462070#H933462070\">",
"     \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\", section on 'Tamoxifen'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the first and largest trial of an aromatase inhibitor versus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    , the ATAC (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/49/22294?source=see_link\">",
"     Anastrozole",
"    </a>",
"    Tamoxifen Alone and in Combination) trial, five years of anastrozole was significantly superior to five years of tamoxifen alone or the combination of tamoxifen and anastrozole in terms of disease-free survival (DFS), time to recurrence, distant metastases, and incidence of contralateral breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/32\">",
"     32",
"    </a>",
"    ]. Overall survival was similar in both groups.",
"   </p>",
"   <p>",
"    Perhaps more importantly, there were differences between",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/49/22294?source=see_link\">",
"     anastrozole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    in terms of adverse effect profile. Compared to tamoxifen, the incidence of ischemic cerebrovascular events, endometrial cancer, hot flashes, venous thromboembolic events, and vaginal bleeding were all less during treatment with anastrozole, but the incidence of bone fractures and musculoskeletal pain was higher [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other trials have demonstrated that sequencing of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    followed by an AI, compared to adjuvant therapy with tamoxifen alone, reduces breast cancer recurrence and the incidence of contralateral breast cancer, but has no significant impact on overall survival. The optimal timing of switching from tamoxifen to an AI is unknown, as is the optimal duration of treatment with an AI after switching from tamoxifen. These trials are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20106?source=see_link&amp;anchor=H933462070#H933462070\">",
"     \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\", section on 'Tamoxifen'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In some [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/35\">",
"     35",
"    </a>",
"    ] but not all trials, AIs have been associated with a higher risk of grade 3 to 5 ischemic cardiac events compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    . A meta-analysis of seven trials comparing tamoxifen versus an AI as upfront therapy concluded that longer duration of AI therapy or use of an AI alone was associated with significantly greater odds of developing cardiovascular disease as compared to tamoxifen alone (or tamoxifen plus short duration of an AI) (odds ratio [OR] 1.26, 95% CI 1.10-1.43) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/36\">",
"     36",
"    </a>",
"    ]. Although this approach is not validated, these data suggest that it may be useful to select the specific adjuvant endocrine therapy, either an AI or tamoxifen, based upon a patient&rsquo;s risk of cardiovascular events, such that patients with documented history of cardiovascular disease be preferentially prescribed tamoxifen and only an AI if their risk of breast cancer recurrence is very high. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20106?source=see_link&amp;anchor=H933462070#H933462070\">",
"     \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\", section on 'Tamoxifen'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has been hypothesized that cumulative life-threatening toxicity from AIs when used upfront may contribute to the lack of survival benefit when compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    . The meta-analysis mentioned above found that adjuvant therapy five years of treatment with an AI was associated with a greater odds of death without recurrence compared to either five years of tamoxifen alone or tamoxifen for two to three years followed by an AI for two to three years, although the difference was not statistically significant (odds ratio for death 1.11, 95% CI 0.98-1.26) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/36\">",
"     36",
"    </a>",
"    ]. The authors concluded that switching between AIs and tamoxifen (use of AIs for two to three years after or before tamoxifen) might provide the best balance between efficacy and toxicity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20106?source=see_link&amp;anchor=H933462070#H933462070\">",
"     \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\", section on 'Tamoxifen'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An expert panel convened by ASCO in 2004 recommended that adjuvant endocrine therapy for postmenopausal women with",
"    <span class=\"nowrap\">",
"     ER/PR-positive",
"    </span>",
"    breast cancer include an AI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/37\">",
"     37",
"    </a>",
"    ]. However, given the lack of an overall survival benefit in the comparative trials, the preferential use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    or a switch to tamoxifen after two to three years of an AI is recommended over five years of an AI alone, especially in cases where tolerability of an AI or cardiovascular effects or bone loss are significant issues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Benefits and risks in older women",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is little evidence to suggest that the benefits of an AI over",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    alone are less in older as compared to younger postmenopausal women. Patterns of toxicity associated with AI therapy are, however, slightly different (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Aromatase inhibitors'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the BIG I-98 trial (five years of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/26/36261?source=see_link\">",
"       letrozole",
"      </a>",
"      versus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      ), the DFS benefits of letrozole appeared to be present in all age groups, including women 75 years of age or older [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/38\">",
"       38",
"      </a>",
"      ]. The overall incidence of cardiac adverse events was similar between the treatment groups, but a significant difference favoring tamoxifen was observed in older postmenopausal women aged 65 to 74 after adjusting for risk factors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/38\">",
"       38",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Women age 65 to 74 were more likely to have cardiac and ischemic heart events than were postmenopausal women below age 65 or women age 75 and older. For cardiac events overall, history of hypertension and prior cardiac event were risk factors. For ischemic heart events, history of hypertension and prior ischemic heart events were risk factors. The incidence of bone fractures was higher with letrozole but did not differ by age group. Women age 75 and older were less likely to complete treatment.",
"     </li>",
"     <li>",
"      In a subgroup analysis of older women in the NCIC Intergroup Trial MA 17 (five years of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/26/36261?source=see_link\">",
"       letrozole",
"      </a>",
"      versus placebo after five years of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      ), there was no evidence of a heterogeneous treatment effect in different age groups, although the improvement in DFS with letrozole relative to placebo was statistically significant only in patients under the age of 60 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/39\">",
"       39",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The side effect pattern did differ according to age. Compared to placebo, women younger than age 60 receiving letrozole had a significantly lower incidence of vaginal bleeding and a higher incidence of arthralgias. Women in the 60 to 69 year age range who were taking letrozole had a significantly higher incidence of hot flashes, insomnia, arthralgias, and alopecia. In general, women 70 and older had significantly higher rates of fracture, new osteoporosis, and cardiac disease compared to younger individuals. However, in this age group, there were no significant differences between the two treatment groups in fracture (6 versus 8 percent with letrozole and placebo, respectively), new development of osteoporosis (10 versus 8 percent) or cardiac disease (10 versus 11 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of its favorable therapeutic index, adjuvant endocrine therapy should be offered to all non-frail older women with ER-positive breast tumors &gt;1 cm, regardless of age. For older, postmenopausal women with smaller (&le;1 cm), low grade, node-negative, ER-positive tumors, observation or endocrine therapy are both acceptable options. There is no significant benefit to adjuvant endocrine therapy for ER-negative disease.",
"   </p>",
"   <p>",
"    Based upon mounting evidence in favor of an AI over",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    alone in decreasing the risk of disease relapse and contralateral breast cancers, an AI should be considered as a component of adjuvant endocrine therapy for most women. However, given the lack of an overall survival benefit in the comparative trials, in cases where tolerability of an AI or cardiovascular effects or bone loss are significant clinical issues, a switch to tamoxifen after two or three years of an AI or five years of tamoxifen alone is a reasonable alternative. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20106?source=see_link\">",
"     \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     BENEFITS OF CYTOTOXIC CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared to its widespread acceptance in premenopausal women, the use of adjuvant chemotherapy in postmenopausal women is a controversial topic, particularly for women with ER-positive disease. For older postmenopausal women, the decision to use adjuvant chemotherapy is even more complicated because of the following issues:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With advancing age, organ function declines and the number of comorbidities increases, potentially magnifying the risks associated with chemotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Accurately estimating life expectancy is difficult, and there is understandable hesitation to deliver potentially toxic treatment when it is unclear if an older woman will live long enough to justify the risks and side effects. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/58/13226?source=see_link&amp;anchor=H7#H7\">",
"       \"General principles on the treatment of early stage and locally advanced breast cancer in older women\", section on 'Factors that affect treatment decisions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The efficacy of chemotherapy may decline with advancing age.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Magnitude of benefit in older women",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least some data suggest that chemotherapy efficacy declines with increasing age. In the EBCTCG overview, there were statistically significant reductions in recurrence and breast cancer-specific mortality with adjuvant polychemotherapy (compared to no therapy) in both younger and older women, but the absolute magnitude of benefit was three times greater in younger women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For women under age 50 at randomization, polychemotherapy reduced the annual risk of disease relapse and death from breast cancer by 37 and 30 percent, respectively. This translated into a 10 percent absolute improvement in 15-year survival (42 versus 32 percent).",
"     </li>",
"     <li>",
"      For women aged 50 to 69 receiving adjuvant chemotherapy, the risk of relapse or death was decreased by 19 and 12 percent, respectively. This translated into a 3 percent absolute gain in 15-year survival (50 versus 47 percent).",
"      <br/>",
"      <br/>",
"      The stepwise reduction in the relative efficacy of adjuvant chemotherapy with advancing age is illustrated in the following table (",
"      <a class=\"graphic graphic_table graphicRef81265 \" href=\"ONC_81265\">",
"       table 4",
"      </a>",
"      ). The data were insufficient to show a statistically significant benefit for chemotherapy in the group of women age 70 years and older. Of the 29,000 women enrolled in the 60 adjuvant polychemotherapy trials included in the meta-analysis, only about 1200 (4 percent) were age 70 or older.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other factors may reduce the incremental benefit from chemotherapy seen in clinical trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As women age, the risk of death from competing causes increases, making the difference in breast-cancer specific mortality smaller [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/41-43\">",
"       41-43",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Life expectancy, comorbidity, and expected benefit from chemotherapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      As a group, older women have less \"aggressive\" breast cancers, seen as requiring less treatment. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/58/13226?source=see_link&amp;anchor=H518871776#H518871776\">",
"       \"General principles on the treatment of early stage and locally advanced breast cancer in older women\", section on 'Tumor biology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The level of risk for older women entered into clinical trials of adjuvant chemotherapy (ie, the level of risk that was perceived as justifying the use of chemotherapy) has historically been higher than for younger women.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These and other issues help to explain why older women with early breast cancer have received adjuvant chemotherapy significantly less often in the past than did their younger counterparts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/44-54\">",
"     44-54",
"    </a>",
"    ]. Current trends suggest that chemotherapy use is increasing in this population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/55,56\">",
"     55,56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Influence of ER status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Older women are more likely to have ER-positive breast cancers, for which the benefit of chemotherapy is less pronounced as compared to ER-negative disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most illustrative data come from the Early Breast Cancer Trialists Collaborative Group (EBCTCG) overview analysis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. For women aged 50 to 69 years, the ratio of annual event rates for breast cancer recurrence and mortality for adjuvant polychemotherapy versus nil were 0.67 versus 0.84 for ER-poor disease, compared to 0.74 versus 0.95 for ER-positive disease, respectively. For polychemotherapy plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      versus tamoxifen alone, the ratio of annual event rates for recurrence and mortality were 0.75 versus 0.85 for ER-poor disease, and 0.86 versus 0.89 for ER-positive disease, respectively.",
"      <br/>",
"      <br/>",
"      The corresponding values for women age &lt;50 years were as follows: polychemotherapy versus nil, 0.61 versus 0.56 for ER-poor, and 0.68 versus 0.69 for ER-positive, respectively; for polychemotherapy plus tamoxifen versus tamoxifen alone for ER-positive breast cancer 0.64 and 0.65. Ratios were not given for polychemotherapy plus tamoxifen versus tamoxifen only in the younger women. These data support the view that the magnitude of benefit from adjuvant chemotherapy is greater in younger women and in those with ER-negative disease.",
"     </li>",
"     <li>",
"      Similar conclusions were reached in a retrospective analysis of data from three consecutive randomized trials of the Cancer and Leukemia Group B (CALGB) involving 6644 women with node-positive breast cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/13\">",
"       13",
"      </a>",
"      ]. The benefits attributable to improvements in adjuvant systemic chemotherapy over the last 20 years were disproportionately greater among those with ER-negative as compared to ER-positive disease. Compared to the earliest study of CAF at three different dose levels, subsequent trials incorporating a taxane and dose-dense chemotherapy administration resulted in 23 percent more patients with ER-negative tumors surviving to five years disease-free versus only 7 percent of those with ER-positive tumors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     ER-negative disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to the lack of efficacy for adjuvant endocrine therapy in women whose breast cancers are ER-negative, adjuvant chemotherapy is the standard of care for these women if the risk of recurrence is felt to warrant adjuvant systemic therapy.",
"   </p>",
"   <p>",
"    Three separate population-based retrospective analyses of breast cancer treatment in older women, two based upon linked data from the Surveillance, Epidemiology and End Results",
"    <span class=\"nowrap\">",
"     (SEER)/Medicare",
"    </span>",
"    database, support the view that the benefits derived from chemotherapy in women with ER-negative breast cancer do not vary according to age, particularly for those women aged 70 and older compared to younger women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. All three studies showed that chemotherapy use increased over time, varied significantly across geographic areas, decreased with advancing age and higher comorbidity level, and was greater in women who had tumors with poorer prognostic factors, such as involved lymph nodes. However, all three used survival as the sole endpoint. Although survival is typically considered the most robust endpoint for such studies, a decrease in relapse risk is also important as a disease recurrence decreases quality of life.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Influence of nodal status",
"    </span>",
"    &nbsp;&mdash;&nbsp;The absolute benefits of chemotherapy are greater in women with node-positive breast cancer than in node-negative disease, because the risk of recurrence is higher. In the EBCTCG analysis, compared to no adjuvant therapy, the proportional reductions in risk for both recurrence and death from adjuvant chemotherapy were similar in women with node-negative or node-positive breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Contemporary randomized trials comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    alone versus tamoxifen plus oral (but not IV) CMF, anthracycline-based regimens or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    alone in women with node-positive disease all show significant benefits for combined chemoendocrine therapy in terms of improved DFS. An overall survival benefit for adding chemotherapy to tamoxifen has also been shown in two trials, both of which used a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    -containing regimen. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20106?source=see_link\">",
"     \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Only one trial addressing this issue has been conducted exclusively in older women. In this French Adjuvant Study Group trial, 338 women with node-positive operable breast cancer were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    (30 mg daily for three years) with or without six cycles of weekly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    (30 mg on days 1,8, and 15 of every 28-day cycle) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/58\">",
"     58",
"    </a>",
"    ]. Chemotherapy was well tolerated. With a median follow-up of 72 months, the addition of epirubicin was associated with a significant prolongation of six-year DFS (73 versus 69 percent) in women with ER-positive disease but no overall survival benefit was found.",
"   </p>",
"   <p>",
"    Taken together, these data provide a strong rationale for the benefit of adding chemotherapy to endocrine therapy for older women with ER-positive, node-positive early breast cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Node-negative disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relatively high risk-to-benefit ratio for chemotherapy makes recommendations regarding its use in node-negative disease less certain than in node-positive disease. Contemporary randomized trials in postmenopausal women with node-negative ER-positive disease published since the year 2000 EBCTCG analysis yield conflicting results. One (NSABP B-20) showed a DFS and overall survival benefit for adding six cycles of oral CMF to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    , while another (IBCSG trial IX) showed no benefit for adding three courses of oral CMF to tamoxifen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. These data are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20106?source=see_link\">",
"     \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As noted above, a tool that is potentially useful to select those women with node-negative hormone receptor-positive early breast cancer for whom chemotherapy may provide the greatest benefit is the 21-gene recurrence score assay (eg, Oncotype&trade;). Acceptance of this assay for clinical decision making is not universal due to the lack of prospective validation. Nevertheless, guidelines from ASCO and the NCCN (but not the International Consensus Panel) endorse the use of the 21-gene recurrence score assay for clinical decision making in women with node-negative",
"    <span class=\"nowrap\">",
"     ER/PR-positive",
"    </span>",
"    breast cancer. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Analysis of gene expression'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A relative lack of benefit for chemotherapy in older women with ER-negative, node-negative disease was also suggested in a study from the linked",
"    <span class=\"nowrap\">",
"     SEER/Medicare",
"    </span>",
"    database described above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/55\">",
"     55",
"    </a>",
"    ]. The use of chemotherapy did not improve survival among women with lymph node-negative disease, regardless of ER status, nor did it improve survival in women with node-positive and ER-positive disease. The only subgroup in which chemotherapy was associated with a significant survival benefit was women with ER-negative, node-positive disease. Breast cancer-specific and overall survival were the only endpoints in this analysis, and risk of relapse was not considered. Furthermore, the duration of follow-up, which may have been too short to see benefit from chemotherapy in this relatively low-risk population, was not stated. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'ER-negative disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Selection of patients for chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As is evident from the preceding discussion, several issues must be considered when contemplating adjuvant chemotherapy in older women with breast cancer. Many of these are general principles that guide the use of chemotherapy in the adjuvant setting regardless of age. As an example, nodal status,",
"    <span class=\"nowrap\">",
"     ER/PR",
"    </span>",
"    and HER2 expression, and tumor gene expression analysis influence the selection of adjuvant treatment in patients of any age. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Prognostic and predictive factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The following are perhaps more crucial considerations in older women:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Estimated life expectancy, based upon functional status and the presence of other potentially life-limiting comorbid illnesses",
"     </li>",
"     <li>",
"      The risk of side effects from chemotherapy, some of which may be life-threatening",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Life expectancy, comorbidity, and expected benefit from chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major issues to consider when weighing the risks and benefits of adjuvant chemotherapy in older women are anticipated non-breast cancer-related survival (ie, life expectancy independent of the diagnosis of breast cancer) and the possibility of a higher risk of treatment-related side effects. Both of these are dependent not only on age but also on comorbidity, functional status, and frailty. Estimated life expectancies for women who are in good health, of average health, or sick are presented in the following figure (",
"    <a class=\"graphic graphic_figure graphicRef68925 \" href=\"ONC_68925\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Comorbidity has an adverse effect on both overall and breast cancer-specific survival. Two models have been generated to determine the relative benefits of adjuvant chemotherapy in older women, taking into account age and comorbidity:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One analysis used a Markov model and data from the 1992 EBCTCG overview to provide threshold estimates of relapse risk at 10 years in women age 65 to 85 years old at which adjuvant treatment achieved an absolute 1 percent reduction in relapse or mortality (the threshold level of benefit identified by patients as the desired target to make chemotherapy worthwhile), taking into consideration age and comorbidity level [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/61\">",
"       61",
"      </a>",
"      ]. This model was constructed such that patients with ER-positive tumors were treated in one of three ways: chemotherapy plus five years of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      , tamoxifen alone for five years, or no adjuvant treatment; patients with ER-negative disease were treated with either chemotherapy or no adjuvant therapy. It was assumed that all patients received standard initial local treatment.",
"      <br/>",
"      <br/>",
"      The authors provided a series of graphs with which clinicians could plot a patient's age and then determine what threshold risk of recurrence would be necessary to achieve a 1 percent reduction in relapse and likewise what threshold risk of death would be necessary to achieve a 1 percent reduction in mortality by adjuvant therapy (",
"      <a class=\"graphic graphic_figure graphicRef52507 \" href=\"ONC_52507\">",
"       figure 2",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Although the threshold risk for an absolute 1 percent reduction in relapse by tamoxifen or chemotherapy was minimally influenced by age or comorbidity, mortality benefit was strongly influenced by age and comorbidity. For tamoxifen alone, the threshold risk of relapse to see a 1 percent benefit in 10-year survival for healthy women at age 65 was 11 percent; it was 20 percent for sick women of the same age. At age 85, the threshold risks of relapse needed to see a 1 percent benefit in five-year survival for healthy and sick women were 28 and 35 percent, respectively, and benefit was limited to five but not 10 years.",
"      <br/>",
"      <br/>",
"      The threshold for risk of recurrence and breast cancer-related death above which adjuvant chemotherapy was beneficial for older women increased more dramatically: it was 19 percent for a healthy 65-year-old, and 62 percent for a sick 85-year-old. The presence of comorbidity increased the threshold risk of relapse to see a 1 percent benefit in survival by approximately 10 and 20 percent for tamoxifen and chemotherapy, respectively.",
"     </li>",
"     <li>",
"      Another model explored the cost-effectiveness of chemotherapy in women aged 60 to 80 with ER-negative, node-negative breast cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/62\">",
"       62",
"      </a>",
"      ]. Assuming an estimated baseline risk of relapse of 5 percent per year (23 percent at five years), administering adjuvant chemotherapy to a 75-year-old patient was associated with a 1.8 month average gain in quality-adjusted survival (compared to 5.1 months in a 45-year-old women) and a 3 percent decrease in the risk of relapse at five years, at a cost of $44,000 per year of life saved. While the cost-benefit ratio was high, it was within the range of other commonly reimbursed procedures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, these studies suggest that the benefits of chemotherapy in women with hormone receptor-positive and node-negative hormone receptor-negative tumors are likely to be very small in women 75 years of age and older who have breast cancer, particularly if they have other comorbid conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Competing causes of death",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another reason for the relative decrease in effectiveness of chemotherapy with advancing age is that, as women age, mortality attributable to breast cancer decreases, while nonbreast cancer-related mortality increases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. The relationship between age, disease extent, and breast cancer versus non-breast cancer-related mortality was explored in a series of women aged 55 or older with breast cancer derived from the San Antonio Breast Cancer Database (n = 35,154) and the SEER registry (n = 171,424) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/43\">",
"     43",
"    </a>",
"    ]. For women over age 70 who had small (&lt;2 cm), node-negative tumors, the observed survival rates were almost identical to those expected for similarly aged women without breast cancer. By comparison, for women with node-positive disease, observed survival was lower than expected for all age groups, although the gap narrowed with increasing age. At eight years, the relative survival of women with one to three positive nodes at ages 50 to 54, 60 to 64, 70 to 74, and 80 to 84 were 0.74, 0.81, 0.78, and 0.89, respectively.",
"   </p>",
"   <p>",
"    Breast cancer was responsible for 73 percent of all deaths in women age 50 to 54, but only 29 percent of the deaths in women 85 years and older. The relative decrease in breast cancer-related deaths with advancing age was especially pronounced in patients with small tumors (&lt;1 cm); breast cancer was the cause of death in only 12 to 16 percent of patients aged 75 years and older with tumors &lt;1 cm in size.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Frailty",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, frail elderly individuals have diminished survival and a higher risk of treatment-related complications, particularly with chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/23,63\">",
"     23,63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/26/34215?source=see_link&amp;anchor=H3#H3\">",
"     \"Failure to thrive in elderly adults: Evaluation\", section on 'Frailty'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, frail individuals with hormone receptor-negative breast cancer and an expected survival of less than five years are not candidates for adjuvant chemotherapy, even if they have extensive nodal involvement. The marginal benefits of chemotherapy in these patients can be estimated using the online program Adjuvant! Online, which factors in US Census-derived mortality data by age and the impact of comorbidity on treatment benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     CHOICE OF REGIMEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;When chemotherapy is indicated, the choice of regimen is influenced by HER2 expression status.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As for younger patients, the chemotherapy regimen for healthy older patients with high-risk (particularly node positive) HER2+ breast cancer should contain",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      and a taxane, with or without an anthracycline. We use TCH (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      and trastuzumab) rather than an anthracycline-containing trastuzumab-based regimen in elderly women because of its more favorable side effect profile [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/65\">",
"       65",
"      </a>",
"      ]. This regimen consists of docetaxel (75",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      plus carboplatin (dosed at an area under the concentration x time curve [AUC] 6) every three weeks x 6, with trastuzumab as above for one year. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'HER2 overexpression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      is not indicated (ie, if HER2 is not overexpressed by the tumor), the main issues are use of an anthracycline-containing versus a nonanthracycline-containing CMF-type regimen and whether to include a taxane as a component of the regimen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These concepts are discussed in detail elsewhere. The following sections will emphasize issues that pertain to older women. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/7/11384?source=see_link\">",
"     \"Adjuvant medical therapy for HER2-positive breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Trastuzumab not indicated",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Anthracycline versus nonanthracycline-based regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the advent of taxanes, the two main categories of adjuvant chemotherapy regimens were anthracycline-based and CMF-type regimens. A modest but statistically significant survival benefit for anthracyclines was suggested in the EBCTCG overview analysis, which directly compared anthracycline-containing regimens versus CMF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/11\">",
"     11",
"    </a>",
"    ]. Compared to CMF, anthracycline-based regimens were associated with a modest but statistically significant 11 percent proportional reduction in disease recurrence and a 16 percent reduction in death. In each case, the absolute difference in outcomes was about 3 percent at five years and 4 percent at 10 years, and was about the same for women aged 60 to 69 compared to younger women. Few women &ge;70 were studied.",
"   </p>",
"   <p>",
"    However, interpretation of these data is confounded by differing administration schedules of CMF. The duration and intensity of the anthracycline-containing regimen and whether HER2 is overexpressed by the tumor may also be important factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overall, the data support the view that results with standard doses of AC or EC are similar to oral (but not IV) CMF.",
"     </li>",
"     <li>",
"      It is likely that longer duration or more intense anthracycline-based regimens (eg,",
"      <span class=\"nowrap\">",
"       FAC/CAF,",
"      </span>",
"      FEC, dose-dense therapy with AC followed by a taxane) are better than oral CMF x 6.",
"     </li>",
"     <li>",
"      Women whose tumors overexpress HER2 are more likely to benefit from anthracyclines than from CMF-type regimens. Guidelines from the ASCO expert panel suggest that an anthracycline-based regimen be strongly considered in women with HER2+ tumors, in the absence of a contraindication to the use of these agents [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/66\">",
"       66",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/22/30058?source=see_link&amp;anchor=H16#H16\">",
"       \"HER2 and predicting response to therapy in breast cancer\", section on 'Anthracyclines'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite these issues, older women (particularly those with preexisting heart disease) are less likely to be offered anthracycline-based adjuvant chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/67\">",
"     67",
"    </a>",
"    ]. Regimens that do not contain an anthracycline are often considered preferable for older patients, largely because the risk of anthracycline-related cardiotoxicity is higher than in younger patients.",
"   </p>",
"   <p>",
"    The magnitude of the risk attributable to the use of adjuvant anthracyclines was addressed in an analysis from the linked",
"    <span class=\"nowrap\">",
"     SEER/Medicare",
"    </span>",
"    database that included 43,338 women aged 66 to 80 who were diagnosed with stage I to III breast cancer between 1992 and 2002, and had no history of preexisting heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/68\">",
"     68",
"    </a>",
"    ]. An anthracycline-containing chemotherapy regimen was administered to 4712, while 3921 received a nonanthracycline-containing regimen, and 34,705 received no chemotherapy.",
"   </p>",
"   <p>",
"    At a median follow-up of 56 months, 10,096 patients (23.3 percent) had subsequent claims for heart failure. There was a significant interaction between age and adjuvant anthracycline use. The five-year incidence of heart failure in women treated with anthracyclines, nonanthracycline-containing chemotherapy, and no chemotherapy was 19, 18, and 15 percent, respectively; the corresponding 10-year rates were 38, 33, and 29 percent, respectively. In contrast, for women age 71 to 80, adjuvant chemotherapy type was not associated with heart failure. Besides age, other baseline characteristics that were associated with heart failure included black race,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    treatment, hypertension, diabetes, and coronary artery disease.",
"   </p>",
"   <p>",
"    Further support for the favorable balance of benefit versus risk for anthracycline-based chemotherapy in older women was provided by an analysis of data from four randomized CALGB trials of adjuvant chemotherapy in 6489 women with node-positive breast cancer, 159 age 70 or older [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/69\">",
"     69",
"    </a>",
"    ]. The trials differed according to chemotherapy regimen (three used anthracyclines), dose, and schedule. Across age groups, patients receiving more intense treatment (higher chemotherapy doses, anthracyclines in addition to CMF-type regimens or taxanes in addition to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    [AC]) had superior relapse-free and overall survival compared to those receiving less treatment.",
"   </p>",
"   <p>",
"    The difference was especially pronounced in women 65 and older, where the reduction in hazard of relapse and death attributed to more chemotherapy compared to less was 42 and 27 percent; comparatively, the reduction in hazard of relapse and death was 20 and 16 percent for women aged 51 to 64, and 18 and 17 percent for women age 50 or less. Notably, older women in these trials had a higher risk of recurrence based upon number of involved axillary nodes: 25 percent of women &ge;65 had &ge;10 involved lymph nodes, versus 17 and 11 percent of women 51 to 64 years and &le;50 years, respectively. The added benefit from more versus less treatment in older women in these trials outweighed the higher rates of treatment-related mortality in older as compared to younger women (1.5 versus 0.2 to 0.7 percent, respectively).",
"   </p>",
"   <p>",
"    Although oral CMF does not include an anthracycline, it is not necessarily less toxic for older patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/70-72\">",
"     70-72",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one trial, women &ge;65 years of age receiving CMF had significantly more toxicity compared to younger postmenopausal women, even though they received significantly less than planned doses (48 percent of women &ge;65 received at least 85 percent of the protocol-specified CMF compared to 65 percent of women &lt;65) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/71\">",
"       71",
"      </a>",
"      ]. Furthermore, the five-year DFS benefit from the addition of CMF to endocrine therapy was negligible in women aged 65 and older, whereas there was a statistically significant benefit in postmenopausal women younger than age 65.",
"     </li>",
"     <li>",
"      While anthracycline-based regimens are more often associated with alopecia and vomiting, CMF (especially oral CMF) is more likely to cause nausea and prolonged myelosuppression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/73\">",
"       73",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/33/41496?source=see_link\">",
"       \"Acute side effects of adjuvant chemotherapy for early stage breast cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41706?source=see_link\">",
"       \"Cardiotoxicity of anthracycline-like chemotherapy agents\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Capecitabine alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     Capecitabine",
"    </a>",
"    (Xeloda&reg;), because of its ease of administration and promising efficacy in the setting of metastatic breast cancer, was investigated as an adjuvant therapy in older women. However, capecitabine monotherapy is not as effective as standard adjuvant chemotherapy regimens in older women with early-stage breast cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/53/29528?source=see_link\">",
"     \"Systemic treatment for metastatic breast cancer: Single agent chemotherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CALGB 49907, which was designed to compare adjuvant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    (2000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day in two divided doses for 14 consecutive days every three weeks for six cycles) to standard adjuvant chemotherapy (six cycles of oral CMF or four cycles of AC, per clinician choice) for older women (aged 65 and older) with breast cancer, was prematurely closed when analysis suggested that capecitabine was highly likely to be inferior [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/74\">",
"     74",
"    </a>",
"    ]. Adjuvant endocrine therapy and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    were allowed as indicated. Based upon analysis of 633 women enrolled and followed for a median duration of 2.4 years, the rates of both relapse and death with capecitabine were nearly twice those with standard chemotherapy. The three-year relapse-free survival and overall survival rates were 68 and 86 percent in the capecitabine group versus 85 and 91 percent in the standard chemotherapy group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     The benefit of adding a taxane",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials provide a strong rationale for the routine use of taxane-containing adjuvant therapy for women with node-positive early stage breast cancer; limited data support a benefit for high-risk (eg,",
"    <span class=\"nowrap\">",
"     ER/PR-negative,",
"    </span>",
"    &gt;1 cm) node-negative disease as well.",
"   </p>",
"   <p>",
"    Benefit seems to be comparable in older as in younger women. A meta-analysis of 13 trials (22,903 patients) testing the efficacy of adding a taxane to anthracycline-based adjuvant chemotherapy came to the following conclusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/75\">",
"     75",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The addition of a taxane significantly improved both DFS (pooled HR 0.83) and OS (pooled HR 0.85). This translated into an absolute five-year risk reduction of 5 percent for DFS and 3 percent for OS.",
"     </li>",
"     <li>",
"      Risk reduction was not influenced by the type of taxane, administration schedule, ER expression, the number of axillary metastases, or by patient age or menopausal status. Benefit in the subgroup of patients with node-negative disease was not addressed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One concern about combinations of a taxane plus an anthracycline is cardiotoxicity. Both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    appear to potentiate the cardiotoxicity of anthracyclines, causing the development of heart failure at lower than expected doses. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/12/40138?source=see_link&amp;anchor=H16#H16\">",
"     \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\", section on 'Taxanes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Regimens combining a taxane with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    may represent a less cardiotoxic alternative for patients who have a contraindication to anthracyclines, and they appear to be as well tolerated by older as compared to younger women. A US Oncology trial compared four cycles of AC versus four cycles of TC (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    75",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    plus cyclophosphamide 600",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    every three weeks) in 1016 women with node-negative (48 percent) or node-positive disease. In the latest update, TC was associated with a significantly lower risk of recurrence (six-year disease-free survival 85 versus 79 percent) and death (six-year overall survival 88 versus 84 percent), it caused significantly less nausea and vomiting, and was as well tolerated in women over age 65 as in younger individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/76\">",
"     76",
"    </a>",
"    ]. There was more fever and neutropenia with TC, however, a particular concern for older individuals. We advise use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    (G-CSF) for hematopoietic support with all cycles of TC in older women. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/4/37961?source=see_link\">",
"     \"Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although these data are compelling, there are no trials directly comparing TC with modern anthracycline-taxane combinations, such as standard-dose or dose-dense AC followed by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    or FEC followed by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    . Most clinicians consider that these regimens are preferred in women (including healthy older women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/77\">",
"     77",
"    </a>",
"    ]) with high-risk (particularly node-positive) disease. In our experience, dose-dense AC followed by paclitaxel is safe and well tolerated, and we use it for healthy women aged 75 and younger with",
"    <span class=\"nowrap\">",
"     ER/PR-negative,",
"    </span>",
"    HER2-negative disease, more than one or two positive nodes, and minimal comorbidity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/4/37961?source=see_link&amp;anchor=H32#H32\">",
"     \"Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer\", section on 'Dose density'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;For healthy older women with adequate cardiac function who do not have a strong preference for keeping their hair during treatment, an anthracycline-based regimen is preferred, particularly if their tumor overexpresses HER2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/66\">",
"     66",
"    </a>",
"    ]. Another option for patients who have a contraindication to anthracyclines is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (TC), which at least in one trial provided superior survival over four cycles of AC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/76\">",
"     76",
"    </a>",
"    ]. Non-anthracycline and non-taxane-based, CMF-type treatment could also be considered in the setting of a preexisting cardiomyopathy or for women at high risk for cardiotoxicity.",
"   </p>",
"   <p>",
"    If an anthracycline-based regimen is chosen, either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    are reasonable choices, although epirubicin may be a less cardiotoxic alternative and is preferred by many clinicians for elderly patients. Four cycles of AC or EC are similarly effective as oral CMF x 6 and add benefit to endocrine therapy alone in postmenopausal women. Single agent epirubicin (30 mg total dose given on days 1, 8, and 15 on a 28 day schedule), when added to adjuvant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    , also improves DFS compared to tamoxifen alone in older women and may be better tolerated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/58,78\">",
"     58,78",
"    </a>",
"    ]. Whether epirubicin monotherapy is equivalent to EC, AC or CMF is unknown, since no randomized trials are available.",
"   </p>",
"   <p>",
"    For women with node-positive breast cancer, for whom the risk of recurrence is higher, a more intensive chemotherapy regimen is recommended. Regimens that are six to eight cycles in length and contain a taxane are preferred.",
"   </p>",
"   <p>",
"    One option for healthy older women with minimal comorbidity is dose-dense AC followed by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/77\">",
"     77",
"    </a>",
"    ]. Another well-tolerated regimen that is often used in older women with node-positive breast cancer is three cycles of FEC followed sequentially by three cycles of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    , as used in the PACS 01 trial. Since both FEC and single agent docetaxel carry a &ge;20 percent risk of febrile neutropenia, G-CSF should be used for hematopoietic support with all cycles of treatment, in keeping with guidelines from ASCO [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An important new finding is that the recommended maximum cumulative dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    (900",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    is probably too high, particularly in older women who have preexisting risk factors for heart failure (including prior endocrine therapy or mediastinal irradiation for breast cancer, hypertension, obesity, and diabetes). Recommended maximum doses based upon the presence of risk factors other than epirubicin are presented in the table (",
"    <a class=\"graphic graphic_table graphicRef56455 \" href=\"mobipreview.htm?31/54/32621\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/80\">",
"     80",
"    </a>",
"    ]. This subject is addressed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41706?source=see_link&amp;anchor=H18#H18\">",
"     \"Cardiotoxicity of anthracycline-like chemotherapy agents\", section on 'Epirubicin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Trastuzumab indicated",
"    </span>",
"    &nbsp;&mdash;&nbsp;High levels of amplification",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    overexpression of HER2 identify those patients who might benefit from treatment with the anti-HER2 monoclonal antibody",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    . The potential benefit of adding trastuzumab to systemic chemotherapy should be discussed with fit older women who have high-risk HER2-positive cancers. Four large randomized trials evaluating the addition of one year of trastuzumab to",
"    <span class=\"nowrap\">",
"     anthracycline/taxane-based",
"    </span>",
"    chemotherapy are strikingly positive in terms of preventing recurrence and decreasing mortality in women with HER2-positive tumors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Cardiotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    is associated with a small but real increase in the risk of cardiac events, and older age appears to be one of the risk factors for cardiotoxicity. For women with HER2-overexpressing early breast cancer who are being considered for adjuvant trastuzumab outside a clinical trial setting, exclusion criteria on the basis of excess cardiac risk have not been established, and there are no published guidelines. It is reasonable to use the cardiac ineligibility criteria as used in the North American adjuvant trastuzumab trials (",
"    <a class=\"graphic graphic_table graphicRef74571 \" href=\"mobipreview.htm?10/30/10731\">",
"     table 6",
"    </a>",
"    ). Stringent attention must be paid to monitoring cardiac function during treatment. (See",
"    <a class=\"medical medical_review\" href=\"./cardiotoxicity-of-trastuzumab-and-other-her2-targeted-agents?source=see_link\">",
"     \"Cardiotoxicity of trastuzumab and other HER2-targeted agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;For fit older women with HER2-overexpressing breast cancer, the addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    to cytotoxic chemotherapy significantly improves survival and diminishes recurrence risk. However, despite close monitoring and aggressive management, combined treatment is associated with a small but real increase in the risk of myocardial dysfunction. Approximately 2 to 3 percent of women who undergo one year of trastuzumab after anthracycline-based adjuvant chemotherapy will develop symptomatic congestive heart failure; a higher number will have an asymptomatic decline in the LVEF. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/7/11384?source=see_link\">",
"     \"Adjuvant medical therapy for HER2-positive breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risks associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    must be balanced against the poor prognosis of women with node-positive, HER2-overexpressing breast cancer and the prognosis of women with node-negative but small HER2-overexpressing T1 tumors, compared to those that do not overexpress HER2.",
"   </p>",
"   <p>",
"    We often use the TCH regimen in older women, due to its more favorable safety profile with respect to cardiotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/65\">",
"     65",
"    </a>",
"    ]. This regimen consists of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    (75",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    (dosed at an area under the concentration x time curve [AUC] 6) every three weeks x 6, with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    for one year. As with other docetaxel-containing regimens, we recommend the use of G-CSF for hematopoietic support with all cycles of treatment containing docetaxel in older patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/52/26437?source=see_link\">",
"       \"Patient information: Early stage breast cancer treatment in postmenopausal women (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The same general principles that guide the use of adjuvant systemic therapy in younger women with breast cancer apply to older women. The most important factors influencing the choice of the adjuvant therapy strategy in older as in younger women are whether the tumor expresses hormone receptors and HER2, tumor size and nodal status, and for women with ER-positive node-negative tumors, analysis of tumor gene expression profile. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Prognostic and predictive factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Our recommendations for adjuvant systemic therapy in healthy older women are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef81185 \" href=\"mobipreview.htm?41/56/42892\">",
"     table 7",
"    </a>",
"    ) and largely reflect those of the International Consensus Group (",
"    <a class=\"graphic graphic_table graphicRef58370 \" href=\"ONC_58370\">",
"     table 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef63198 \" href=\"ONC_63198\">",
"     table 9",
"    </a>",
"    ), with minor exception [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/81\">",
"     81",
"    </a>",
"    ]. Consensus statements such as these have dropped the age limit of 70 years from their recommendations. However, for women over age 75 and those with significant comorbid illness or frailty, the clinician and patient must carefully weigh the benefits and risks of chemotherapy.",
"   </p>",
"   <p>",
"    Although age and general health status clearly influence adjuvant treatment recommendations, evidence-based guidelines for older individuals with breast cancer that take age and health into consideration are lacking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/82\">",
"     82",
"    </a>",
"    ]. Caution is recommended in the treatment approach to frail individuals or those with extensive comorbidity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Endocrine therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Because of its favorable therapeutic index, we recommend adjuvant endocrine therapy for all women with ER-positive tumors &gt;1 cm, regardless of age (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). For women with ER-negative breast cancer, there is no significant benefit to adjuvant endocrine therapy, and we recommend against its use (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Adjuvant endocrine therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with smaller (&le;1 cm), ER-positive tumors, observation or endocrine therapy are both acceptable options. We tend to use estimated life expectancy to assist in this decision, although estimates of life expectancy based upon a woman's general health are imprecise. For older women whose life expectancy is five years or longer (",
"      <a class=\"graphic graphic_figure graphicRef68925 \" href=\"ONC_68925\">",
"       figure 1",
"      </a>",
"      ), we suggest endocrine therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ), while for those with a more limited life expectancy, observation alone is reasonable. For patients aged 60 or older who have node-negative, grade 1, tumors &lt;1 cm, adjuvant endocrine therapy may not improve survival but it does reduce morbidity in terms of lower disease recurrence rates, and we generally suggest its use unless there are mitigating circumstances (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In keeping with ASCO guidelines, we suggest an aromatase inhibitor (AI) as a component of adjuvant therapy for most older women (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/66\">",
"       66",
"      </a>",
"      ]. Acceptable options include five years of an AI alone, two to three years of an AI followed by",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      to complete a five year course, or five years of tamoxifen followed by an AI for five years. However, five years of tamoxifen alone may be a preferred option for women who are intolerant of an AI, those with preexisting osteoporosis or a history of fracture and whose risk of a breast cancer recurrence is low (ie, &lt;2 cm low-grade, node-negative, strongly ER-positive tumor), or those with significant cardiac morbidity. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Aromatase inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Chemotherapy and trastuzumab",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age alone is not a contraindication to chemotherapy or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      if an older woman is in good general health and her estimated life expectancy is at least five years. If chemotherapy is considered, a careful discussion with the patient addressing issues of",
"      <span class=\"nowrap\">",
"       risks/benefits",
"      </span>",
"      and patient preference is required [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/83\">",
"       83",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In general, our indications for chemotherapy and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      follow those of the International Consensus Group (",
"      <a class=\"graphic graphic_table graphicRef58370 \" href=\"ONC_58370\">",
"       table 8",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef63198 \" href=\"ONC_63198\">",
"       table 9",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/81\">",
"       81",
"      </a>",
"      ], except that we use the 21-gene recurrence score assay to assist in decisions about chemotherapy for women with node-negative, ER-positive tumors, in keeping with guidelines from ASCO and the NCCN(",
"      <a class=\"graphic graphic_table graphicRef70157 \" href=\"ONC_70157\">",
"       table 10",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/3,66\">",
"       3,66",
"      </a>",
"      ]. We recommend chemotherapy plus endocrine therapy rather than endocrine therapy alone for",
"      <span class=\"nowrap\">",
"       ER/PR-positive,",
"      </span>",
"      node-positive tumors (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). When combined chemotherapy and endocrine therapy are given, endocrine therapy should be started only after chemotherapy is completed.",
"     </li>",
"     <li>",
"      For healthy women with ER-positive, node-negative breast cancer, we use gene expression analysis (ie, a 21-gene recurrence score assay, Oncotype DX&trade;) to identify those whose risk of recurrence is high enough to justify the addition of adjuvant chemotherapy. For women with a high recurrence score (&ge;31), we suggest chemotherapy in addition to endocrine therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Analysis of gene expression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who have hormone-nonresponsive tumors that are either node-positive or &gt;1 cm in size, we recommend chemotherapy rather than endocrine therapy or observation alone (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Every effort should be made to administer full standard doses of chemotherapy on time. The use of hematopoietic colony stimulating factors (CSFs) starting with the first cycle of therapy is justified for most standard adjuvant chemotherapy regimens, which have a &ge;20 percent risk of febrile neutropenia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/84\">",
"       84",
"      </a>",
"      ]. This is the threshold recommended by ASCO for routine prophylactic CSF use [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/79\">",
"       79",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      High-risk patients who are treated with less myelosuppressive regimens may also benefit from prophylactic CSFs; this includes the elderly. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/9/33945?source=see_link\">",
"       \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Choice of regimen",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"       Trastuzumab",
"      </a>",
"      <strong>",
"       indicated",
"      </strong>",
"      &mdash; For healthy older women with HER2-overexpressing, node positive breast cancer or high-risk (ie, tumor size &gt;1 cm) node-negative breast cancer who do not have excess cardiac risk (",
"      <a class=\"graphic graphic_table graphicRef74571 \" href=\"mobipreview.htm?10/30/10731\">",
"       table 6",
"      </a>",
"      ), we recommend the addition of trastuzumab to a taxane with or without an anthracycline (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Guidelines for cardiac eligibility for trastuzumab as were used in the North American adjuvant trastuzumab trials are outlined in the table (",
"      <a class=\"graphic graphic_table graphicRef74571 \" href=\"mobipreview.htm?10/30/10731\">",
"       table 6",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'HER2 overexpression'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/7/11384?source=see_link\">",
"       \"Adjuvant medical therapy for HER2-positive breast cancer\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The optimal regimen has not been established. One option is the regimen used in the N-9831 trial: AC (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      60",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      600",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      every three weeks) x 4, followed by",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      (80",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      weekly for 12 weeks) plus concurrent trastuzumab (initial loading dose 4",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      then 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      weekly), and then trastuzumab alone (2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      weekly) to complete a total 52 weeks of treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/22\">",
"       22",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Another option is the TCH regimen, which appears to have a more favorable safety profile than AC followed by a taxane and concurrent trastuzumab [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/65\">",
"       65",
"      </a>",
"      ]. As used in the BCIRG 006 trial, this regimen consists of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      (75",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      (dosed at an area under the concentration x time curve [AUC] 6) every three weeks x 6, with trastuzumab (4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      loading doses then 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      weekly during chemotherapy, then 6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every three weeks to complete a total of 52 weeks).",
"      <br/>",
"      <br/>",
"      Adjuvant treatment with trastuzumab alone, without concurrent or preceding chemotherapy, has not been studied, and is generally not acceptable outside of the context of a clinical trial.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"       Trastuzumab",
"      </a>",
"      <strong>",
"       not indicated",
"      </strong>",
"      &mdash; For women with HER2-nonoverexpressing tumors or low-risk (node-negative, size &lt;1 cm) HER2+ tumors in whom trastuzumab is not indicated, we recommend an anthracycline- or taxane-based regimen rather than CMF, particularly for women with HER2-overexpressing tumors (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Trastuzumab not indicated'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For women with a contraindication to anthracyclines, we suggest the TC regimen rather than a CMF-like regimen&nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/85\">",
"       85",
"      </a>",
"      ]. We generally use G-CSF for hematopoietic support with all four cycles of therapy. CMF is a reasonable alternative, but it should be administered as the standard, six-month regimen with oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , rather than all-IV.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h3\">",
"     Frail elderly women",
"    </span>",
"    &nbsp;&mdash;&nbsp;From a risk:benefit standpoint, frail elders with ER-positive disease are only likely to benefit from adjuvant endocrine therapy if they have a high risk of relapse within a five-year period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/23\">",
"     23",
"    </a>",
"    ]. Frail elders with ER-negative breast cancer with an expected survival of less than five years are not candidates for adjuvant chemotherapy. Estimates of five-year survival and DFS and the benefits of treatment can be made using the web-based program Adjuvant! Online, which factors in the US Census-derived mortality data by age, and the impact of comorbidity on treatment benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/0/34826/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Surveillance, Epidemiology and End Results (SEER) program: SEER state database: Incidence-SEER 12 regs Public-Use, Nov 2002 Sub (1973-2000). National Cancer Institute DCCPS Surveillance Research Program, Cancer Statistics Branch, release April 2003, based on the November 2002 submission www.seer.cancer.gov. (Accessed on April 08, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/2\">",
"      Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/4\">",
"      Extermann M, Aapro M, Bernabei R, et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 2005; 55:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/5\">",
"      Balducci L. Geriatric oncology. Crit Rev Oncol Hematol 2003; 46:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/6\">",
"      Hamerman D. Toward an understanding of frailty. Ann Intern Med 1999; 130:945.",
"     </a>",
"    </li>",
"    <li>",
"     Chaibi P, Breton S, Tresallet C, et al. Influence of geriatric consultation with Comprehensive Geriatric Assessment (CGA) on therapeutic decision in elderly cancer patients (abstract). J Clin Oncol 2008; 26:522s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/8\">",
"      Egorin MJ. Cancer pharmacology in the elderly. Semin Oncol 1993; 20:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/9\">",
"      Swedko PJ, Clark HD, Paramsothy K, Akbari A. Serum creatinine is an inadequate screening test for renal failure in elderly patients. Arch Intern Med 2003; 163:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/10\">",
"      Gelman RS, Taylor SG 4th. Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: the elimination of age trends in toxicity by using doses based on creatinine clearance. J Clin Oncol 1984; 2:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/11\">",
"      Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/12\">",
"      Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Clarke M, Coates AS, et al. Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet 2008; 371:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/13\">",
"      Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006; 295:1658.",
"     </a>",
"    </li>",
"    <li>",
"     Slamon D, Eiermann W, Robert N, et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastsuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2neu positive early breast cancer patients (abstract). Data presented at the 29th annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 15th, 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/15\">",
"      Jansen SJ, Otten W, Stiggelbout AM. Review of determinants of patients' preferences for adjuvant therapy in cancer. J Clin Oncol 2004; 22:3181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/16\">",
"      Jansen SJ, Kievit J, Nooij MA, et al. Patients' preferences for adjuvant chemotherapy in early-stage breast cancer: is treatment worthwhile? Br J Cancer 2001; 84:1577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/17\">",
"      Thewes B, Meiser B, Duric VM, et al. What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile? Lancet Oncol 2005; 6:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/18\">",
"      Goldhirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009; 20:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/19\">",
"      Christiansen P, Bjerre K, Ejlertsen B, et al. Mortality rates among early-stage hormone receptor-positive breast cancer patients: a population-based cohort study in Denmark. J Natl Cancer Inst 2011; 103:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/20\">",
"      Arnesson LG, Smeds S, Fagerberg G. Recurrence-free survival in patients with small breast cancer. An analysis of cancers 10 mm or less detected clinically and by screening. Eur J Surg 1994; 160:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/21\">",
"      Fisher B, Bryant J, Dignam JJ, et al. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol 2002; 20:4141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/22\">",
"      Ferrucci L, Guralnik JM, Studenski S, et al. Designing randomized, controlled trials aimed at preventing or delaying functional decline and disability in frail, older persons: a consensus report. J Am Geriatr Soc 2004; 52:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/23\">",
"      Dittus K, Muss HB. Management of the frail elderly with breast cancer. Oncology (Williston Park) 2007; 21:1727.",
"     </a>",
"    </li>",
"    <li>",
"     Adjuvant! available online www.adjuvantonline.com (Accessed on April 08, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/25\">",
"      Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011; 378:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/26\">",
"      Silliman RA, Guadagnoli E, Rakowski W, et al. Adjuvant tamoxifen prescription in women 65 years and older with primary breast cancer. J Clin Oncol 2002; 20:2680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/27\">",
"      Blackman SB, Lash TL, Fink AK, et al. Advanced age and adjuvant tamoxifen prescription in early-stage breast carcinoma patients. Cancer 2002; 95:2465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/28\">",
"      Malek K, Fink AK, Thwin SS, et al. The relationship among physicians' specialty, perceptions of the risks and benefits of adjuvant tamoxifen therapy, and its recommendation in older patients with breast cancer. Med Care 2004; 42:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/29\">",
"      Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 2003; 21:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/30\">",
"      Demissie S, Silliman RA, Lash TL. Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol 2001; 19:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/31\">",
"      Fink AK, Gurwitz J, Rakowski W, et al. Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor--positive breast cancer. J Clin Oncol 2004; 22:3309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/32\">",
"      Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/33\">",
"      Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349:1793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/34\">",
"      Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/35\">",
"      Mouridsen H, Keshaviah A, Coates AS, et al. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. J Clin Oncol 2007; 25:5715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/36\">",
"      Amir E, Seruga B, Niraula S, et al. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst 2011; 103:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/37\">",
"      Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005; 23:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/38\">",
"      Crivellari D, Sun Z, Coates AS, et al. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. J Clin Oncol 2008; 26:1972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/39\">",
"      Muss HB, Tu D, Ingle JN, et al. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. J Clin Oncol 2008; 26:1956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/40\">",
"      Muss HB, Berry DA, Cirrincione C, et al. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. J Clin Oncol 2007; 25:3699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/41\">",
"      Chapman JA, Meng D, Shepherd L, et al. Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer. J Natl Cancer Inst 2008; 100:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/42\">",
"      Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 1994; 120:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/43\">",
"      Diab SG, Elledge RM, Clark GM. Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst 2000; 92:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/44\">",
"      Ortholan C, Hannoun-L&eacute;vi JM, Ferrero JM, et al. Long-term results of adjuvant hypofractionated radiotherapy for breast cancer in elderly patients. Int J Radiat Oncol Biol Phys 2005; 61:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/45\">",
"      Maher M, Campana F, Mosseri V, et al. Breast cancer in elderly women: a retrospective analysis of combined treatment with tamoxifen and once-weekly irradiation. Int J Radiat Oncol Biol Phys 1995; 31:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/46\">",
"      Silliman RA, Guadagnoli E, Weitberg AB, Mor V. Age as a predictor of diagnostic and initial treatment intensity in newly diagnosed breast cancer patients. J Gerontol 1989; 44:M46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/47\">",
"      Gennari R, Curigliano G, Rotmensz N, et al. Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopasual patients. Cancer 2004; 101:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/48\">",
"      DeMichele A, Putt M, Zhang Y, et al. Older age predicts a decline in adjuvant chemotherapy recommendations for patients with breast carcinoma: evidence from a tertiary care cohort of chemotherapy-eligible patients. Cancer 2003; 97:2150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/49\">",
"      H&eacute;bert-Croteau N, Brisson J, Latreille J, et al. Compliance with consensus recommendations for the treatment of early stage breast carcinoma in elderly women. Cancer 1999; 85:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/50\">",
"      Du XL, Key CR, Osborne C, et al. Discrepancy between consensus recommendations and actual community use of adjuvant chemotherapy in women with breast cancer. Ann Intern Med 2003; 138:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/51\">",
"      Bernstein V, Truong P, Speers C, et al. Breast cancer biology, treatment and survival in elderly women (abstract). Proc Am Soc Clin Oncol 2001; 20:247a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/52\">",
"      Bouchardy C, Rapiti E, Fioretta G, et al. Undertreatment strongly decreases prognosis of breast cancer in elderly women. J Clin Oncol 2003; 21:3580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/53\">",
"      Pierga JY, Girre V, Laurence V, et al. Characteristics and outcome of 1755 operable breast cancers in women over 70 years of age. Breast 2004; 13:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/54\">",
"      Woodard S, Nadella PC, Kotur L, et al. Older women with breast carcinoma are less likely to receive adjuvant chemotherapy: evidence of possible age bias? Cancer 2003; 98:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/55\">",
"      Giordano SH, Duan Z, Kuo YF, et al. Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol 2006; 24:2750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/56\">",
"      Elkin EB, Hurria A, Mitra N, et al. Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort. J Clin Oncol 2006; 24:2757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/57\">",
"      Du XL, Jones DV, Zhang D. Effectiveness of adjuvant chemotherapy for node-positive operable breast cancer in older women. J Gerontol A Biol Sci Med Sci 2005; 60:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/58\">",
"      Fargeot P, Bonneterre J, Roch&eacute; H, et al. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial. J Clin Oncol 2004; 22:4622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/59\">",
"      Fisher B, Dignam J, Wolmark N, et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 1997; 89:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/60\">",
"      International Breast Cancer Study Group (IBCSG). Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst 2002; 94:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/61\">",
"      Extermann M, Balducci L, Lyman GH. What threshold for adjuvant therapy in older breast cancer patients? J Clin Oncol 2000; 18:1709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/62\">",
"      Desch CE, Hillner BE, Smith TJ, Retchin SM. Should the elderly receive chemotherapy for node-negative breast cancer? A cost-effectiveness analysis examining total and active life-expectancy outcomes. J Clin Oncol 1993; 11:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/63\">",
"      Mitnitski AB, Song X, Rockwood K. The estimation of relative fitness and frailty in community-dwelling older adults using self-report data. J Gerontol A Biol Sci Med Sci 2004; 59:M627.",
"     </a>",
"    </li>",
"    <li>",
"     Adjuvant! available online at www.adjuvantonline.com (Accessed on May 16, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/65\">",
"      Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011; 365:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/66\">",
"      Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25:5287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/67\">",
"      Doyle JJ, Neugut AI, Jacobson JS, et al. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol 2005; 23:8597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/68\">",
"      Pinder MC, Duan Z, Goodwin JS, et al. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 2007; 25:3808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/69\">",
"      Muss HB, Woolf S, Berry D, et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 2005; 293:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/70\">",
"      Colleoni M, Price KN, Castiglione-Gertsch M, et al. Mortality during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil. International Breast Cancer Study Group. Lancet 1999; 354:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/71\">",
"      Crivellari D, Bonetti M, Castiglione-Gertsch M, et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. J Clin Oncol 2000; 18:1412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/72\">",
"      De Maio E, Gravina A, Pacilio C, et al. Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: a single-center experience. BMC Cancer 2005; 5:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/73\">",
"      Hurria A, Brogan K, Panageas KS, et al. Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy. Breast Cancer Res Treat 2005; 92:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/74\">",
"      Muss HB, Berry DA, Cirrincione CT, et al. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 2009; 360:2055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/75\">",
"      De Laurentiis M, Cancello G, D'Agostino D, et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 2008; 26:44.",
"     </a>",
"    </li>",
"    <li>",
"     Jones S, Holmes F, O'Shaughnessy J, et al. Extended follow-up and analysis by age of the US Oncology adjuvant trial 9735: docetaxel/cyclophosphamide is associated with an overall survival benefit compared to doxorubicin/cyclophosphamide and is well tolerated in women 65 or older (abstract). Data presented at the 30th annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 13, 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/77\">",
"      Zauderer M, Patil S, Hurria A. Feasibility and toxicity of dose-dense adjuvant chemotherapy in older women with breast cancer. Breast Cancer Res Treat 2009; 117:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/78\">",
"      Wils JA, Bliss JM, Marty M, et al. Epirubicin plus tamoxifen versus tamoxifen alone in node-positive postmenopausal patients with breast cancer: A randomized trial of the International Collaborative Cancer Group. J Clin Oncol 1999; 17:1988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/79\">",
"      Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24:3187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/80\">",
"      Ryberg M, Nielsen D, Cortese G, et al. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. J Natl Cancer Inst 2008; 100:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/81\">",
"      Goldhirsch A, Wood WC, Gelber RD, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007; 18:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/82\">",
"      Hurria A, Wong FL, Villaluna D, et al. Role of age and health in treatment recommendations for older adults with breast cancer: the perspective of oncologists and primary care providers. J Clin Oncol 2008; 26:5386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/83\">",
"      Mandelblatt J, Kreling B, Figeuriedo M, Feng S. What is the impact of shared decision making on treatment and outcomes for older women with breast cancer? J Clin Oncol 2006; 24:4908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/84\">",
"      Balducci L, Al-Halawani H, Charu V, et al. Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist 2007; 12:1416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/0/34826/abstract/85\">",
"      Jones SE, Savin MA, Holmes FA, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 2006; 24:5381.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 769 Version 23.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.38",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Queens Family Health Team",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-178.173.136.2-E371FC2C7B-S317699.S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_0_34826=[""].join("\n");
var outline_f34_0_34826=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H36\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Comprehensive geriatric assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28327637\">",
"      Organ function and drug metabolism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28327644\">",
"      - Hepatic insufficiency and hepatotoxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28327651\">",
"      - Renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28329344\">",
"      - Cardiotoxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Prognostic and predictive factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Hormone receptors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - HER2 overexpression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Analysis of gene expression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Estimating the risks and benefits of systemic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5367648\">",
"      - Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5367655\">",
"      - Endocrine therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5367501\">",
"      - Frail elderly patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ADJUVANT ENDOCRINE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Tamoxifen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Aromatase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Benefits and risks in older women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      BENEFITS OF CYTOTOXIC CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Magnitude of benefit in older women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Influence of ER status",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - ER-negative disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Influence of nodal status",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Node-negative disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Selection of patients for chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Life expectancy, comorbidity, and expected benefit from chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Competing causes of death",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Frailty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      CHOICE OF REGIMEN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Trastuzumab not indicated",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Anthracycline versus nonanthracycline-based regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Capecitabine alone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - The benefit of adding a taxane",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Trastuzumab indicated",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Cardiotoxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Endocrine therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Chemotherapy and trastuzumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Choice of regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      - Frail elderly women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/769\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/769|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?4/10/4270\" title=\"algorithm 1\">",
"      CGA groups BC Rx recommend",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/769|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"ONC_68925\" title=\"figure 1\">",
"      Life expectancy elderly women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"ONC_52507\" title=\"figure 2\">",
"      Threshold for benefit adjuv Rx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/769|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/18/20779\" title=\"table 1\">",
"      Taxonomy of aging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/11/21694\" title=\"table 2\">",
"      Chemo dose modify liver disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/42/1708\" title=\"table 3\">",
"      Chemo dose adj renal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"ONC_81265\" title=\"table 4\">",
"      Risk reduction chemo EBCTCG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/54/32621\" title=\"table 5\">",
"      Epirub cum dose cardiotox",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/30/10731\" title=\"table 6\">",
"      Card inelig adjuv trastuz",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/56/42892\" title=\"table 7\">",
"      Recom Adj Sys Rx in Older women with br ca",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"ONC_58370\" title=\"table 8\">",
"      St Gallen define risk category",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"ONC_63198\" title=\"table 9\">",
"      Chemoendo rx ERpos HER2neg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"ONC_70157\" title=\"table 10\">",
"      NCCN guidelines for early stage breast cancer adjuvant therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/33/41496?source=related_link\">",
"      Acute side effects of adjuvant chemotherapy for early stage breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/4/37961?source=related_link\">",
"      Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20106?source=related_link\">",
"      Adjuvant endocrine therapy for hormone receptor-positive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/7/11384?source=related_link\">",
"      Adjuvant medical therapy for HER2-positive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41706?source=related_link\">",
"      Cardiotoxicity of anthracycline-like chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/12/40138?source=related_link\">",
"      Cardiotoxicity of nonanthracycline cancer chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./cardiotoxicity-of-trastuzumab-and-other-her2-targeted-agents?source=related_link\">",
"      Cardiotoxicity of trastuzumab and other HER2-targeted agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/2/44074?source=related_link\">",
"      Chemotherapy hepatotoxicity and dose modification in patients with liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41738?source=related_link\">",
"      Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/26/30122?source=related_link\">",
"      Clinical manifestations and natural history of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/56/41864?source=related_link\">",
"      Comprehensive geriatric assessment for patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/26/34215?source=related_link\">",
"      Failure to thrive in elderly adults: Evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/58/13226?source=related_link\">",
"      General principles on the treatment of early stage and locally advanced breast cancer in older women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/22/30058?source=related_link\">",
"      HER2 and predicting response to therapy in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26009?source=related_link\">",
"      Hepatitis B virus reactivation associated with immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/47/19194?source=related_link\">",
"      Hormone receptors in breast cancer: Clinical utility and guideline recommendations to improve test accuracy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/24/6538?source=related_link\">",
"      Lamivudine monotherapy for chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/28/43465?source=related_link\">",
"      Measurement of prognostic factors in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/51/24378?source=related_link\">",
"      Overview of the management of hepatitis B and case examples",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/46/19177?source=related_link\">",
"      Overview of the treatment of newly diagnosed, non-metastatic breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/52/26437?source=related_link\">",
"      Patient information: Early stage breast cancer treatment in postmenopausal women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/22/6503?source=related_link\">",
"      Prognostic molecular profiles of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/42/10922?source=related_link\">",
"      Systemic chemotherapy for cancer in elderly persons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/53/29528?source=related_link\">",
"      Systemic treatment for metastatic breast cancer: Single agent chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/9/33945?source=related_link\">",
"      Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_0_34827="Noninvasive methods hibernation";
var content_f34_0_34827=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F59009&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F59009&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Approaches to identifying viability in hibernating myocardium",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"1\">",
"        A. Assessment",
"of regional myocardial function using radionuclide methods,",
"echocardiography, or magnetic resonance imaging during or after:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Nitroglycerin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Postextrasystolic potentiation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Catecholamine (dobutamine) infusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Exercise",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Synchronized diastolic coronary venous retroperfusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"1\">",
"        B. Assessment",
"of perfusion, membrane integrity, and metabolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        1. Thallium-210 scintigraphy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        a. Rest: early redistribution-late distribution",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        b. Exercise: redistribution-reinjection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Technetium-99m sestamibi",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        3. Positron emission tomography",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        a. Flow: rubidium-8, N-ammonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        b. Metabolism: fluorine-18-fluorodeoxyglucose,",
"carbon-11-acetate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Magnetic resonance spectroscopy",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Castro, PF, Bourge, RC, Foster, RE. Am J Med 1998; 104:69.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_0_34827=[""].join("\n");
var outline_f34_0_34827=null;
var title_f34_0_34828="Drugs causing cholestasis";
var content_f34_0_34828=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F57682&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F57682&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drugs reported to cause chronic cholestasis and ductopenia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Aceprometazine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ajmaline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Allopurinol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amineptine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amoxicillin/clavulanic acid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ampicillin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Androgenic anabolic steroids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Azathioprine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Azithromycin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Barbiturates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carbamazepine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carbutamide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chlorothiazide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chlorpromazine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cimetidine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ciprofloxin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clindamycin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Co-trimoxazole",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyamemazine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyclohexylpropionate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyproheptadine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Erythomycin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flucloxacillin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glibenclamide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glycyrrhizin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Haloperidol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ibuprofen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Imipramine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meropenem",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methyltestosterone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Moxifloxacin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nevirapine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Norandrostenolone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oestradiol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phenytoin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prochlorperazine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tetracyclines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thiabendazole",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tiopronin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tolbutamide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trimethoprim-sulfamethoxazole",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trioleandomycin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Valproic acid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Xenalamine",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: J Gastroenterol Hepatol 2000; 15:1232, J Hepatol 1997; 26S:31, Clin Liver Dis 2003; 7:311, and Korean J Hepatol 2005; 11:80.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_0_34828=[""].join("\n");
var outline_f34_0_34828=null;
var title_f34_0_34829="Prevalence of atrial fibrillation in CKD pts";
var content_f34_0_34829=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F55373&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F55373&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 584px\">",
"   <div class=\"ttl\">",
"    Prevalence of atrial fibrillation in chronic kidney disease patients",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 564px; height: 310px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The prevalance (percent) of atrial fibrillation in the general population and different cohorts of patients with CKD are shown: while patients with peritoneal dialysis appear to suffer less frequently from atrial fibrillation, in those on hemodialysis the prevalance was observed to be 10- to 20-fold higher than in the general population. Age was in all groups a key factor.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Reinecke H, Brand E, Mesters R, et al. Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol 2009; 20:705. Copyright &copy; 2009 American Society of Nephrology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_0_34829=[""].join("\n");
var outline_f34_0_34829=null;
var title_f34_0_34830="Complexity of IgE response";
var content_f34_0_34830=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F69136&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F69136&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 599px\">",
"   <div class=\"ttl\">",
"    Complexity in patients' IgE responses",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 579px; height: 307px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    On the basis of the allergogram in&nbsp;figure&nbsp;2, the precipitates are ordered according to their relative importance in terms of IgE binding score. Allergen D is fel D 1. The",
"    <br>",
"     blue bars represent the sum of a graduated score of the IgE binding of each of the 22 patients. The red line represent the percentage of patients having all their IgE reactivities covered by the allergens to the left of the point.",
"     <br>",
"      NOTE: 1) None of the patients have all their IgE reactivity covered by the two most important allergens. 2) In order to cover all IgE reactivity in half of the patients, 6 allergens are needed.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_0_34830=[""].join("\n");
var outline_f34_0_34830=null;
var title_f34_0_34831="Dry tap medial fat pad MRI";
var content_f34_0_34831=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F72085&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F72085&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Magnetic resonance imaging of medial fat pad in knee explaining dry tap",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 342px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Failed arthrocentesis due to focal triangular fat pad. T2 weighted axial image through the mid-pole of the patella shows a prominent triangular fat pad located in the notch of the medial aspect of the patellofemoral joint (white arrow). A 1.5 inch needle (long arrow) could only reach the joint effusion in this relatively thin patient if the needle were placed to the hub.",
"    <div class=\"footnotes\">",
"     M: medial. L: lateral.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Roberts WN, Hayes CW, Breitbach SA, et al. Am J Med 1996; 100:461.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_0_34831=[""].join("\n");
var outline_f34_0_34831=null;
